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ABSTRACT
Retinitis pigmentosa (RP) is a genetically and clinically heterogenous retinal 
degenerative disease, which is characterised by night blindness and constriction of 
visual fields in the early stages which progress to blindness. X-linked RP (XLRP) is 
the most severe form of the disease and 2 causative genes have been identified, 
RP2 and RPGR. RP2 encodes a ubiquitously expressed 350 amino acid protein with 
a tubulin folding cofactor C (TBCC) homology domain and a C-terminal NDK 
homology domain. Despite the ubiquitous expression of the RP2 protein, the disease 
pathogenesis in patients carrying RP2 gene mutations appears to be restricted to 
retina. The function of RP2 in retina, or other tissues, has yet to be determined. This 
study aims to increase the understanding of the pathobiology of RP2 by unravelling 
novel molecular pathways of RP2 function.
The approach taken to elucidate the cellular roles of RP2 in retina was to identify 
potential interacting partner proteins from a retina library using a yeast-two-hybrid 
approach. The Sos Recruitment System (SRS) was exploited, as RP2 had previously 
been shown to be predominantly localised on the plasma membrane. Several 
candidate protein partners for RP2 were identified. ADP-ribosylation like factor 3 
(Arl3) was the most common cDNA identified in the yeast-two-hybrid screen. The 
interaction between RP2 and Arl3 was further defined using site directed 
mutagenesis to model pathogenic mutations in RP2 and a series of deletion mutants. 
RP2 preferentially interacted with the active GTP-bound form of Arl3 via the RP2 
TBCC-homology domain. An altered cellular localisation and behaviour of RP2 was 
observed when co-transfected with GTP-bound Arl3. Both Arl3 and RP2 exhibit 
partial relocalisation to the Golgi and increased intracellular transport of RP2-GFP. 
Arl2 is structurally very similar to Arl3, and was also identified as a potential interactor 
of RP2, however the physiological significance of the RP2-Arl2 interaction is unclear. 
Interestingly, TBCC did not bind Arl2 or Arl3 confirming that RP2 and TBCC have 
different cellular functions.
Four other novel potential interactors were also identified from the yeast two-hybrid 
screen including another small GTPase, and their interaction mapped to the C- 
terminus of RP2. The cellular localisation and function of these novel interactors 
suggest RP2 may have multiple cellular functions.
3
PUBLICATIONS AND ABSTRACTS
Publications
Evans, R. J., Chappie, J. P., Grayson, C., Hardcastle, A. J., and Cheetham, M. E. 
(2005). Assay and functional analysis of the ARL3 effector RP2 involved in X-linked 
retinitis pigmentosa. Methods Enzymol. 404, 468-480.
Evans, R. J., Hardcastle, A. J., and Cheetham, M. E. (2006). Focus on molecules: X- 
linked Retinitis Pigmentosa 2 protein, RP2. Exp.Eye Res. 82, 543-544.
Hidalgo-de-Quintana, J, Evans, R. J, Cheetham, M. E, and van der Spuy, J. (2007). 
The LCA protein AIPL1 functions as part of a chaperone heterocomplex. Submitted.
Abstracts
Characterisation of the Interaction Between the X-linked Retinitis Pigmentosa Protein 
RP2 and Arl Proteins.
R. Jane Evans, Alison J. Hardcastle, and Michael E. Cheetham.
ARVO (2005) 5170-8373.
Investigation of the Interaction of RP2 and Arl3.
R. Jane Evans, Alison J. Hardcastle, and Michael E. Cheetham.
ISOCB (2006) P13.
4
ACKNOWLEDGEMENTS
Firstly I would like to thank my supervisors Alison Hardcastle and Mike Cheetham for 
giving me the opportunity to work on such a fantastic project and who have been 
incredibly supportive during the last four years. It’s been a fabulous experience, so 
thank you so much. Thank you also to everyone in MCN, past and present, it’s been 
great to work with so many lovely people. In particular I’d like to say huge thanks to 
Juan for all the yeast chats and to Jacqui for all the advice and perfectly written 
protocols!
I’d especially like to thank Simon not only for his guru-like advice but also his calm 
manner and friendship which has got me through many stressful times! Naheed, I 
can’t thank you enough for your amazing patience and lovely chats which I have 
appreciated no end, especially in the last few months. Marghe, it’s been fabulous 
having you in the lab this year, your cheerfulness has made us all smile! Thanks also 
to Suba and Neil who may have left but have always still been there. Thank you also 
to Shazeen, Sakina and Louise.
Thank you also to Peter Munro for all his help with the confocal microscope and to 
Beverley Scott who always seemed to ensure my sequencing worked!
I’d like to say a big thank you to Corin, who really has put up with a lot, I promise my 
constant lateness will soon be a thing of the past (I hope)! Thank you for being such 
a fantastic friend.
Lastly I would like to thank my family. Thank you to my parents, without all your 
support I’m quite sure I wouldn’t be writing this now, it’s hard to say quite how much I 
owe you and how much I appreciate everything you’ve done. Thanks also to Kay, 
Brian, Angus and Magdalen who have been so supportive. To Patrick, thank you for 
being so lovely! And to Breanainn, I hope I can do the same for you one day.
5
Dedication
This thesis is dedicated to Breanainn and Patrick who I think are brilliant.
6
TABLE OF CONTENTS
Title Page 1
Declaration 2
Abstract 3
Publications and Abstracts 4
Acknowledgements 5
Dedication 6
Table of contents 7
List of Figures 13
List of Tables 15
List of Abbreviations 16
CHAPTER 1 -  INTRODUCTION 18
1.1 The Eye 18
1.2 The Retina 19
1.2.1 The retinal pigment epithelium 19
1.2.2 The neural retina 19
1.2.3 Rod and cone photoreceptors 21
1.2.3.1 The connecting cilium 22
1.2.4 Phototransduction 23
1.3 Inherited retinal dystrophies 24
1.3.1 Leber Congenital Amaurosis 24
1.3.2 Cone-rod dystrophy 24
1.3.3 Retinitis pigmentosa 26
1.3.3.1 Syndromic RP 26
1.3.4 Genes and pathways implicated in retinal diseases 27
1.3.4.1 Transcription 29
1.3.4.2 mRNA splicing 29
1.3.4.3 Visual cycle and phototransduction 29
1.3.4.4 Photoreceptor structure and cilia 30
1.3.4.5 Other retinal disease pathways 31
7
1.3.5 X-linked retinits pigmentosa
1.3.5.1 Retinitis pigmentosa GTPase regulator (RPGR)
31
32
1.4 RP2 33
1.4.1 RP2 gene 34
1.4.2 RP2 sequence homology 36
1.4.2.1 The TBCC/TBCCD1 homology domain 36
1.4.2.2 The NDK homology domain 37
1.4.3 Cellular localisation of RP2 39
1.4.4 RP2 protein structure 39
1.5 Tubulin and the cytoskeleton 41
1.5.1 The cytoskeleton 41
1.5.2 Tubulin folding model 41
1.5.2.1 Regulation of tubulin folding 42
1.6  ADP-ribosylation factor (Arf)-like proteins 45
1.6.1 Arl3 45
1.6.2 Arl2 47
1.6.3 Arl3 and Arl2 interacting partners 47
1.6.4 Arl6 49
1.7 Aims of this study 49
CHAPTER 2 -  MATERIALS AND METHODS 51
2.1 Basic Molecular Techniques 51
2.1.1 Vectors Used in this Study 51
2.1.1.1 Construction of the pMyr cDNA Library 52
2.1.2 Subcloning 52
2.1.3 Precipitation and Purification of DNA 52
2.1.4 Alkaline Phosphatase Treatment 52
2.1.5 Agarose Gel Electrophoresis 53
2.1.6 Ligation of DNA 53
2.1.7 Bacterial Transformation 53
2.1.8 Plasmid Purification (Miniprep) 54
8
2.1.8.1 DNA Quantification 54
2.1.9 DNA Sequencing 55
2 .1.10 Polymerase Chain Reaction 55
2 .1.10.1 Primer Design 56
2.1.11 TA Cloning into pGem T-Easy 56
2.1.12 Site Directed Mutagenesis (SDM) 57
2.2 Yeast two-hybrid Techniques 58
2.2.1 Verification of Yeast Strain Phenotype 58
2.2.2 Yeast Glycerol Stocks 58
2.2.3 pMyr Target Library Construction 58
2.2.4 Yeast Transformation 59
2.2.5 Bait Transactivation 60
2.2.6 Verification of Bait Protein Expression 60
2.2.7 SDS-PAGE Analysis and Coomassie Staining 60
2 .2.8  Western Blotting 61
2 .2.8.1 Antibody peptide blocking 62
2.2.9 Library Screening 62
2.2.9.1 Co-transformation of yeast 62
2.2.9 2 Replica Plating of Yeast Co-transformations 62
2.2.9.3 Identification of Putative Positive Interactors 63
2.2.9.4 Extraction of DNA from Putative Interactors 63
2.2 9.5 Transformation of Total Yeast DNA into E. coli 63
2.2.9.6 Analysis for Revertants 64
2.2.9.7 Yeast Spheroblast PCR 64
2.2.10 Southern Blotting 65
2.3 Cell Culture and Immunocytochemistry 67
2.3.1 Cell Culture Maintenance (Adherent cells) 67
2.3.2 Liquid Nitrogen Storage of Cells 67
2.3.3 Resuscitation of Cells from Liquid Nitrogen 67
2.3.4 Lipofectamine Transfection 67
2.3.4.1 Transfection of eight-well chamber slides 68
2.3.4 2 Transfection of six-well plates 6 8
2.3.4.3 Preparation of cell lysates 68
2.3.5 Immunocytochemistry 69
2.3.6 Co-lmmunoprecipitations 70
9
2.3.7 GST-Pulldown Assay
2.3.8 Live Cell Imaging
2.3.8.1 Confocal scanning microscopy
70
72
72
CHAPTER 3 -  IDENTIFICATION OF RP2 INTERACTING PROTEINS 73
3.1 Introduction 73
3.1.1 Yeast two-hybrid 73
3.1.2 Son of Sevenless Recruitment System 75
3.2 Optimisation of CytoTrap for screening a retina cDNA library using RP2 as 
bait 79
3.3.1. Sub-cloning of RP2 into the pSos vector 79
3.3.2 Functional analysis of pSos-RP2 in CytoTrap 80
3.3.3 Screening strategies 80
3.3 Strategies to expedite processing of revertant and Arl clones 84
3.3.1 Identifying Arl clones 85
3.4 Overview of bovine retina cDNA library screening 86
3.5 Putative Interactors 87
3.6 Discussion 89
CHAPTER 4 -  CHARACTERISATION OF THE INTERACTION OF RP2 AND ARL3
93
4.1 Introduction 93
4.2 Arl3 and Arl2 95
4.2.1 RP2 interacts with Arl3 95
4.2.2 RP2-Arl2 interaction 97
4.2.3 Domain mapping 99
4.2.4 RP2 interacts preferentially with GTP-bound Arl3 101
4.2.4.1 GST pulldown assays to confirm the RP2-Arl3 interaction 101
10
4 2.4.2 Co-immunoprecipitations to confirm an RP2-Ar13 interaction 101
4.2.5 RP2 pathogenic mutants disrupt the RP2-Arl3 interaction 104
4.3 Arl6  does not interact with RP2 108
4.4 Cofactor C (TBCC) does not interact with any Arl proteins tested 108
4.5 Cellular localisation of RP2 and Arl3 110
4.5.1 Cellular localisation of tagged Arl3 protein 110
4.5.2 Localisation of endogenous RP2 when Arl3 was over-expressed 112
4.5.3 Investigation of the co-localisation of RP2-GFP and myc-Arl3-Q71 L 112
4.5.4 Characterisation of the RP2 and Arl3-Q71 L interaction 112
4.6 Live imaging of RP2-GFP 118
4.7 Discussion 124
CHAPTER 5 -  CHARACTERISATION OF NOVEL PUTATIVE RP2 INTERACTORS
131
5.1 RAN 131
5.1.1 Introduction 131
5.1.2 Characterisation of the RP2-RAN interaction 135
5.1.2.1 RAN interacts with the C-terminal domain of RP2 135
5.1.2.2 GDP-bound RAN preferentially interacts with RP2 138
5.1.2.3 Pulldown assays for the RP2-RAN interaction 138
5.1.2.4 Subcellular localisation of RAN 140
5.1.3 Discussion 145
5.2 Cyclin dependent kinase inhibitor 1B 148
5.2.1 Introduction 148
5.2.2 Characterisation of the RP2-CDKN1B interaction 148
5.2.2.1 The RP2-CDKN1B interaction is mediated through the C-terminus of 
RP2 148
5.2.2.2 Cellular localisation studies of CDKN1B and RP2 151
5.2.3 Discussion 151
11
5.3 Transportin 3 156
5.3.1 Introduction 156
5.3.2 Characterisation of the RP2-TNP03 interaction 157
5.3.2.1 TNP03 interacts with the C-terminal domain of RP2 160
5.3.2.2 Immunocytochemical analysis of the RP2-TNP03 interaction 160
5.3.3 Discussion 163
5.4 Sperm associated antigen 7 165
5.4.1 Introduction 165
5.4.2 Characterisation of the RP2-SPAG7 interaction 165
5.4.2.1 SPA G 7 interacts with the C-terminus of RP2 167
5.4.3 Characterisation of a SPAG7 antibody 167
5.4.2.3 Immunocytochemical analysis of SPAG7 and its interaction with RP2 169
5.4.3 Discussion 171
5.5 Discussion 173
CHAPTER 6 -  DISCUSSION 175
6.1 Discussion and future work 175
REFERENCES 185
Appendix 1 214
Appendix 2 221
12
LIST OF FIGURES
Figure 1.1 Structure of the human eye 18
Figure 1.2 Structure of the retina 20
Figure 1.3 A fundus image of a human retina 21
Figure 1.4 The rod photoreceptor 23
Figure 1.5 Schematic representation of the RP2 protein 36
Figure 1.6 Alignment of RP2, TBCC and TBCCD1 38
Figure 1.7 Localisation of RP2 in human retina 40
Figure 1.8 A model for tubulin folding 43
Figure 1.9 Phylogenetic analysis of Arl family members 45
Figure 3.1 Schematic representation of the transcription-based yeast two-hybrid 
system 74
Figure 3.2 Schematic showing how the SRS system is used to identify interacting 
proteins for a protein of interest 77
Figure 3.3 Rearrangements of pSos/RP2 plasmids 79
Figure 3.4 Functional analysis of the hSos-RP2 bait 81
Figure 3.5 Bacterial colony PCR to detect Arl clones 86
Figure 4.1 Arl3 cDNAs that interacted with RP2 96
Figure 4.2 RP2-Arl2 interaction detected with CytoTrap 98
Figure 4.3 Delineation of the Arl binding domain of RP2 100
Figure 4.4 RP2 preferentially interacts with Arl3-GTP 102
Figure 4.5 Analysis of the RP2-Arl3 interaction using co-immunoprecipitation 103 
Figure 4.6 Effects of RP2 missense mutations on the affinity of the RP2-Arl3 
interaction 105
Figure 4.7 Subcellular localisation of RP2 pathogenic mutants 107
Figure 4.8 Interaction of the Arl family of proteins with RP2 and its homolog TBCC109 
Figure 4.9 Subcellular localisation of tagged Arl3 111
Figure 4.10 Localisation of endogenous RP2 with Arl3 over-expression 113
Figure 4.11 RP2-GFP co-localised with myc-Arl3-Q71 L 114
Figure 4.12 RP2-GFP co-localised with (3-COP in the presence of Arl3-GTP 116
Figure 4.13 RP2-GFP did not co-localise with EEA1 117
Figure 4.14 Live imaging of RP2-GFP 119
13
Figure 4.15 Live imaging of RP2-GFP co-expressed with myc-Arl3-T31 N 120
Figure 4.16 Live imaging of RP2-GFP co-expressed with myc-Arl3-Q71L 121
Figure 4.17 Live imaging of a truncated RP2-GFP construct or RP2-R118H-GFP co­
expressed with myc-Arl3-T31 N 123
Figure 5.1 RAN is involved in nuclear import 133
Figure 5.2 RAN is involved in nuclear export as well as nuclear import 134
Figure 5.3 RAN interacts with RP2 136
Figure 5.4 Characterisation of the RP2-RAN interaction 137
Figure 5.5 RP2-GST pulldown assays using RAN as a target 139
Figure 5.6 Subcellular localisation of endogenous RAN and RP2-GFP 141
Figure 5.7 Altered localisation of myc-RAN in the presence of RP2-GFP 143
Figure 5.8 Cellular localisation of myc-RAN-Q69L mutant 144
Figure 5.9 CDKN1B is involved in cell cycle control 149
Figure 5.10 CDKN1B interacts with RP2 150
Figure 5.11 CDKN1B interacts with RP2 through the C-terminus of RP2 152
Figure 5.12 Cellular localisation of endogenous CDKN1B 153
Figure 5.13 Alternative splicing of the TNP03 gene 158
Figure 5.14 Transportin 3 interacts with RP2 159
Figure 5.15 TNP03 interacts with the C-terminus of RP2 161
Figure 5.16 Cellular localisation of endogenous TNP03 162
Figure 5.17 SPAG7 interacts with RP2 166
Figure 5.18 SPAG7 interacts with the C-terminus of RP2 168
Figure 5.19 Characterisation of an antibody to SPAG7 170
Figure 5.20 SPAG7 is localised predominantly in the nucleus 172
Figure 6.1 The RP2 interactome 182
14
LIST OF TABLES
Table 1.1 Genes and pathways implicated in retinal diseases 27
Table 1.2 The six known XLRP loci 32
Table 1.3 Reported mutations in RP2 35
Table 2.1 Details of the vectors used for CytoTrap yeast two-hybrid 52
Table 2.2 Antibiotics used and their concentrations 54
Table 2.3 Primary antibodies used for Western blotting 61
Table 2.4 Primary Antisera for Immunocytochemistry 69
Table 2.5 Secondary Antisera for Immunocytochemistry 70
Table 3.1 A comparison of screening strategies 84
Table 3.2 Summary of all screens for RP2 interactors 88
Table 4.1 Estimated rates for components of the axonal transport system 128
Table 6.1 Putative candidate retinal disease genes 183
Table 7.1 Oligonucleotide primers used for PCR and sequencing 219
Table 7.2 Mutant oligonucleotide primers used for SDM 220
15
LIST OF ABBREVIATIONS
ADP Adenosine diphosphate
Arf ADP-ribosylation factor
Arl ADP-ribosylation factor-like
ATP Adenosine triphosphate
BART1 Binder of Arl2
BSA Bovine serum albumin
CAP Cyclase associated protein
CC Connecting cilia/cilium
CCT Cytosolic chaperonin
CDKN1B Cyclin dependent kinase inhibitor 1B
cDNA complementary DNA
cGMP cyclic guanosine monophosphate
CHO Chinese hamster ovary
CIAP Calf intestinal alkaline phosphatase
CRD Cone-rod dystropy
DAPI 4’6-diamidimo-2-phenylindole
ddHzO Double distilled water
DMEM Dulbecco’s modified eagles medium
DNA Deoxyribonucleic acid
ECL Enhanced chemiluminescence
FBS Fetal bovine serum
GAP GTPase activating protein
GCL Ganglion cell layer
GDP Guanosine diphosphate
GEF Guanine nucleotide exchange factor
GFP Green fluorescent protein
GTP Guanosine triphosphate
HBSS Hanks balanced salt solution
HRP Horse radish peroxidase
IPTG Isopropyl-beta-D-thiogalactopyranoside
IMS Industrial methylated spirit
INL Inner nuclear layer
IPL Inner plexiform layer
16
IS Inner segment
kb kilobase
kDa kilo Dalton
LCA Leber congenital amaurosis
MAP Microtubule associated protein
mRNA messenger RNA
MTOC Microtubule organising centre
NP40 Nonidet P40
OLM Outer limiting membrane
ONL Outer nuclear layer
OPL Outer plexiform layer
OS Outer segment
PCR Polymerase chain reaction
PDE Phosphodiesterase
Pi Phosphate
RAN Ras-related nuclear protein
RP Retinitis pigmentosa
RPE Retinal pigment epithelium
RPGR Retinitis pigmentosa GTPase regulator
SDS Sodium dodecyl sulphate
SDS-PAGE SDS polyacrylamide gel electrophoresis
SPAG7 Sperm associated antigen 7
SRS Sos recruitment system
TAE Tris acetate buffer
TEMED N, N, N N ’-tetramethylethylenediamine
TNP03 Transports 3
Tris 2-amino-2-(hydroxymethyl)-1,3-propanediol
Tween 20 Polyoxyethylene sorbitan monolaurate
XLRP X-linked retinitis pigmentosa
17
Chapter 1 - Introduction
CHAPTER 1
INTRODUCTION
1.1 The Eye
The human eye comprises three basic layers; a fibrous (corneoscleral) coat, the uvea 
(formed by the choroids, ciliary body and iris) and the neural layer (retinal layer) 
(Figure 1.1). Light enters the eye through the lens which is able to relax and contract 
thus altering its shape and allowing a sharp image to be formed on the retina. The 
amount of light passing through the lens is controlled by the iris, a pigmented circular 
muscle surrounding the pupil. The transparent cornea acts as a barrier to infection 
and trauma as well as being partially responsible for the refractive properties of the 
eye. Continuous to the cornea is the sclera which is a dense fibrous opaque coat 
which forms the site of attachment for the intrinsic muscles of the eye.
Figure 1.1 Structure of the human eye
A cross-sectional view of the human eye, adapted from Fight for Sight 
(www.fightforsight.org.uk)
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1.2 The Retina
The retina is the light-detecting part of the eye consisting of three major neuronal 
layers. The neuro sensory retina and the outer pigmented epithelium are linked by 
the interphotoreceptor matrix (IPM) (Bridges, 1995). Images are focused onto the 
retina by the cornea and lens.
1.2.1 The retinal pigment epithelium
The non-neuronal monolayer of columnar epithelial cells which separate the retina 
from its blood supply (the choroid) is known as the retinal pigment epithelium (RPE). 
The RPE cells play a role in the turnover of outer segments (OS) discs as well as 
functioning in the visual cycle by recycling vitamin A; all-frans-retinol is converted 
back to 11-c/s-retinal and released across the apical membrane for reabsorbtion by 
the photoreceptors (Bok, 1993). The phagocytosis of the OS occurs through the 
apical processes of the RPE cells which surround the photoreceptor OS. Shed discs 
are then packaged into phagosomes which are subsequently degraded. Each RPE 
cell contacts approximately 45 outer segments, and the estimated turnover of outer 
segment discs is 10% daily (Young and Bok, 1969). The RPE also absorbs scattered 
light as it is rich in melanosomes. (Bron, Tripathi and Tripathi, 8th Ed, 1997).
1.2.2 The neural retina
The sensory neural retina is comprised of five layers; the outer nuclear layer (ONL), 
the outer plexiform layer (OPL), the inner nuclear layer (INL), the inner plexiform layer 
(IPL) and the ganglion cell layer (GCL) (Figure 1.1 A). The ONL contains the 
photoreceptor cell bodies, the OPL is formed from the photoreceptor inner fibres and 
contains the synaptic junctions between the axon fibres of the photoreceptors and 
those of the second-order neurons in the retina (e.g. bipolar cells). The INL contains 
the cell bodies of the neural cells of the retina (e.g bipolar, amacrine, Muller and 
horizontal cells), and the IPL denotes the point at which the bipolar cells synapse with 
the third order neural cells; the ganglion cells (Figure 1.2). The GCL contains the cell 
bodies of the ganglion cells predominantly, but Muller cell processes are also found in 
this layer (Bron, Tripathi and Tripathi, 8th Ed, 1997).
The most direct way to signal to the brain is through a chain of three neurons; the 
photoreceptor to bipolar to ganglion cell, however the lateral synaptic connections 
made by the horizontal and amacrine cells exert additional control over the
19
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transmission of the signal from the photoreceptor to the visual cortex of the brain 
(Rowe, 1991).
Figure 1.2 Structure of the retina
A A schematic representation of the human retina showing the organisation of the 
various cell types in the retina. B A vertical light micrograph section through the 
central human retina showing the distinctive layers of the retina. Adapted from 
http://webvision.med.utah.edu/. Outer limiting membrane (OLM), outer nuclear layer 
(ONL), outer plexiform layer (OPL), inner nuclear layer (INL), inner plexiform layer 
(IPL), ganglion cell layer (GCL) and inner limiting membrane (ILM).
The optic disc is located near the centre of the retina to the nasal side, this is the 
point at which the optic nerve departs and the major blood vessel enters the retina, 
this area of the retina contains no photoreceptors and as such is known as the ‘blind 
spot’. Near the optic disc the fovea is located, which marks the centre of the macula 
region (Figure 1.3) (Hendrickson and Yuodelis, 1984). The macula region of the 
retina is densely populated with photoreceptors, while the central region of the fovea, 
the foveal pit, is populated exclusively with cone photoreceptors and is the area of 
most acute vision (Provis et al., 1998).
20
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1.2.3 Rod and cone photoreceptors
There are two major types of photoreceptor cell in the human retina, located in the 
outer layer of the retina, which are responsible for light perception; rods and cones.
Figure 1.3 A fundus image of a human retina
An ophthalmoscopic photograph of a healthy human retina showing the optic disc, 
macula region and the fovea. Adapted from Webvision.
Rods are responsible for detection of dim light (scotopic vision) and for contrast 
sensitivity, while the cone cells are responsible for daylight (photopic) and colour 
perception. There are approximately 90 million rod cells in the human retina and 
approximately 4.5 million cones (Curcio etal., 1990).
Rods and cones have a similar basic structure consisting of an outer segment (OS) 
and inner segment (IS) connected by the connecting cilium (CC). The cell body 
contains the nucleus, and a synaptic terminal (Figure 1.4). In the outer segment of 
photoreceptors, membranous structures known as discs are found. These are rich in 
visual pigment proteins and are surrounded by plasma membrane. In rods these 
discs are pinched off from the plasma membrane. Whereas in cones, the discs are 
continuous with one another and the surrounding plasma membrane except for the 
basal discs which are a separate structure. These discs undergo a high rate of 
turnover, the old discs are shed from the tip of the photoreceptor and are
21
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phagaocytosed by the RPE cells while the OS continuously forms new discs (Bron, 
Tripathi and Tripathi, 8 thEd, 1997, Pierce 2001).
1.2.3.1 The connecting cilium
The connecting cilium (CC) is a specialised non-motile cilium which actively 
transports proteins synthesised in the IS to the OS and acts as a support structure for 
the outer segments (Figure 1.4, Liu et al. 2007, Schmitt and Wolfrum, 2001). The 
cilium develops from the basal body, a modified centriole, which also acts as a 
microtubule organising centre for the photoreceptor (Figure 1.4) (Muresan et al., 
1993). The cilium is non-motile and as such the microtubule arrangement of a 9+0 
configuration lacks the central microtubule doublet (9+2) and dynein arms seen in 
motile cilia (Rolich, 1975). The high turnover rate of proteins in the OS, (it has been 
estimated that as many as 2,000 photopigment molecules are required by the OS per 
minute), means that an efficient transport system is required (Besharse and Horst, 
1990).
This transport occurs through intraflagellar transport (IFT) along the connecting 
cilium’s axoneme doublet microtubules. The cargo is transported along with IFT 
particles that are associated with the axonemal structure (Eley et al., 2005). 
Heterotrimeric kinesin II is the molecular motor responsible for anterograde transport 
and cytoplasmic dynein 1B is the motor that controls retrograde transport (Eley et al., 
2005). Maintenance of this process is vital to the function of the photoreceptor cell 
and the retina. A study by Pazour et al (2002) showed that mice with a mutation in 
the gene encoding the IFT protein IFT88  exhibited abnormal development of the 
outer segments and retinal degeneration, suggesting IFT based transport along the 
connecting cilium is vital to normal retinal function (Pazour et al., 2002). Defects in 
IFT have also been implicated in Bardet Biedl Syndrome (BBS), a syndrome in which 
one of the phenotypes is RP (Blacque et al., 2004). Furthermore, other retinal 
disease proteins have been shown to localise to the connecting cilium (e.g. RPGR) 
(Hong e ta l, 2003).
A recent proteomic screen by Liu et al (2007) of the photoreceptor sensory cilium of 
mouse revealed that there is a much higher degree of complexity in mammalian cilia 
compared to those of unicellular organisms; of the 1968 proteins detected in the 
screen ~1500 were not detected in lower organisms (Liu et al., 2007), although many 
of these were outer segment proteins rather than cilia proteins.
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Figure 1.4 The rod photoreceptor
Schematic representation of a rod photoreceptor. A The rod cell is formed by the 
outer segment (OS) and the inner segment (IS) connected by the connecting cilium 
(CC), and the cell body which contains the nucleus (N) and the synaptic terminal (ST) 
which connects the rod to the bipolar cell. The OS extends toward the retinal 
pigment epithelium (RPE) cells which are involved in phagocytosing the shed OS 
disks. B The rod connecting cilium, which extends from the rootlet (R) through the 
basal body (BB) at the top of the IS all the way along the axoneme which extends to 
the top of the OS. From Liu et al (2007).
1.2.4 Phototransduction
Phototransduction is the process which converts the light detected by the 
photoreceptors into an electrical signal. Rod photoreceptors detect light through 
photoactivation of the visual pigment, rhodopsin, specifically, isomerisation of 11-c/s- 
retinal to all-frans-retinal which leads to a conformational change in rhodopsin and 
consequently activates transducin, this is the first step in the phototransduction 
pathway (Yau, 1994).
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The photoreceptor cell is kept in a depolarised state in the absence of light through 
the cGMP-gated cation channels on the OS plasma membrane remaining open and 
allowing sodium ions to enter the cell. When light is detected the consequential 
decrease in cGMP levels in the cell leads to the closure of the cGMP-gated cation 
channels. The decrease in intracellular cations leads to the plasma membrane 
becoming hyper-polarised and a graded decrease in neurotransmitter release at the 
photoreceptor synapse. This is then detected by the bipolar cells which ultimately 
results in the signal being interpreted in the visual cortex of the brain (Rattner et al.,
1999).
1.3 Inherited retinal dystrophies
Inherited retinal dystrophies are relatively common, estimated to affect 1 in 2000 
people worldwide (Rivolta et al., 2002). These retinal dystrophies are both clinically 
and genetically heterogeneous. There are currently 181 loci for diseases exhibiting 
an abnormal retinal phenotype with 129 of the causative genes having been identified 
(Daiger et al., 2007). Autosomal dominant, autosomal recessive, X-linked, digenic, 
mitochondrial, complex and syndromic inheritance patterns have all been reported. 
Retinal dystrophies are often categorised according to the age of onset, severity of 
diease, pattern of visual loss and inheritance pattern.
1.3.1 Leber Congenital Amaurosis
Leber Congenital Amaurosis (LCA) is a rare severe retinal dystrophy with an 
incidence of approximately 1 in 50-100,000, the onset of disease is early and results 
in blindness in childhood characterised by no detectable electroretinogram (ERG) 
response in rods and cones. LCA is genetically heterogenous with 9 known loci, of 
which 7 of the causative genes are known (Allikmets, 2004, RetNet, OMIM). LCA is 
inherited in an autosomal recessive pattern.
1.3.2 Central retinal disorders
Central retinal disorders encompass a number of dystrophies such as cone-rod 
dystrophy, Stargardt disease, and macular degeneration, as well as stationary 
disorders such as colour blindness and achromatopsia.
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Mutations in the genes encoding the red and green cone opsins can result in a 
stationary visual disorder called colour blindness, with no effect on rod photoreceptor 
function (McIntyre D, 2002). There is currently little evidence to suggest that 
mutations in these genes result in cone cell death, in contrast, mutations in the gene 
encoding rod opsin can result in severe retinal degeneration (Section 1.2.4 and 
1.3.4.3).
Cone-rod dystrophies (CRD) are a group of phenotypically and genetically 
heterogeneous retinal disorders in which there is visual field loss or abnormalities in 
colour vision. Cone-rod dystrophies can be inherited in an autosomal recessive, 
autosomal dominant or X-linked pattern. There are currently 13 known causative 
genes for cone-rod dystrophy (Michaelides et al., 2006, RetNet) and 6  mapped loci 
(RetNet). ERGs show initial impairment of the normal cone response. The disease 
can either remain stationary or can be progressive (Michaelides et a/., 2006). If 
stationary the disorder is often diagnosed soon after birth while if progressive the 
diagnosis is usually made in childhood or adolescence. The disease primarily affects 
the cone photoreceptors, and diagnosis is often made based on impairment of central 
vision. There is frequently later involvement of the rod photoreceptors (Michaelides 
eta!., 2006).
Stargardt disease is the most common form of macula degeneration in childhood with 
an estimated incidence of 1:10,000 (Blacharski, 1988). Disease onset is between 7 
and 12 years of age and progression is rapid, visual acuity is severely reduced 
although peripheral vision remains normal. Mutations in three genes (ABCA4, 
CNGB3 and ELOVL4, which causes a different form of Stargardt) have been shown 
to cause Stargardt disease and there is currently one mapped locus (RetNet). 
ABCA4 transcripts were initially found to be expressed exclusively in the disc 
membrane of rod outer segments (Sun and Nathans, 1997) and ABCA4 is thought to 
be involved in transport between the rod outer segments and the RPE (Sun and 
Nathans, 1997) (Section 1.3.4.3). However, Molday et al showed that ABCA4 is also 
found in cone cells of the fovea and the peripheral retina as well as in rod cells thus 
explaining the loss of central vision experienced by Stargardt patients (Molday et al.,
2000). Interestingly, there is evidence of genotype-phenotype correlations in ABCA4 
mutations with truncation mutations causing Stargardt disease, and missense 
mutations affecting uncharged amino acids leading to late-onset fundus 
flavimaculatus (FFM), an adult onset macula degeneration (Rozet et al., 1998). 
Mutations in ABCA4 have also been shown to be responsible for a number of other
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retinal dystrophies (Table 1 .1), indicating that ABCA4 is vital to the normal function of 
the retina.
1.3.3 Retinitis pigmentosa
Retinitis pigmentosa (RP) is a clinically and genetically heterogenous condition which 
results in blindness due to photoreceptor cell death, the condition commonly presents 
with night blindness as the rod photoreceptors begin to dysfunction and degenerate 
followed by peripheral vision loss as the rods continue to die. Eventually central 
vision becomes compromised as the cone photoreceptors also degenerate (Bird, 
1975). The incidence of RP has been estimated to be approximately 1 in 3,500 
(Vervoort and Wright, 2002) The name ‘RP’ is derived from the distinctive clusters of 
pigment that can be seen to overlie a depigmented fundus in RP patients; the 
pigmented clusters, known as bone-spicules, result from accumulation of pigment 
granules from degenerating RPE cells. RP is distinguished from cone rod dystrophy 
as it is principally a peripheral retinal disease, whereas cone-rod dystrophy is a 
central retinal disease. LCA and early-onset RP are harder to distinguish but LCA 
has a much earlier age of onset, is a more rapid degeneration and has an increased 
cone involvement characterised by the rapid loss of central vision compared to the 
peripheral vision loss that characterises RP. There are currently 46 known loci for 
RP with 36 causative genes cloned (Daiger et al., 2007, RetNet). RP can be 
inherited in an autosomal dominant, autosomal recessive or X-linked fashion.
1.3.3.1 Syndromic RP
RP can also occur as a phenotype in syndromes such as Bardet Biedl syndrome 
(BBS) and Usher syndrome. BBS is a genetically heterogeneous syndrome 
characterised by obesity, polydactyly, renal abnormalities and RP. The disorder is 
characterised as a cilia disease or ‘allopathy’ as primary defects in cilia, ciliary 
transport and signalling underlie the phenotype (Beales 2005). The implication is that 
the retinal phenotype may be due to defects in the connecting cilium of the 
photoreceptors. There are 12 known causative genes for BBS (OMIM, RetNet). 
Usher syndrome is a genetically heterogeneous deafness/blindness syndrome 
(Kremer et al., 2006). Interestingly, mutations in the USH2A gene have been shown 
to be responsible for arRP without hearing loss, as well as for Usher syndrome (Eudy 
et al., 1998, Rivolta et al., 2000,). Delineation of the phenotypes of Usher is ongoing, 
however some explanations are emerging. Defects in morphogenesis of the 
stereocilia bundle in hair cells, the calycal processes of photoreceptor cells, and
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defects in the synaptic processes of these cells have been shown to result in Usher 
syndrome. Also, connections to the dynamics of the actin cytoskeleton are emerging, 
more specifically the involvement of actin in cellular morphology, cell polarity and 
cell—cell interactions (Kremer et al., 2006). There are 9 known causative genes for 
Usher syndrome and 2 mapped loci (RetNet).
Senior-Loken syndrome (SLSN) is another example of a syndrome in which a retinal 
dystrophy is a phenotype, in this case LCA or RP is reported with nephronophthisis 
(anemia, polyuria, polydipsia, isosthenuria, and death in uremia) (Otto et al., 2002). 
SLSN is inherited in an autosomal recessive mode and is genetically heterogenous, 
there are currently 3 known causative genes and 1 mapped locus (OMIM). Joubert 
syndrome (JBTS), inherited in an autosomal recessive manner, has the same 
phenotype as SLSN but with additional cerebellar and cognitive impairments (Keeler 
et al., 2003, Maria et al., 1999), suggestive of a ciliary disease. There are currently 4 
known causative genes for JBTS and 2 further mapped loci (Helou et al., 2007).
1.3.4 Genes and pathways implicated in retinal diseases
Genes in which mutations have been shown to result in retinal dysfunction or 
degeneration can be broadly categorised according to their expression profile; those 
that exhibit a retina- or ocular-specific expression profile or have a known function in 
a retinal pathway, and those that are ubiquitously expressed (Table 1.1). 
Phototransduction, the visual cycle, and photoreceptor structure are all retinal- 
specific pathways or functions which when perturbed have been shown to result in 
retinal dysfunction (Sections 1.3.4.3-4).
Interestingly, mutations in ubiquitously expressed genes have also been shown to 
cause retinal dysfunction, either as an aspect of a syndromic disorder (e.g Usher 
syndrome and Bardet-Beidl syndrome) or as an isolated retinal dystrophy. For 
example, mutations in the ubiquitously expressed genes PRPF31 and RP2 cause 
retinitis pigmentosa (RP) (Section 1.3.4.2). Examples of the genes and the pathways 
implicated in retinal disease are shown in Table 1.1.
Pathway/Function Gene Reference Disease
caused
Expression
Profile
Visual cycle LRAT Thompson et al., 2001 arRP/arLCA Retina-specific
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ABCA4
RPE65
Cremers et al., 1998, 
Valverde et al., 2007 
Allikmets et al., 1997 
Morimura et al., 1998 
Gu et al., 1997
arRP 
arCRD  
ar Stargardt 
arRP 
arLCA
Retina-specific
Retinal pigment 
epithelium (RPE)
Phototransduction PDE6A
PDE6B
RHO
Dryja et al., 1999 
Bayes et al., 1995 
Gal et al., 1994 
Dryja et al., 1990 
Rosenfeld et al, 1992 
Dryja et al., 1993
arRP
arRP
adCSNB
adRP
arRP
adCSNB
Retina-specific
Retina-specific
Retina-specific
Photoreceptor
structure
RDS
(PRPH2)
Kajiwara et al., 1991 adRP Retina and 
nervous system
Retinal polarity CRB1 den Hollander et al., 1999 
den Hollander et al., 2001
arRP
arLCA
Retina and brain
Extracellular matrix USH2A Rivolta et al., 2000 ar Usher
syndrome
arRP
Broad but not 
ubiquitous
Transcription NRL
TULP1
CRX
Bessant et al., 1999 
Banerjee et al., 1998 
Hanein et al., 2004 
Freund et al., 1997 
Freund et al., 1998, 
Hanein et al., 2004
adRP/arRP
arRP
arLCA
adCRD
de novo LCA
arLCA
Retina-specific 
Retina and 
nervous system 
Retina and 
pineal gland
Cilia function RPGRIP1
RP1
BBS2
Dryja et al., 2001 
Hameed et al., 2003 
Bowne et al., 1999 
Khaliq et al., 2005 
Nishimura et al., 2001
arLCA
arCRD
adRP
arRP
arBBS
Retina and testis
Retina
Ubiquitous
mRNA splicing PRPF31
PRPF8
PRPF3
PAP1
Vithana et al., 2001 
McKie et al., 2001 
Chakarova et al., 2002 
Maita et al., 2004
adRP
adRP
adRP
adRP
Ubiquitous
Ubiquitous
Ubiquitous
Ubiquitous
Unknown function RP2 Schwahn et al., 1998 XLRP Ubiquitous
Mitochondrial function MTATP6
M TTS2
OPA1
Lamminen et al., 1995 
Mansergh et at., 1999
Alexander et al., 2000  
Delletre et al., 2000
LHON
Dominant RP 
with hearing 
loss
ad Optic
atrophy
(ADOA)
Mitochondrially-
encoded
Mitochondrially-
encoded
Ubiquitous
Table 1.1 Examples of genes and pathways implicated in retinal diseases
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1.3.4.1 Transcription
Transcription factors that control the expression of genes important for photoreceptor 
function have been shown to be causative for RP. NRL has been shown to promote 
the transcription of Rod Opsin and other retinal genes (Mears et al., 2001, 
Rehemtulla et al. 1996). CRX has also been shown to control the expression of Rod 
Opsin and act synergistically with NRL in this function (Mitton et al., 2000). 
Pathogenic mutations in CRX were shown to not only impair the DNA binding ability 
of CRX but also to reduce its interaction affinity for NRL, indicating that compromised 
control over expression of certain photoreceptor genes (e.g. Rod opsin) is likely to 
result in disease (Mitton et al., 2000).
1.3.4.2 mRNA splicing
Four pre-mRNA splicing factors have been implicated in retinal disease despite being 
ubiquitously expressed and evolutionary conserved (Sullivan et al., 2006, McKie et 
al., 2001, Chakarova etal., 2002, Maita etal., 2004). The mechanism by which these 
splicing factors result in disease remains unclear, but other neurodegenerative 
disorders (e.g. amyotrophic lateral sclerosis) have also shown to be caused by 
defects in pre-mRNA splicing (Grabowski and Black, 2001) A study by Mordes et al 
has investigated retinal transcripts which are affected by mutations in one of this 
group of genes; PRPF31. In this study, using immunoprecipitations and microarrays, 
it was found that mutated PRPF31 led to a reduced expression of RDS/PRPH2 which 
is an important retinal protein involved in photoreceptor structure (Mordes et al., 
2007). Mutations in RDS also lead to RP, thus indicating that mutations in 
ubiquitously expressed splicing factors can result in alterations of retinal-specific 
gene expression (Mordes etal., 2007).
1.3.4.3 Visual cycle and phototransduction
The visual cycle involves the recycling of all-frans-retinal back to 11-c/s-retinal after 
photoactivation, which occurs in the RPE. Dysfunction of this process can result in 
RP. RPE65, for example, is involved in the isomerisation of all-frans-retinol to 11-c/s- 
retinol and mutations in this gene can result in arRP and LCA (Morimura et al., 1999, 
Gu et al., 1997). Furthermore, another protein involved in the visual cycle has been 
shown to the causative gene for Stargardt retinal dystrophy, RP and CRD: ATP 
binding cassette transporter rods (ABCA4) (Allikmets et al., 1997) (Section 1.3.2), 
has been shown to transport retinoids across the outer segments of the rods (Azarian
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et al., 1997, Cremers et al., 1998) and mutations in ABCA4 result in accumulation of 
lipofuscin in the RPE, indicating defects in the transport between the RPE and rod 
outer segments leading to retinal dysfunction (Sun and Nathans, 1997).
Phototransduction is a vital process for normal vision (section 1.2.4) and as such 
proteins involved in this process have been shown to be causative for RP. For 
example, mutation of the rod opsin which, combined with the chromophore 11 -c/s 
retinal, forms the visual pigment rhodopsin, can result in RP or CSNB (Dryja et al., 
1990). Rhodopsin is involved in the initiation of the phototransduction cascade when 
a photon of light strikes rhodopsin and causes the isomerisation of the chromophore 
(section 1.2.4). Mutations in rod opsin have been characterised according to the 
affect the mutation imparts, for example mutations have been shown to prevent the 
correct localisation of rhodopsin, to cause the proteins to misfold and be retained in 
the ER, to be constitutively active or to have an increased activation rate for 
transducin (Mendes et al., 2005) (section 1.2.4). All of these defects in the normal 
function of rhodopsin lead to abnormal phototransduction and eventually RP.
Rod phosphodiesterase is a heterotrimeric enzyme responsible for the hydrolysis of 
cGMP in early phototransduction which leads to a decrease in cGMP and closure of 
the cGMP-gated channels in the photoreceptor plasma membrane (section 1.2.4). 
Mutations in both the alpha and beta subunits of rod phosphodiesterase have been 
shown to be responsible for RP (Bayes et al., 1995, Bowes et al., 1992, Huang et al.,
1995). Furthermore mutations in the gene encoding the cGMP channel also result in 
autosomal recessive RP (Bareil et al., 2001). The exact mechanisms by which 
defective phototransduction leads to rod cell death and RP remains to be fully 
elucidated.
1.3.4.4 Photoreceptor structure and cilia
Photoreceptor structure is crucial for the detection and correct processing of light. 
Mutations in RDS which has been shown to be important for OS disc morphogenesis 
result in ADRP (Arikawa et al., 1992). Proteins localised to the connecting cilia have 
been shown to cause retinal disease (e.g. RPGR and RP1) (Hong et al., 2003, Liu et 
al., 2002), as have proteins that disrupt the I FT system of the cilia (e.g. IFT88 ) 
(Pazour et al., 2002). Therefore transport through the connecting cilium is absolutely 
required for normal retinal function and perturbation of this function can lead to 
disease (Sections 1.2.3.1, 1.3.3.1, 1.3.5.1).
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1.3.4.5 Other retinal disease pathways
Mutations in mitochondrial genes have also been shown to result in retinal disease. 
Keams-Sayre syndrome which is caused by deletions in mtDNA, can include RP and 
progressive hearing loss among its symptoms (Kogelnik et al., 1996). Although 
unraveling how mitochondrial mutations result in retinal disease is inherently 
complex, it has been suggested that the high energy requirements of the ganglion 
cells may be important to pathogenesis. In Leber's hereditary optic neuropathy 
(LHON), caused by mutations in MTATP6, there is notable ganglion cell death, 
implying these neurons are significantly affected (Careli et a!., 2004). Optic atrophy, 
which is characterized by ganglion cell degeneration and eventual optic nerve 
atrophy, has also been reported to be caused by mutations in OPA1, a gene 
important for mitochondrial function (Alexander et al., 2000, Delletre et al., 2000). 
Interestingly, despite the specificity of the degeneration in optic atrophy, OPA1 was 
found to be expressed in the inner and outer plexiform layers and the inner nuclear 
layer as well as the ganglion cell layer (Aijaz et al., 2004). A mouse model of 
autosomal dominant optic atrophy (ADOA) with a mutation in OPA1 was observed to 
have mitochondrial dysfunction and visual defects, indicating that the neural atrophy 
in ADOP may be due to abnormal mitochondrial function (Davies et al., 2007).
Retinal development is also a key pathway that may be disrupted and lead to retinal 
dystrophy, for example mutations in the CRB1 gene cause retinal disease (den 
Hollander et al., 1999, den Hollander et al., 2001). A study of a mouse model with a 
mutation in the Crb1 gene exhibits shortened inner and outer segments of the 
photoreceptors as early as two weeks after birth leading the authors to suggest that 
there is a defect in photoreceptor development and differentiation, rather than 
degeneration (Mehalowetal., 2003).
1.3.5 X-linked retinits pigmentosa
X-linked retinitis pigmentosa (XLRP) is regarded as the most severe form of RP with 
early onset and rapid disease progression resulting in clinical blindness by the fourth 
decade of life (Bird, 1975). Female carriers tend to exhibit a milder phenotype than 
hemizygous males which is due to random X-inactivation. XLRP is estimated to 
account for 6-17% of familial RP cases (Vervoort and Wright, 2002). There are 
currently six mapped loci on the X chromosome for RP (see Table 1.2). For four of 
these loci the causative gene is not known. The causative gene for the RP3 locus 
has been shown to be Retinitis pigmentosa GTPase regulator (RPGR) (Meindl et al.,
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1996, Roepman et al., 1996) and for the RP2 locus the disease gene has been 
named RP2 (Schwahn et al., 1998).
Genetic Locus Symbol Causative
Gene
Reference
Xq26-q27 RP24 ? Gieser etal., 1998
Xp11.4 RP3 RPGR Musarella etal., 1988
Xp21.3-p21.2 RP6 ? Ott etal., 1990
Xp22 RP23 ? Hardcastle et al., 2000
Xp11.23 RP2 RP2 Bhattacharya etal., 1984
Xq28-qter RP34 ? Melamud etal., 2006
Table 1.2 The six known XLRP loci
1.3.5.1 Retinitis pigmentosa GTPase regulator (RPGR)
RPGR is a large gene which spans approximately 60 kb of genomic DNA. Originally 
RPGR was described as having 19 exons (Meindl et al., 1996, Roepman et al.,
1996). However studies of potential alternative splicing of RPGR revealed the 
presence of an alternative 3’ terminal exon, named ORF15, in which many RP- 
causing mutations were located (Vervoort et al., 2000). ORF15 has been described 
as a mutational hotspot: in one study of 47 families 60% of XLRP cases were due to 
mutations found in ORF15 of RPGR (Vervoort et al., 2000; Breuer et al., 2002). 
Expression studies showed that RPGR is ubiquitously expressed (Meindl etal., 1997) 
but a study by Vervoort et al showed that the RPGR transcript containing the 
alternatively spliced ORF15 exon was only detected in testis and retina. Therefore it 
is possible that ORF15-containing transcripts have a retina-specific role (Vervoort et 
al., 2000 ).
The RPGR protein contains a domain conserved with another protein; an RCC1-like 
domain. RCC1 is a guanine exchange factor (GEF) for the small GTP-binding protein 
RAN which has led to the speculation that RPGR may also act as a GEF for a 
GTPase. Many of the mutations in RPGR, excluding those found in ORF15, are 
found in this domain. Meindl et al showed that many of the residues affected by RP- 
causing missense mutations were conserved residues in the RCC1-like domain 
(Meindl etal., 1996).
RPGR has been localised to the connecting cilia in rods and cones in retina (Hong et 
al., 2003). The RCC1-like domain of RPGR was shown to interact with a novel
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protein, RPGRIP1, using yeast two-hybrid (Boylan et al., 2000, Roepman et al.,
2000). Interestingly RPGRIP1 is photoreceptor-specific and has been shown to be a 
causative gene for LCA and CRD (Gerber et al., 2001, Hameed et al., 2003), (section 
1.3.1), implying that this interaction is important for normal retinal function as both 
proteins are implicated in retinal disease. RPGR has been shown to localise to the 
ciliary axoneme in photoreceptors where it co-localised with RPGRIP1, furthermore 
this localisation pattern was lost in the Rpgripl knock-out mouse, implying the 
interaction is important for the localisation of RPGR (Pawlyck et al., 2005). Recently 
a homolog of RPGRIP1 has been identified; RPGRIP1L (Arts et al., 2007). 
RPGRIP1L was found to be ubiquitously expressed and has been localised to basal 
bodies (Arts et al., 2007). The gene has also been reported to be causative for 
Joubert syndrome, a syndrome consistent with defects in cilia (Arts et al., 2007, 
Delous et al., 2007, section 1.3.3.1). In retina the protein was found to localise to the 
connecting cilium, further strengthening the proposed role for the protein in cilia (Arts 
et al., 2007).
Another of RPGR’s interacting proteins, PDE 5, which also interacts through the 
RCC1-like domain of RPGR, is ubiquitously expressed (Linari et al., 1999). 
Mutations in RPGR have also been shown to result in CORD, (described in 1.3.2), 
atrophic macular atrophy and syndromal retinal dystrophies with ciliary dyskinesia, 
sensorineural hearing loss, and respiratory problems thus implying a wider role for 
RPGR outside the retina, and a role in cilia function (Zito et al., 2003, lannaccone et 
al., 2004, Shu et al., 2007). The putative retina-specific ORF15 isoform of RPGR has 
also been shown to interact with Nucleophosmin 1 (NPM), a nuclear chaperone 
thought to have a role in centrosome duplication (Shu et al., 2005). Shu et al (2005) 
also report that RPGR and RPGRIP1 co-localise at basal bodies in ciliated cells and 
that RPGR and NPM co-localise at metaphase centrosomes (Shu et al., 2005). The 
mechanism by which mutations in RPGR result in retinal disease remains unclear but 
the implication is that RPGR is involved in an important cilia-related pathway.
1.4 RP2
The only other identified gene in which mutations result in XLRP is RP2. RP2 maps 
to Xp11.3 and was cloned by Schwahn and colleagues (Schwahn et al., 1998). 
Phenotypically, mutations in RPGR and RP2 are indistinguishable.
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1.4.1 RP2 gene
RP2 is a ubiquitously expressed 5 exon gene which codes for a 350 amino acid 
protein, RP2 (Schwahn et al., 1998, Chappie et al., 2000). Mutations in RP2 account 
for between 7-20% of XLRP cases (Hardcastle et al., 1999, Sharon et al., 2003; 
Vorster et al., 2004). Mutations in RP2 have also been shown to be a cause of 
macular and peripapillary atrophy, thus expanding the clinical phenotype to central 
retina, as opposed to peripheral retina, disease (Dandekar etal., 2004).
There are currently 53 reported mutations in RP2 leading to RP (Table 1.3). The 
majority of RP2 mutations are predicted to result in premature truncation of the 
protein (67%), missense mutations account for 22% of the reported mutations in RP2 
while the other 11% are splice-site mutations. The majority of the missense 
mutations cluster in the N-terminus of the protein but there are 2 missense mutations 
in the C-terminal half of the protein (R211H and L253R). The mutated residues are 
likely, therefore, to be key to either the structure or function of the RP2 protein.
The most common mutation is the Arg120Stop mutation, resulting in no detectable 
protein (Grayson et al., 2002b) (Table 1.3). It has been proposed by Vorster et al 
that this residue acts as a mutational hotspot since the mutation is found in several 
families with different ethnicities. Vorster and colleagues also present evidence of 
the mutation occurring as a de novo mutation, in this instance as a germ line mutation 
in the obligate carrier mother (Vorster et al., 2004). Patient mutations also imply that 
the R118 residue is significant to the function of RP2. This residue has been mutated 
to histidine, cysteine, or leucine in different XLRP families, and while the R118H 
mutation is the most common variant, the high incidence of missense mutations at 
position 118 supports its significance to the normal function of RP2 (see Table 1.3). 
Furthermore the pathogenic E138G mutation has been analysed by Kuhnel et al and 
was found to disrupt the formation of a salt bridge in the protein which is required for 
the correct placement of the R118 residue, implying that the R118 residue must be 
specifically located to be catalytically active (Kuhnel et al., 2006). There is currently 
no evidence of genotype-phenotype correlation for RP2 mutations, suggesting that 
missense mutations either result in no functional protein due to misfolding, or alter the 
function or localisation of the protein to the equivalence of a null mutation. The 
mutation spectrum of RP2 suggests that the development of RP results from a total 
loss of RP2 protein.
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R118L
R118H
R118C
C105W
C86Y
C67Y
E138G
S140F
L188P
I R211H I
R120X W186X
E183X
E18X
Q26X Q134X
Y27X W150X
Y151X
INTRON/
EXON
POSITION CHANGE CONSEQUENCE REFERENCE
ALL Gene deletion Pelletier et al. 2007
Exon 1 delete all Truncated protein Bader et at 2003
Exon 1 16-18 Delete 3 bp AS6 Schwahn e ta l 1998; Rosenberg e ta l. 1999;
Exon 1 77/78 Insertion CA Q26fsX19 Mears e ta l  1999
Intron 1 IVS1+3A>T Splice site mutation Sharon et al. 2000
Intron 1 IVS1+3A>G Splice site mutation Breuer et a l .2002
Intron 1 LINE 1
retrotransposition
Not known Schwahn e ta l 1998
Intron 1 IVS1-2A>G Splice site mutation Vigo e/ al. ARVO 2000; Miano et al. 2001
Exon 2 292 Insert A Gly98fsX123 Pelletier et al. 2007
Exon 2 297 Insert 5 bp Ser99fsX114 Pelletier et al. 2007
Exon 2 301 Delete T F101fsX11 Pelletier et al. 2007
Exon 2 302 or 299 Insertion T F101faX22 Vigo et a l ARVO 2000; Miano e t a l 2001; 
Garcla-Hoyos et a l 2006
Exon 2 330-342 del 330-342 C110fsX40 Mears et al 1999
Exon 2 350-351 350-351 del F117fsX38 Breuer et al. 2002
Exon 2 409 Del 3 bp (ATT) AI137 Sharon et al. 2000, Breuer et a l 2002
Exon 2 419-426 Del 8 bp S140fsX151 Pelletier et al. 2007
Exon 2 453 Delete 1 bp (C) Y151fsX1 Schwahn e ta l. 1988
Exon 2 483/484 Insertion GGGCTAA D161fsX13 Mears e ta l  1999
Exon 2 515 Insert G at 515 S172fsX1 Breuer et al. 2002
Exon 2 538-539 Del 2 bp (GT) V180fsX38 Pelletier et al. 2007
Exon 2 670 Insert C at 670 R225fsX9 Breuer e ta l  2002
Exon 2 688-692 Delete 5 bp Q229fsX2 Hardcastle et al. 1999: 
Sharon et al.
Exon 2 723 Delete 1 bp (T) 
723delT
F241feX12 Thiselton et al. 2000
Intron 2 IVS2-1G>A Splice site mutation Pelletier ef al. 2007
Exon 3 796-799 Delete 4 bp 
(CAGA)
V265fsX3 Thiselton et a l 2000; Sharon e t a l 2003
Exon 3 801-804 Del 4 bp (AAAG) T267fsX4 Pelletier et a l 2007
Exon 3 834 2bp insertion Q278fsX15 Mashima et al. 2000
Exon 3 853 853/854insG F284fsX4 DeLuca et al. 2001
Exon 4 Delete entire exon Schwahn e ta l. 1998
Exon 4 925/926 Insertion AG V308fsX7 Mears et a l 1999
Exon 4 929 Insertion 1 bp (T) E309fsX18 Hardcastle ef a l 1999
Intron 4 IVS4+3A—fC Splice site mutation Sharon et al. 2003
Intron 4 IVS4+3A—+G Splice site mutation Sharon et al. 2003
Table 1.3 All reported mutations in the RP2 gene
A Schematic of RP2 showing exon structure and the positions of all known missense 
(above) and nonsense (below) pathogenic mutations. Shaded areas indicate coding 
sequence B Table showing all reported insertion, deletion and frameshift mutations 
in RP2.
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1.4.2 RP2 sequence homology
RP2 protein has sequence similarity to two defined domains of other proteins. At the 
N-terminus there is a region homologous to tubulin specific cofactor C (TBCC) and 
the C-terminus of RP2 exhibits homology to the nucleoside diphosphate kinase 
(NDK) domain (Figure 1.5).
CAP/CARP CAP/CARP______________  NDK-homology
TBCC/TBCCD1-like homology 
Figure 1.5 Schematic representation of the RP2 protein
Schematic diagram of RP2 showing the TBCC homology domain (42-192) and the C- 
terminal NDK homology domain (251-346). The N-terminal acylation motif 
(MGCFFS) is shown by the two tags representing the myristoylation and 
palmitoylation that RP2 undergoes which results in its plasma membrane localisation.
1.4.2.1 The TBCC/TBCCD1 homology domain
TBCC is involved in the folding of native tubulin and will be discussed further in 
section 1.5. The TBCC homology domain in RP2 stretches over 151 amino acids, 
from position 42-192 (Figure 1.5). This region shows 30.4% identity with TBCC and 
43.7% similarity (Schwahn et al., 1998). The TBCC-RP2 homology covers a region 
which includes homology to the C-terminal domain of cyclase associated protein (C- 
CAP). Cyclase associated proteins (CAPs) are involved in binding to actin 
monomers and regulating the remodelling of actin in response to extracellular and/or 
intracellular signalling and are conserved among eukayotes (Stevenson and 
Theurkauf, 2000). Within the C-CAP region lie 2 CARP domains, the CARP domains 
are the actin binding domains of C-CAP. The CARP domain is found as a tandem 
repeat in the C-terminal of many CAPs (Ponting et al., 2001). The presence of two 
CARP domains in tandem suggests there may be an ability for TBCC, and RP2, to 
bind to actin. There is currently no experimental evidence to suggest whether the 
CAP/CARP domains are functional in TBCC or RP2.
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A novel protein with homology to both RP2 and TBCC has been identified (personal 
communication, Alison Hardcastle, Celene Grayson thesis), named TBCC domain 
containing 1 (TBCCD1) (Accession No. AK001422.). The region of homology 
between the 3 proteins extends over the same residues as the RP2 TBCC-homology 
domain (RP2:42-192; TBCC: 186-339 and TBCCD1:312-464) (shown in Figure 1.6). 
Many of the reported pathogenic missense mutations in RP2 are found in the 
TBCC/TBCCD1 homology domain (Table 1.3), implicating the domain has an 
important function. Figure 1.6 shows that all but one of the reported pathogenic 
mutations in RP2 is conserved between either RP2 and TBCC or RP2 and TBCCD1. 
In 2006, Garcia-Hoyos et al reported the first missense mutation in RP2 (Ser140Phe) 
in the TBCC homology domain that is not conserved with either TBCC or TBCCD1 
(Garcia-Hoyos et al., 2006). The serine 140 residue makes up part of the “Ser/Cys” 
stack in the predicted RP2 structure which stabilizes the p-helix (Dodatko et al., 2004, 
section 1.3.4), and as such a non-conservative change at this residue is likely to 
destabilize the protein and this is likely to be the reason for disease (see section 
1.4.4).
1.4.2.2 The NDK homology domain
RP2 also has a region of homology to nucleoside diphosphate kinase (NDK) at the C- 
terminus of the protein. The domain spans 95 amino acids (from aa251 to aa346) 
and exhibits 21% identity and 43% similarity to E.coli NDK (Figure 1.5). Nucleoside 
diphosphate kinases are enzymes involved in synthesis of nucleoside triphosphates 
(NTP), but not ATP. They provide NTPs (including GTP) for numerous processes 
within the cell, for example, signal transduction and microtubule polymerisation 
(Nickerson and Wells, 1984, Patel-King et al., 2004). There is evidence that NDK 
proteins may also be involved directly in DNA processing (Postel et al., 2003), 
although this has been disputed (Bennett et al., 2004). Alignment of RP2 with E.coli 
NDK indicates that the conserved catalytic histidine residue (at position 117 in E.coli) 
required for NDK function is not present in the RP2 NDK-homology domain, and is 
instead replaced with a phenylalanine residue. RP2 is also lacking the complete 
substrate-binding domains for NDK activity found in E.coli NDK, suggesting that it 
may not exhibit NDK function (Yoon et al., 2006). Whether this domain exhibits any 
residual NDK activity or any other function associated with NDK proteins has been 
investigated recently and will be discussed in Chapter 5.
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186
TBCC
TBCCD1
339
557
RP2
42 189
1 ^  \  350
TBCC FSNLESQVLEKRASELHQRDVLLTELSNCTVRLYGNPNTLRLT
TBCCD1 MSQVYKQT LAKS S DTLAGAHVKIHRCNE SFIYLLS PLRSVTIE
RP2 FSGLKDETVGRLPGTVAGQQFLIQDCENCNIYIFDHSATVTID
*  *  *  *
TBCC KAHSCKLLCGPVS T SVF LE DCS DCVLAVACQQLR T H S TKDTRI
TBCCD1 KCRN SIFVL GPVG T TLHL H SC DNVKVIAVC HRL SISSTTGCIF
RP2 DCTNCIIFLGPVKGSVFFRNCRDCKCTLACQQFRVRDCRKLEV
TBCC FLQVTSRAIVEDCSG-IQFAPYTWSYPEIDKDFESSGLDRSKN
TBCCD1 HVLTPTRPLILSGNQTVTFAPFHTHYPMLEDHMARTGLATVPN
RP2 FLCCATQPIIESSSN-IKFGCFQWYYPELAFQFKDAGLSIF DN
TBCC NWNDVDDF-NWLARDMASPNWSILPE
TBCCD1 YWDKPMWCRENSDTR VFQLLPP
RP2 TtfSN IHDF-TPVSGEL NWSLLPE
Figure 1.6 Alignment of RP2, TBCC and TBCCD1
Schematic diagram showing the region of homology shared by RP2, TBCC and 
TBCCD1 and the amino acid sequence of the homology domain. Residues marked 
in blue are those conserved between RP2 and TBCC, red are conserved between 
RP2 and TBCCD1 and green are conserved between TBCC and TBCCD1. Residues 
marked in bold are conserved between all three proteins. The R118 residue in RP2 
is underlined. Asterisks denote residues that are mutated in RP2 in families with RP.
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1.4.3 Cellular localisation of RP2
RP2 has a signature motif for dual acylation at its N-terminus. This motif of Met-Gly- 
Cys-X-X-Ser facilitates myristoylation at G2 and subsequently facilitates 
palmitoylation at C3. As a consequence the RP2 protein is targeted predominantly to 
the plasma membrane in all cell lines tested (Chappie et al., 2000, Chappie et al., 
2002). The 3bp in-frame deletion, AS6 , which is a pathological mutation was one of 
the first mutations investigated. Chappie and colleagues showed that the AS6 
mutation prevented the normal targeting of RP2 to the plasma membrane. The loss 
of serine at position 6 prevents this dual acylation, and as a consequence the protein 
is mis-targeted in the cell which may be the mechanism of disease. This was not 
observed for the Arg118His mutant, which localised to the plasma membrane 
(Chappie et al., 2000; Chappie et al., 2002). Furthermore a mutation has been 
recently reported by Pelletier and colleagues (2007) in which the Glycine 2 residue, 
which is part of the myristoylation consensus sequence, is mutated to Valine (Table
1.3), the consequence being the loss of the myristoylation modification which would 
be predicted to result in cellular mislocalisation of RP2 (Pelletier et al., 2007). An 
engineered mutation G2A did indeed result in the mislocalisation of RP2 (Chappie et 
al., 2000 ).
RP2 localised predominantly to the plasma membrane in all cells of the retina, 
including the rod and cone photoreceptors (Grayson et al., 2002) (Figure 1.7). It was 
also observed that there was no enhanced staining of RP2 in any of the 
photoreceptor organelles. RP2 was not observed to be sorted to macro-domains of 
the membrane (Grayson et al., 2002) but extended from the tips of the outer 
segments through to the outer plexiform layer (OPL) (Grayson et al., 2002) (Figure 
1.7). RP2 appeared to localise to the cytoplasmic face of the plasma membrane as 
expected from previous staining of all cultured cells tested (Grayson et al., 2002, 
Chappie etal., 2000, Schwahn etal., 2001).
1.4.4 RP2 protein structure
Dodatko et al (2004) reported a predicted structure for the N-terminal domain of RP2 
based on the structural similarity of this region of RP2 with the C-terminal domain of 
cyclase associated protein (C-CAP) (see section 1.4.3.1) (Dodatko et al., 2004, 
Evans et al., 2006). The structure was predicted to be a p-helix, from this structure it 
can be speculated as to what effects some of the pathogenic RP2 mutations may 
have on the protein. For example the Cys67Tyr and Cys86Tyr mutations would both
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Figure 1.7 Localisation of RP2 in human retina
Immunohistochemical analysis of the localisation of RP2 in peripheral human retina. 
NFL, nerve fibre layer; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner 
nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; IS, inner 
segments; OS, outer segments. Arrowheads are used to highlight plasma membrane 
staining for RP2. RP2 is seen in cells throughout the retina. Scale bar is 10 pm. 
From Grayson et al., 2002.
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appear to destabilise the protein as the Cys residues form part of the ‘backbone’ of 
the helix and the non-conservative change from Cys to Tyr would almost certainly 
cause destabilisation of the protein (Dodatko et al., 2004). The crystal structure of 
RP2 has been solved recently and will be discussed further in section 4.7 (Kuhnel et 
al., 2006).
1.5 Tubulin and the cytoskeleton
1.5.1 The cytoskeleton
Microtubules comprise an important part of the cytoskeleton of the cell which acts as 
a scaffold for the cell, maintaining shape and assisting in cellular movement and 
providing a network for internal vesicular trafficking. The main components of the 
cytoskeleton include microfilaments comprising actin, intermediate filaments 
comprising, for example, lamin and vimentin, and microtubules comprising tubulin.
Microtubules are polar and consist of tubulin heterodimers, made up of two subunits, 
a and p. Microtubules are believed to exist in either a slowly growing or a rapidly 
shrinking state. This is controlled by the hydrolysis and binding of GTP by the 13- 
subunit (Kirschner and Mitchison, 1986) such that when the p-subunit is bound to 
GTP the tubulin dimers assemble into microtubules and when the p-subunit 
hydrolyses the bound GTP the microtubules disassemble. The microtubule 
organising centre (MTOC) is where the microtubules are nucleated and a third form 
of tubulin is found here, y-tubulin, which is involved in the initial assembly of the 
tubulin heterodimers into microtubules (Moritz etal., 1995).
1.5.2 Tubulin folding model
As described in section 1.4.3.1 RP2 contains a homology domain to TBCC. TBCC is 
one of five cofactors implicated in the tubulin folding pathway. TBCC has been 
proposed to facilitate the release of the native a/p heterodimer by inducing the 
formation of a complex containing a tubulin, p tubulin, Cofactor E and Cofactor D 
(Tian et al, 1996). The specific role for each of the cofactors in this pathway are not 
fully understood but a model for the process has been proposed by Bhamidipati et al 
(2000) (Figure 1.8).
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Figure 1.8 shows the proposed pathway which leads to the generation of correctly 
folded tubulin forming the microtubules. Unfolded a- and fB-tubulin are brought to the 
cytosolic chaperonin (CCT) by prefoldin (PFDN), which interacts directly with CCT to 
allow the transfer of the polypetides (Vainberg et al. 1998). The model proposed by 
Bhamidipati et al suggests that CCT then assists in the folding of tubulin monomers 
(Martin, 2000), and releases them to allow completion of their folding, aided by the 
tubulin cofactors. Tubulin specific cofactor A (TBCA) then binds to the p-tubulin 
monomer and tubulin specific cofactor B binds to the a-tubulin monomer. These 
intermediate complexes of A-p and B-a then transfer the tubulin subunits to cofactors 
D (TBCD) and E (TBCE) respectively, at which point cofactor C (TBCC) binds to form 
a complex of TBCC, TBCD and TBCE with a- and p-tubulin. This tubulin-cofactor 
complex exhibits tubulin-GAP activity, the hydrolysis of GTP to GDP acts as a switch 
mechanism for the release of the native tubulin heterodimer which can now 
polymerise into microtubules when the p-subunit binds GTP (see Figure 1.8) 
(Bhamidipati et al., 2000).
RP2 was shown to be able to stimulate the GAP activity of p-tubulin in combination 
with TBCD, substituting for TBCC in this function (Bartolini et al., 2002). However, 
RP2 was not able to substitute for TBCC in the heterodimer assembly pathway 
(Bartolini et al., 2002). It is thought that GTPase activators have a relatively 
conserved active site which includes an arginine finger (Scheffzek et al., 1998). It 
has been proposed that the Arg118 residue of RP2 and the Arg262 in TBCC may 
form a crucial part of this arginine finger, since they are the only conserved arginine 
residues between RP2 and TBCC (Figure 1.6). When these arginine residues in RP2 
and TBCC were mutated by Bartolini and colleagues, the tubulin-GAP activity of both 
TBCC and RP2 was abolished (Bartolini et al., 2002). This suggests the loss or 
mutation of the arginine residue at position 118 causes the RP2 protein to lose a 
crucial function which results in the development of retinitis pigmentosa (see Table
1.3). There is an Arginine residue in TBCCD1 (at position 386) (Figure 1.6) close to 
the conserved residue between RP2 and TBCC which may also be the catalytic 
residue for an arginine finger in TBCCD1.
1.5.2.1 Regulation of tubulin folding
There are some additional mechanisms of regulation throughout various aspects of 
the tubulin folding pathway. Gigaxonin is mutated in human giant axonal neuropathy 
(GAN), a neurodegenerative disorder with an autosomal recessive mode of
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Figure 1.8 A model for tubulin folding
Schematic showing the proposed mechanism by which nascent tubulin is folded and incorporated to form microtubules. The 
cytosolic chaperonin (CCT) receives the unfolded tubulin polypetide chains from prefoldin (PFDN). The involvement of the tubulin 
cofactors (TBCA-E) and the regulation of TBCD by Ar12 is shown. Adapted from Bhamidipati et al, 2000 with additional information 
from Wang etal, 2005 and Vainberg etal, 1998.
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inheritance (Bomont et al., 2000). One of the characteristics of the disease is 
cytoskeletal abnormalities including reduced microtubule levels, suggesting gigaxonin 
has a role in normal cytoskeletal function (Yang et al., 2007). Gigaxonin has also been 
shown to interact with TBCB (see Figure 1.8) and to target it for degradation via the 
ubiquitin-proteasome pathway (Wang et al., 2005). The levels of TBCB were examined 
in gigaxonin knock out mice and found to be elevated compared to wild type animals, 
implying that the loss of gigaxonin directly results in accumulation of TBCB. 
Consequently, when TBCB was over-expressed in COS7 cells the authors noted a 
reduction in microtubules, thus confirming that the loss of microtubules in gigaxonin null 
mice can be explained by the lack of degradation of TBCB (Wang et al., 2005). 
Overexpression of TBCD has also been shown to have a destabilising effect on 
microtubules implying the regulation of the levels of the tubulin cofactors is crucial to the 
maintenance of the cytoskeleton (Bhamidipati etal., 2000, Martin etal., 2000).
A novel protein related to TBCE has been identified by Bartolini and colleagues (2005). 
This protein, E-like, was shown to be important for microtubule dynamics (Bartolini et al., 
2005). Over-expression of E-like resulted in tubulin depolymerisation and degradation of 
microtubules, while suppression of E-like led to an increase in the amount of stable 
microtubules (Bartolini et al., 2005). E-like appears to exert a direct effect on the folding 
of tubulin as when it is over-expressed, the depolymerised tubulin was noted to be 
misfolded and targeted to the proteosome for degradation. The authors suggest that E- 
like has a role in the turnover of microtubules (Bartolini et al., 2005). The identification of 
E-like and the as yet undefined role of TBCCD1 (described in section 1.4.2.1) implies 
there is an additional level of control involved in the tubulin folding pathway that is still to 
be elucidated.
ADP-ribosylation factor (Arf)-like 2 (Arl2) has also been shown to be involved in the 
regulation of the tubulin cofactor TBCD (Bhamidipati et al., 2000). Loss of Arl2 function 
has been shown to result in a loss of microtubule stability (Hoyt et al., 1990, Radcliffe et 
al., 2000). Ari2 has been shown by Bhamidipati and colleagues to regulate the binding 
of TBCD to tubulin and the microtubule destabilisation induced by over-expression of 
TBCD in HeLa cells can be rescued by co-expression of Ari2 (Bhamidipati etal. 2000).
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1.6 ADP-ribosylation factor (Arf)-like proteins
The ADP-ribosylation factor (Arf)-like (Arl) family of proteins is part of the Ras 
superfamily of small GTPase proteins (Fan et al., 2004) (Figure 1.9). As part of the Arf 
protein family, the mammalian Arls have approximately 40-60% protein sequence
identity with Arfs. They have been classed as Arf-like because although they are similar
in sequence to Arfs, there are considerable functional differences between the proteins. 
While Arfs are characterised by their ability to activate cholera toxin-catalysed ADP 
ribosylation, activate phospholipase D and complement the lethal arf1-/arf2- mutation in 
S.cerevisiae, Arls do not possess these functional characteristics (Tamkun et a!., 1991; 
Amor etal., 2001). Arl1 is the exception with a very weak ability to act as a functional Arf 
(Hong et al., 1998). The GTP-binding ability of Arl proteins means that they are able to 
adopt two conformations: an ‘active’ conformation when GTP-bound, and an ‘inactive’ 
conformation when GDP-bound (Burd etal, 2004).
------------------------------------------------------------------------------------------ Arl1
  ------------------------------------ Arl5
—   Arl8
------------------------------------------------------- Arl4
----------------------------------------------------- Arl7
----------------------------------------------------------------------------------- Arl2
--------------------------------------------------------------------------------- Arl3
 ----------------------------------------------------------------------------------------------------------------Arl6
Figure 1.9 Phylogenetic analysis of Arl family members
Phylogentic tree of human Arl family members 1-8 using a ClustalW alignment 
programme based on human protein sequences. Arl2 and Arl3 are close phylogenetic 
relatives.
1.6.1 Arl3
Since Arl2 was shown to be an important regulator of tubulin biogenesis (Figure 1.7) and 
RP2 has a region of homology to TBCC (Figure 1.5), a targeted approach was adopted 
to search for an Arl that interacted with RP2. Arl2, Arl3, and Arl4 were tested for an 
interaction with RP2. Ar13 was shown to interact with RP2 (Bartolini et a!., 2002). The 
interaction is dependent on Ar13 being in the active GTP-bound state rather than GDP- 
bound, and appeared to be enhanced if RP2 was not myristoylated (Bartolini et al., 
2002).
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Arl3 was found to be a microtubule associated protein (MAP) in a study by Grayson et al 
(2002) in which Arl3 was observed to localise to microtubule structures (Grayson et al., 
2002). Arl3 was shown to exhibit enhanced microtubule localisation following 
stabilisation of the microtubule network with taxol and shown to be redistributed to the 
nuclear membrane when microtubules were depolymerised (Grayson et al., 2002). Arl3 
was also co-purified with microtubules from bovine brain, indicating that Arl3 behaves as 
a MAP (Grayson et al. 2002).
The localisation of Arl3 in the retina has also been studied by Grayson et al (2002) in 
which it was found that Arl3 was enriched in the photoreceptor connecting cilium of both 
rods and cones, which was in contrast to the plasma membrane staining exhibited by 
RP2 throughout the photoreceptors in the retina (Grayson et al., 2002). Using an RP2 
patient-derived lymphoblastoid cell line (the patient had an Arg120Stop mutation) there 
was no effect on the expression level of Arl3 with the loss of functional RP2 (Grayson et 
al., 2002). As such the cellular and retinal site of the RP2-Ar13 interaction has yet to be 
elucidated, as does the functional significance of the interaction.
Further to the reported connecting cilium localisation of Arl3 (Grayson et al., 2002) there 
is evidence that Arl3 is important to general cilia function. A study in Leishmania showed 
that overexpression of a the GTP-bound form of Z_cfArl3A in Leishmania led to shortened 
flagella implying LdArl3A is required for the normal development of this ciliated structure 
(Cuvillier et al., 2000). Although LdAr13A appears to be a homolog of Arl3 the study 
showed that LdArl3A was myristoylated, and that when a mutant in which myristoylation 
is prevented (G2A) is overexpressed the resultant viability defect in the cells, and 
cytoplasmic staining pattern, was the same as seen with the inactive GDP-bound mutant 
(Cuvillier et a/., 2000). There is currently no evidence that human Arl3 is myristoylated 
or is able to localize to the membrane of any cellular organelle, and as such it is possible 
that Lc/Arl3A is not functionally comparable to human Arl3. A recent report of an Arl3 
knockout mouse further implicates Arl3 in normal cilia function, and this will be discussed 
in Chapter 4 (Schrick et al., 2006). Furthermore, Arl3 was detected in the photoreceptor 
sensory cilium complex proteomic screen performed by Liu and colleagues (Liu et al., 
2007).
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1.6.2 Ar12
Arl2 is the closest phylogenetic relative of Arl3 (Figure 1.9). The S.cerevisiae homolog of 
Arl2, CIN4, is essential for microtubule stability. The fission yeast homolog of CIN4, 
Alp41, when knocked out results in microtubule instability and polarity-based growth 
defects. Radcliffe and colleagues used genetic studies to show that in fission yeast 
Alp41 acts upstream of the TBCD homolog in the “cofactor-dependent pathway” 
(Radcliffe etal., 2000) (Figure 1.7). Another report supports the importance of Arl2 in the 
cytoskeleton using the C.elegans Arl2 homolog, evl-20. Antoshechkin and Han (2002) 
show that the disruption of evl-20 causes vulval malformation due to alteration of the 
normal developmental cell lineage as well as male gonadal defects and other effects. All 
of these visible defects can be attributed to cytoskeletal defects, specifically the 
microtubules. Antoshechkin and colleagues suggest evl-20 has a role in the control of 
the cytoskeleton throughout development (Antoshechkin and Han, 2002).
1.6.3 Ar13 and Arl2 interacting partners
Arl3 has been shown to bind to the GRIP domain of Golgin-245, Arl1 has also been 
shown to bind to the same protein, through the same domain (van Valkenburgh et al.,
2001). The GRIP domain is a targeting sequence which is recruited to specific structures 
of the trans-Go\g\ network (TGN). Aril is known to be involved in mediating this 
targeting in a mainly hydrophobic manner. It has been shown that if this hydrophobic 
interaction is disrupted the correct targeting of Golgin-245 is abolished (van Valkenburgh 
et al., 2001; Wu et al., 2003). The functional importance and physiological relevance of 
the interaction between Arl3 and the GRIP domain is not clear. It should also be noted 
that in the interaction studies by van Valkenburgh and colleagues, dominant active 
mutants of the Arls were used for their screening (Q71L), these exhibit a GTP-bound 
conformation and remain constitutively active.
Arl3 has been shown to interact with the ubiquitously expressed proteins PDE 6 (the 5 
subunit of rod-specific cGMP phosphodiesterase), and BART1 (ARL2BP) (Linari et al., 
1999, Sharer et al., 1999, van Valkenburgh etal., 2001, Hanzal-Bayer etal., 2002). Arl2 
has also been shown to bind to PDE 5 and BART1 (Sharer et al., 1999, Hanzal-Bayer et 
al., 2002). Both Arl2 and Arl3 only bind PDE 5 in their GTP-bound states (Linari et al., 
1999, van Valkenburgh et al., 2001, Hanzal-Bayer et al., 2002). PDE 5 actively
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increases the affinity that Arl3 has for GTP (van Valkenburgh et al., 2001). Although the 
function of PDE 6 itself is not fully understood, it is believed to act as an effector of Arl2 
and it has been suggested it may be a transport mediator (Hanzal-Bayer et al., 2002). It 
has also been proposed that PDE 5 has a more general function as a prenyl-binding 
protein, since PDE 6 interaction with farnesylated rhodopsin kinase (GRK1) was 
prenylation dependent (Zhang et al., 2004). PDE 6 interacts with several other small 
GTPases which are also prenylated but Arl3 and Arl2 are not prenylated, and neither is 
the PDE 6 binding domain of RPGR (see section 1.3.5.1), so it can be assumed that it is 
not an absolutely essential requirement for PDE 6 interactions (Zhang et al., 2004, Linari 
et al., 1999).
Arl3 and Arl2 are also known to interact with HRG4 (Unc119). HRG4 is a retina-specific 
protein and the first known receptor-associated activator of Src family tyrosine kinases 
(Cen et al., 2003). HRG4 shares significant homology with PDE 6 , they are 30% 
identical and 40% similar in their C-terminal regions, and 23% identical overall (van 
Valkenburgh et al., 2001). HRG4 has been shown to be important to retinal function. A 
mutation in HRG4 in a transgenic model resulted in cone-rod dystrophy and a 
heterozygous premature stop codon was reported in a 57 year old woman with late onset 
cone-rod dystrophy (Kobayashi et al., 2000). It appears to be particularly important for 
synaptic function in the retina (Kubota et al., 2002), in transgenic mice there was 
evidence of vacuolation in the outer plexiform layer (where the ribbon synapses are 
located) and apoptosis of the neural cells in the inner nuclear layer (Kobayashi et al., 
2000). Therefore Arl3 appears to be involved in important retinal-specific pathways, their 
precise roles and the delineation of the pathways is yet to be elucidated however.
Arl2 and Arl3 are close phylogenetic relatives (see Figure 1.9), and although they have a 
similar structure and share interacting partners and functional similarities they appear to 
have some divergent capabilities. A recent study by Zhou et al (2006) addressed the 
different microtubule-associated roles of Arl3 and Arl2 and concluded that although Arl2 
and Arl3 both play important roles at the centrosome, they have different functions at this 
cellular compartment. Arl2 has an established role in tubulin assembly and appears to 
be involved in the regulation of this process at the centrosome, while Arl3 seems to be 
involved in the regulation of cytokinesis. The proposed role of Arl3 in cytokinesis was 
suggested to be most likely due to its microtubule association as it was localised to the
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mitotic spindle, midzone and midbodies, all of which are microtubule dense stuctures 
involved in cell division (Zhou et al., 2006). Interestingly, although Arl3 was detected in a 
photoreceptor sensory cilium complex proteomic screen, Arl2 was not detected (Liu et 
al., 2007), suggesting the proteins may have divergent functions in this specialised 
cytoskeletal component.
1.6.4 Arl6
Arl6 was recently reported to be the causative gene for the BBS3 locus (Fan et al., 2006, 
Chiang et al., 2006). Arl6 , like all the known Arl family members exists in either a GTP- 
bound or GDP-bound conformation. The GTP-binding function of Arl6 was determined 
to be important for its wild type function as two independent mutations have been 
reported at the Thr31 position (T31M and T31R) which result in the protein being unable 
to bind GTP and thus constitutively inactive (Fan et al., 2002).
1.7 Aims of this study
The main focus of this study was to further advance the understanding of the disease 
pathogenesis of RP caused by mutations in RP2 through the investigation of the cellular 
pathways in which RP2 may be involved. The approach taken was to use a yeast two- 
hybrid screening strategy to discover novel RP2 interacting partners. As RP2 is 
ubiquitously expressed and it remains unclear how RP2 mutations result in a retina- 
specific disease, a retina cDNA library was screened. Novel interactions detected and 
characterised could unravel important retina cellular pathways, such as photoreceptor 
specific or cilia function, and improve our understanding of how RP2 mutations result in 
retinal degeneration.
It can be hypothesised that due RP2’s subcellular localisation, the ability of RP2 to 
partially substitute the function of TBCC, and the microtubule-associated localisation of 
its interacting partner Arl3, that RP2 may play a role in integrating vital cellular functions 
between the plasma membrane and the cytoskeleton. Furthermore, there is evidence 
that Ar13 and another XLRP protein, RPGR, are involved in cilia biology and therefore 
RP2 may have a role at the connecting cilia of photoreceptor cells, possibly in IFT or in 
connecting the cytoskeletal axoneme with the surrounding environment. The
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identification of novel interacting partners would clarify the potential roles of RP2 at the 
cilia and in the broader retinal environment.
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CHAPTER 2
MATERIALS AND METHODS
2.1 BASIC MOLECULAR TECHNIQUES
All solutions and media described in this thesis are listed in Appendix 1.
2.1.1 Vectors Used in this Study
•pGem T-Easy (Promega, UK). This vector was used for cloning PCR products and 
as a shuttle vector for subcloning into the CytoTrap vectors and other expression 
vectors.
•pSos (Stratagene, UK). This was the bait vector for CytoTrap, used for all RP2 
constructs.
•pMyr (Stratagene, UK). The CytoTrap target vector, the cDNA library is cloned into 
this vector and any directed interactions are achieved by cloning the desired gene into 
this vector. This gene exhibits inducible expression under the control of a Galactose 
promoter.
•pCMV-Tag3b (Stratagene, UK). Mammalian expression vector resulting in an 
expressed protein with an N-terminal myctag, used for Arl2, Arl3 and Arl3 mutants. 
•pcDNA4/TOA/SV (Gift from Prof Karl Matter). A mammalian expression vector which 
expresses a protein with a VSV tag at the C-terminus of the protein. Used for Arl2, 
Arl3 and Arl3 mutants.
•pEGFP-N1 (Clontech, UK). RP2 was cloned into this vector to allow expression of a 
RP2-GFP fusion protein with the GFP at the C-terminus of the protein (Chappie et al., 
2000).
•pGEX-2T (Pharmacia, UK). RP2 (from Prof Michael Cheetham), Arl3-T31N and Arl3- 
Q71L (from Dr Tatyana Novoselova) were cloned into this vector to allow expression 
of N-terminal GST fusion proteins in bacterial cells.
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Plasmid Insert description Genotype Use
pSos No insert LEU2, Amp' Control bait vector
pMyr No insert URA3, Camr Control prey vector
pMyr-cDNA Bovine retinal cDNA library URA3, Camr Prey vector
pSos-RP2 Wt human RP2 LEU2, Ampr RP2 bait vector
pMyrSB Rit protein, interacts with hSos URA3, Camr Positive control vector
pMyrLaminC Human Lamin C (aa 67-230) URA3, Camr Negative control vector
Table 2.1 Details of the vectors used for CytoTrap yeast two-hybrid (Stratagene)
2.1.1.1 Construction of the pMyr cDNA Library
The bovine retina cDNA library was purchased from Stratagene, details can be found 
in section 2.2.3.
2.1.2 Subcloning
All genes and constructs were subcloned into a variety of vectors (section 2.1.1) 
facilitated by PCR to introduce restriction enzyme sites as required and restriction 
enzyme digestion. For restriction digestion between 5 and 20 pg of DNA was 
digested in a total reaction volume of between 20  and 100 pi with 10% (v/v) restriction 
enzyme(s), using x10 buffer supplied by the manufacturer. The reactions were 
incubated at 37°C for 2 hours. High volume restriction digests (100 pi) were used 
when subcloning into the pSos vector.
2.1.3 Precipitation and Purification of DNA
Following high volume restriction digests it was necessary to precipitate and purify the 
DNA for resuspension in a lower volume. To each aliquot of digested DNA 0.1 x 
volume of 3M NaOAc (pH 5.5) was added followed by 2.5-3 x volume of absolute 
ethanol. DNA was precipitated by incubation at -20°C for at least 30 minutes. The 
reactions were centrifuged at 14,000 xg for 10 minutes to pellet the DNA, and the 
supernatant was discarded. 0.5 ml 70% ethanol was added, samples were 
centrifuged for an additional 5 minutes at 14,000 xg, the supernatant was discarded 
and the pellet was dessicated and then resuspended in 10-15 pi of ddH20.
2.1.4 Alkaline Phosphatase Treatment
Digested and purified vector DNA was treated with calf intestinal alkaline phosphatase 
(CIAP) to dephosphorylate the 5’ ends and prevent religation of the vector. 10x CIAP 
reaction buffer was used with 1 pi CIAP (1u/pl) (Promega) and ddH20  to a final 
reaction volume of 50 pi. The reaction was incubated for 30 minutes at 37°C and a
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further 1 u CIAP was added for another 30 minutes at 37°C. The reactions were then 
purified using the Qiagen QIAquick PCR purification kit (Qiagen, UK) to remove the 
enzyme and were resuspended in 30 pi of ddH20.
2.1.5 Agarose Gel Electrophoresis
Agarose gel electrophoresis was used to separate DNA fragments by size. DNA was 
visualised after staining with ethidium bromide (5pl of 5mg/ml) by viewing the gel with 
UV light on a transilluminator. Generally 1.0-0.8% agarose (w/v) in tris-acetate (TAE) 
buffer were used to separate the DNA. Samples were loaded into the wells using 6x 
loading dye (Promega) to a final concentration of 1x. Sizes were determined by 
comparison to a known marker (generally 1kb ladder Promega, UK). When 
necessary DNA was excised from the gel using a clean sharp scalpel and was 
extracted using QIAquck gel extraction kit (Qiagen) according to the manufacturer’s 
instructions, DNA was resuspended in 30 pi ddH20.
2.1.6 Ligation of DNA
Digested and purified insert and vector were ligated at a molar concentration of 
approximately 3:1 respectively. Usually 100-500 ng of plasmid DNA was used with 
the corresponding amount of insert DNA. The reaction consisted of 3 units (3u/pl) of 
T4 DNA ligase (Promega, UK), 5 pi of 2x rapid ligation buffer (Promega, UK), DNA 
and ddH20  up to a total volume of 10pl. The reaction was incubated at room 
temperature (approximately 22°C) for 2 hours, or to obtain the maximum number of 
transformants, at 4°C overnight.
2.1.7 Bacterial Transformation
Ligation reactions (5 pi aliquots) were used to transform competent E. coli cells. For 
constructs in the pSos vector 100 pi SURE® 2 supercompetent cells (Stratagene, UK) 
were used per transformation reaction, 2 pi 1.22 M (3-mercaptoethanol was also 
added to each reaction to enhance the transformation efficiency. The DNA, cells and 
(3-mercaptoethanol were incubated on ice for 30 minutes in 15 ml polypropylene tubes 
(Falcon, Nunc). The cell suspension was then heat shocked at 42°C in a water bath 
for 50 seconds and incubated on ice for 2 minutes. SOC media (preheated to 42°C) 
was then added to 1 ml total volume and the samples were incubated at 37°C with 
shaking for at least 1 hour. The cells were then centrifuged at 1000 xg for 5 minutes 
and resuspended in 200  pi of SOC media and the total volume was plated onto the 
appropriate L-agar antibiotic plates, the plates were then incubated at 37°C overnight.
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All other transformations were performed using JM109 competent cells (Promega). 
Aliquots of ligation reactions (5 pi) were added to 50 pi of cells. The samples were 
incubated on ice for 30 minutes. The cells were then heat shocked in a water bath at 
42°C for 45-60 seconds and incubated on ice for a further 2 minutes. SOC media 
(750 pi) was then added and the cells were incubated at 37°C for 1 hour, with 
shaking. The cells were centrifuged at 1000 xg for 10 minutes and were resuspended 
in 150 pi of SOC and plated onto the appropriate L-agar antibiotic plates. Plates were 
incubated at 37°C overnight until single colonies appeared.
2.1.8 Plasmid Purification (Miniprep)
5 ml of LB+antibiotic (See Table 2.2) was inoculated with a single transformant 
colony. Cultures were grown for 12-16 hours at 37°C with shaking. Cells from 1.5 ml 
of culture were centrifuged at 6,000 xg for 5 minutes and DNA was extracted using 
the GenElute Miniprep kit (Sigma) according to the manufacturer’s instructions. DNA 
was eluted in 60 pi of ddH20. Glycerol stocks were made of selected cultures by 
adding 750 pi of culture to 750 pi of 50% sterile glycerol and freezing at -80°C.
DNA was analysed by restriction enzyme digestion: 2 pi eluted DNA was digested 
with 5-10% (v/v) appropriate restriction enzmye(s), in 10x buffer and ddH20  to a total 
volume of 10 pi for 1-2 hours at 37°C. The samples were then analysed by gel 
electrophoresis (See Sections 2.1.2 and 2.1.5).
Antibiotic Used Concentration of Stock Concentration Used At
Ampicilin 50mg/ml 50pg/ml
Kanamycin 50mg/ml 50 pg/ml
Chloramphenicol 34mg/ml 34pg/ml
Table 2.2 Antibiotics used and their concentrations
2.1.8.1 DNA Quantification
DNA was quantified using a spectrophotometer by measuring absorbance at 260 nm. 
5 pi of DNA was diluted in 1 ml dH20  and absorbance at 260 nm was recorded, 
absorbance of 1 OD (A) is equivalent to 50 pg/ml dsDNA. The purity of the DNA was 
checked by reading the sample’s absorbance at 280 nm. A[26o]/A[28o] provides an 
estimate of purity for DNA, with approximately 1.8 indicating sufficiently pure DNA.
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2.1.9 DNA Sequencing
DNA was sequenced using an automated system which employs a cycling strategy of 
primer annealing and DNA synthesis using a thermostable DNA polymerase. Priming 
occurs in only one direction for each reaction and fluorescently labelled 
dideoxynucleoside triphosphates (ddNTPs) are included with the deoxynucleoside 
triphosphates (dNTPs). The ddNTPs lead to chain termination, as when they are 
incorporated they prevent further elongation due to the lack of an OH at the 3’ 
position, thus they are unable to form the phosphodiester bond.
AmpliTaq DNA polymerase is a form of DNA polymerase that contains a point 
mutation in its active site which results in less discrimination against the ddNTPs and 
a more even peak intensity. The enzyme is used in a pre-made mix (BigDye 3.1 
Applied Biosystems) which also contains dye terminators, dNTPs, MgCI2, and buffer 
(Tris-HCI pH9). Clones were sequenced using ABI BigDye terminator cycle 
sequencing chemistry version 3.1 on an ABI 3100 automated sequencer (Applied 
Biosystems).
Cycle sequencing reactions (10 pi) consisted of 1 pi primer (1.6 pM), 1.5 pi ABI buffer, 
1 pi BigDye, approximately 0.5 pg DNA and made up to 10 pi total volume with 
ddH20. Samples were subjected to 30 cycles of 96°C for 30 s, 50°C for 30 s, and 60 
°C for 4 minutes. The sequencing reactions were then purified to remove 
unincorporated primers and dNTPs: 26 pi ddH20  and 64 pi 96% ethanol was added to 
the 10 pi sequencing reaction, the mixture was vortexed and incubated at room 
temperature for 10 minutes. Reactions were then centrifuged at 14,000 xg for 20 
minutes and the supernatant was carefully removed. 200 pi of 70% ethanol was then 
added and the samples were centrifuged for an additional 20 minutes to pellet the 
DNA. The supernatant was removed without disturbing the pellet and the pellet was 
dried at 65°C for 5 minutes. The sample was then resuspended in 12 pi of 
formamide, denatured, and loaded onto the ABI 3100 automated sequencer. 
Sequence analysis was performed using DNAStar software.
2.1.10 Polymerase Chain Reaction
The polymerase chain reaction (PCR) was used to amplify selected regions of DNA 
using specifically designed oligonucleotide primers. PCR uses in vitro enzyme- 
catalysed DNA synthesis to create multiple copies of a specific region of DNA. The 
oligonucleotide primers are extended towards one another under appropriate
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conditions by a thermostable DNA polymerase in a 3-step reaction: denaturation, 
primer annealing and extension.
Denaturation is achieved by heating the PCR mix to 95°C for 5 minutes to separate 
the dsDNA. The DNA is then put through a 3-step reaction between 15-40 times. 
The first step separates the dsDNA by heating to 95°C for 30 seconds. The primer 
annealing step’s temperature is dependent upon the melting temperature (Tm) of the 
primers being used; 2-5°C below the Tm, this usually varies between 50-72°C and is 
usually maintained for 30 seconds. The extension step is performed at 72°C as this 
the optimum temperature for the Taq ploymerase. Generally the extension step runs 
for 1 minute/kb of DNA to be replicated. PCR was used to amplify SPAG7, Arl3 and 
Arl6  from IMAGE clones and to construct RP2 fragments. In some cases the reaction 
was spiked with 0.5 pi proofreading Taq (Pfu Turbo, Promega, UK) to reduce the 
number of PCR-induced errors.
A typical PCR was 5-50 pg miniprep DNA, 2x PCR Master Mix (Abgene, Epsom, UK), 
1 pi (2pM) of each primer, sterile water up to 25 pi. The Abgene master mix consisted 
of 1.25 units Thermoprime Plus DNA polymerase, 75 mM Tris-HCI, 20 mM NH4, 1.5 
mM MgCI2, 0.01% (v/v) Tween®20, 0.2 mM each of dATP. dCTP, dGTP, dTTP.
2 .1.10.1 Primer Design
Oligonucleotide primers are designed to specific regions of DNA to allow specific 
amplification. Several rules were followed: Random base distribution and similar CG 
content for both primers, an anchoring G or C at the end of each primer, minimal 
secondary structure and no greater than 4°C difference in Tm between each primer. 
A primer length of between 20-25 nucleotides was optimal. Restriction enzyme sites 
can be designed on the 5’ end of the primers if the product is to be cloned to allow 
digestion required for a specific primer or to assist with directional cloning. All primer 
sequences can be found in Appendix 1.
2.1.11 TA Cloning into pGem T-Easy
The Taq used in PCR (Abgene, UK) leaves overhanging A bases on the ends of the 
PCR products. This is used to allow TA cloning into the pGem T-Easy vector which is 
engineered with T overhangs. The ligation and transformation into this vector was 
done according to the manufacturer’s instructions (Promega, UK) and as described in 
section 2.1.6 but for 2 hours at room temperature rather than overnight. Ligation
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reactions (5 (jl aliquots) were used to transform competent E.coli as described in 
section 2.1.7. This method was used as a shuttle vector when a PCR product was to 
be cloned into another vector (e.g Arl6  being cloned into pMyr).
2.1.12 Site Directed Mutagenesis (SDM)
SDM was used to create missense mutations in RP2, Arl3 and RAN. Four mutations 
were chosen for RP2, they are all pathogenic mutations found in XLRP families. The 
Arl3 mutants were chosen according to findings by Bartolini and colleagues (See 
section 1.5) (Bartolini et al., 2002). RAN mutations were chosen according to 
Lounsbery et al (1996) and Palacios et al (1996) (Lounsbery et al., 1996, Palacios et 
al., 1996).
Stratagene’s QuikChange kit was used, the protocol was followed as stated in the 
manufacturer’s instructions (Stratagene, UK). The method employs 12 cycles of PCR 
(annealing temperature of 55°C and extension temperature of 68°C for 1 minute/kb of 
plasmid DNA) to introduce a base change using primers with a designed mutation 
(see Table 7.2 in Appendix 1). Overlapping primers were designed with the change 
centrally located. A proofreading Taq (Pfu Turbo) was used; the enzyme allows high 
fidelity replication without displacing the mutant primers. Incorporation of the mutant 
primers creates a mutant plasmid with staggered nicks. Dpn\ digestion is then used to 
select for mutant plasmids by digestion of the parental plasmids. The nicked mutant 
vector DNA is then transformed into XL1-Blue supercompetent cells as described in 
section 2.1.7 but with the addition of 2 pi 1.22 M (3-Mercaptoethanol. The resulting 
transformants were prepared and analysed as described in section 2 .1.8 and were 
sequenced in both forward and reverse directions to check for the desired change as 
described in section 2.1.9.
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2.2 YEAST TWO-HYBRID TECHNIQUES (CytoTrap, Stratagene)
2.2.1 Verification of Yeast Strain Phenotype
The yeast strain cdc25-2 phenotype was checked to ensure there was no aberrant 
growth on inappropriate selective media. The marker phenotype (ura3-52, his3-200, 
ade2-101, Iys2-801, trp1-901, leu2-3, 112, cdc25-2 Gal+) means that the strain should 
not grow on plates lacking tryptophan, leucine, histidine and uracil. This strain should 
also not grow at 37°C due to a temperature sensitive mutation that affects the Ras 
signalling cascade (see Chapter 3.2). Yeast cells were streaked out onto SD-glucose 
plates each lacking one of the 4 amino acids and incubated at 24°C to check for no 
growth. Yeast cells were also streaked out onto YPAD plates and incubated at 37°C 
to ensure the phenotype had not reverted to allow growth at this temperature.
2.2.2 Yeast Glycerol Stocks
Glycerol stocks of the verified yeast strains were made. YPAD media (10ml) was 
inoculated with a single colony from a YPAD plate, grown for a minimal number of 
generations. The cells were grown until late log phase (OD6oo = 0 .8-1 .0 ) at 24°C. A 
sterile solution of 50% glycerol and 50% YPAD broth (4.5ml) was added to the 10ml 
culture. The glycerol-containing culture was aliquotted into 2ml cryotubes (1 ml/tube) 
and frozen at -80°C. These preparations can be kept for up to two years. Each week 
a stock was streaked out onto a fresh YPAD plate and incubated at 24°C.
2.2.3 pMyr Target Library Construction
The target library was constructed in the pMyr vector by Stratagene. The library 
chosen was a bovine retinal cDNA library. The library was constructed using a hybrid 
oligo(dT) linker-primer system. The library was amplified using the protocol from 
Clontech’s MATCHMAKER Library User Manual (PT1020-1).
To check there was no bias or skewing of the library, 20 individual colonies were 
picked before and after amplification (colonies were picked from the titre plates for the 
‘before’ analysis). These were prepared and digested with Xho\ and EcoRI, as 
described in section 2 .1.8 to check for the size of the inserts and then 10 of these 
were selected for sequencing to ensure the library was representative and did not 
contain an over-representation of ribosomal RNAs, and that the process of 
amplification had not biased the library towards the smaller plasmids. The average
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insert size prior to amplification was 1.23 kb and after was 1.34 kb indicating there 
was no skewing of the library.
2.2.4 Yeast Transformation
Once the bait plasmid had been constructed (subcloning of RP2 from pGem T-Easy 
into pSos) the yeast strain cdc25-2 was transformed with pSos-RP2 to check for 
expression and transactivation of the bait fusion protein, hSos-RP2. Yeast 
transformation was performed using a lithium acetate based method.
The protocol was adapted from http://proteome.wayne.edu/transform.html which was 
itself developed from a protocol described by Gietz et al. (1992). A single colony from 
an YPAD plate was used to inoculate a 10 ml culture of YPAD. This was grown 
overnight at 24°C with shaking until the culture was saturated (approximately 12 
hours). The culture was then used to inoculate 50 ml of fresh YPAD to an OD6oo of 
0.2. This culture was grown until it reached an OD6ooOf approximately 1.0 (4-5 hours).
Yeast cells were pelleted at 2000 xg for 2 minutes and supernatant was removed 
quickly and carefully. The yeast were resuspended in 10 ml sterile water and pelleted 
again under the same conditions, after removing the supernatant the yeast were 
resuspended in 5 ml LiOAc/TE and pelleted as before. The supernatant was removed 
and the yeast were resuspended in 250 pi of LiOAc/TE and incubated at room 
temperature for upto 15 minutes.
For each transformation 55 pi of cdc25-2 yeast were aliquotted into a sterile 1.5 ml 
eppendorf tube and 1 pg of plasmid DNA was added, with 5 pi of sonicated ssDNA 
salmon sperm (10 pg/pl Stratagene) and DMSO (Sigma, UK) to a final concentration 
of 10% (v/v). Finally 300 pi of 40%PEG4ooo in LiOAc/TE was added to each reaction 
and mixed by gently pipetting. The cells were incubated for 1.5 hours at 24 °C. The 
cells were heat shocked in a water bath at 42°C for 10 minutes, the cells were then 
pelleted at 3000 xg for 2 minutes and the supernatant was removed. Cells were 
washed and resuspended in 1 ml sterile water and pelleted as before. Supernatant 
(750 pi) was removed and the cells were resuspended in the remaining 250 pi and 
plated onto appropriate selective SD/glucose plates by spreading with approximately 
10-15 4 mm sterile glass beads. The plates were incubated at 24 °C until colonies 
appeared, usually after about 3-4 days.
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2.2.5 Bait Transactivation
To ensure the bait (pSosRP2) did not cause transactivation of the system single yeast 
colonies transformed with the bait plasmid were resuspended in 25 pi of sterile water, 
and 2.5 pi of the cell suspension was then spotted onto an SD/glucose (-L) plate. The 
same was done for various control transformations using SD/galactose (-UL) plates. 
These plates were then incubated at 37°C for 5 days and growth was compared to the 
positive (pSos and pMyrSB) and negative (pSos and pMyrLaminC) controls.
2.2.6 Verification of Bait Protein Expression
5 ml of SD/glucose (-L) was inoculated with a single pSosRP2 containing yeast 
colony. The culture was grown at 24 °C with shaking until saturated, usually 2 days. 
The yeast cells were pelleted by centrifugation at 1000xg for 5 minutes. The yeast 
cells were resuspended in 1 ml cold dH20. 150 pi freshly made NaOH/|3-ME buffer 
was added to the cell suspension. The cell suspension was vortexed for 30s and 
placed on ice for 15 minutes. The cells were vortexed again briefly and 150 pi of 55% 
TCA (v/v) in water was added to the cell suspension. After briefly vortexing the tubes 
were incubated on ice for a further 10 minutes. The protein extract was then pelleted 
by centrifugation at 12,000xg for 10 minutes at 4°C. The supernatant was removed 
and the protein extract resuspended in 300 pi SU buffer (2 pi 1 M Tris-base (pH 10) 
was added if the suspension turned yellow). Protein concentration was not quantified; 
16 pi of SU buffer suspension was added to 4 pi of SDS-PAGE Sample Buffer and 
heated for 3 minutes at 65°C before loading onto an SDS-PAGE gel (see section 
2.2.7). The same protocol was followed for other transformed yeast colonies to act as 
controls.
2.2.7 SDS-PAGE Analysis and Coomassie Staining
SDS-PAGE is a technique used to separate proteins according only to their molecular 
weights. This is achieved by coating all the proteins with an overall negative charge 
using the ionic detergent sodium dodecyl sulphate (SDS) ensuring the proteins have 
the same ratio of mass:charge and so separating them according only to size. This is 
done on a polyacrylamide gel.
Gels were prepared using BioRad mini-protean II SDS-PAGE equipment. Resolving 
gels varying between 8-15% were used in combination with a 3% stacking gel for all 
applications. The electophoresis was conducted at 200 V in 1 x SDS-PAGE running
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buffer. A comparison with a protein ladder of known molecular weights was used to 
determine protein sizes once resolved (BioRad, Amersahm, Pharmacia). Samples 
were prepared in 2 x SDS-PAGE sample buffer and heated to 96 °C for 3 minutes 
prior to loading on the gel.
The resolved proteins were fixed and stained using Coomassie stain, proteins were 
fixed with methanol and acetic acid and stained with Coomassie brilliant blue R250. 
Gels were immersed in stain for approximately 4 hours and then immersed in de-stain 
solution for approximately 2 hours with several changes of solution in that time. Gels 
were then soaked in a water and glycerol (5% v/v) solution overnight and dried 
between two moistened sheets of cellulose film (Promega gel drying kit).
2.2.8 Western Blotting
Proteins were transferred from the polyacrylamide gel to a nitrocellulose membrane 
(BioRad) using semi-dry electrophoretic transfer (BioRad) at constant voltage (15 V) 
for 20 minutes. The nitrocellulose membrane was pre-soaked in water while the 
blotting paper used for the transfer was pre-wetted with 1 x transfer buffer. Non­
specific binding on the membrane was blocked by immersion in Western blotting 
blocking buffer overnight at 4°C or for 1 hour at room temperature. The blots were 
then incubated with the primary antibody in blocking buffer for 1 hour at room 
temperature and then washed with PBS-Tween20 3 x for 10 minutes each. The 
membrane was subsequently incubated with the HRP-conjugated secondary antibody 
in blocking buffer for 1 hour at room temperature, and again washed in wash buffer for 
3 x 10 minutes. Immunoreactive bands were detected using an enhanced 
chemiluminescence reagent ECL+ (Amersham Pharmacia) according to the 
manufacturer’s instructions and visualised by exposure to X-Ray film (Jet X-ray, UK).
Name Specificity Raised
In
Supplied By Titre 
Used in 
WB
Secondary
Used
Titre of 
Secondary
S974 RP2 Sheep Our lab 
Chappie et al 
2000
1:1000 Sigma HRP 1:2000
Sos hSos Mouse Transduction 1:250 Pierce HRP 1:20,000
Arl3-854 Arl3 Rabbit Gift Nick 
Cowan
1:2000 Pierce HRP 1:30,000
9E10 myc Mouse Sigma 1:1000 Pierce HRP 1:20,000
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vsv VSV Rabbit Gift Karl Matter 1:10 Pierce HRP 1:30,000
av Peptide GFP Rabbit BD
Biosciences
1:50 Pierce HRP 1:30,000
RAN RAN Mouse Transduction 1:5000 Pierce HRP 1:20,000
p27/Kip1 P27 Mouse Transduction 1:2000 Pierce HRP 1:20,000
T N P 03 Transportin3 Rabbit Gift from W .Y  
Tarn
1:500 Pierce HRP 1:30,000
3603 SPAG7 Rabbit This study 1:500 Pierce HRP 1:30,000
Table 2.3 Primary antibodies used for Western blotting
2.2.8.1 Antibody peptide blocking
To determine the specificity of our SPAG7 antibody it was necessary to use peptide 
competition and observe whether the immunoreactivity was lost. The peptide block 
solution was prepared by diluting the specific peptide to 10pg/ml in blocking buffer 
and adding the SPAG7 antibody to a final titre of 1:500 and rotate end-on-end for 2 
hours at room temperature. The membrane was incubated in blocking buffer during 
this time and then the peptide-blocked buffer was added in parallel with the primary 
antibody. The rest of the procedure is carried out as in 2.2.8.
2.2.9 Library Screening
2.2.9.1 Co-transformation of yeast
Yeast was co-transformed with a total of 1 pg plasmid DNA (0.5 pg amplified library 
DNA and 0.5 pg pSosRP2) as described in section 2.2.4. A positive control with 0.5 
pg pSosRP2 and 0.5 pg pMyrSB was also co-transformed in the same way, as was a 
negative control with pSosRP2 and pMyrLaminC. An additional 0.5 pg of library DNA 
was also transformed into the yeast strain to act as an indicator of the proportion of 
revertants in each individual screen (this will be explained in section 2.2.9.3). An 
average screen consisted of 30 individual co-transformations which were plated onto 
SD/glucose (-UL) 90mm plates and grown for approximately 36-40 hours at 24°C.
2.2.9 2 Replica Plating of Yeast Co-transformations
After 36-40 hours of growth on glucose plates the co-transformations were replica 
plated onto SD/galactose (-UL) plates, the ‘library only plate’ was replica plated onto 
an SD/galactose (-U) plate. The orientation was clearly marked on the plates. The 
replica plater and velevteen squares used were from Sigma. The replica 
SD/galactose plates were incubated at 37°C until colonies appeared.
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2.2.9 3 Identification of Putative Positive Interactors
The SD/galactose plates were closely observed every day for up to 10 days after 
replica plating. Any colonies growing at 37°C were marked. Colonies were picked 
from the 30 co-transformation plates as they became apparent, from day 1 until 
colonies were seen on the negative control plate. Due to low level background 
transactivation by the bait it was necessary to have a negative control to compare 
growth to as eventually all colonies containing the bait would grow at 37°C. It was 
also necessary to know how prevalent revertant colonies were in each screen: the 
yeast that had only been transformed with cDNA library should not have any 
interactions, due to the lack of the bait, and so any colonies growing at the restrictive 
temperature were either revertant or contained a false positive cDNA (e.g. Ras). This 
provided an indication of the prevalence of revertants in each screen.
2.2.9.4 Extraction of DNA from Putative Interactors
pMyr plasmid DNA was extracted from the putative interactors to allow further 
analysis. 5 ml of SD/glucose (-UL) liquid media was inoculated with a portion of the 
yeast colony. This was grown at 24 °C with shaking until the culture was saturated. 
The yeast were centrifuged at 2000 xg for 2 minutes and the pellet was resuspended 
in 100 pi freshly made 3% SDS 0.2 M NaOH. The cell suspension was incubated at 
room temperature with occasional mixing by rapid inversions. TE (500 pi) was added 
followed by 60 pi 3 M NaOAc (no pH adjustment) with mixing, and 600 pi of 
phenol:chloroform:isoamyl alcohol (25:24:1) was added to the cell suspension 
followed by vortexing for 2 minutes. The samples were then centrifuged at 14,000 xg 
for 2 minutes and the resulting upper aqueous layer was transferred to a fresh 1.5 ml 
eppendorf tube. Another 600 pi phenol:chloroform:isoamyl alcohol was added and 
the sample was vortexed and centrifuged as described previously. Ice cold 
isopropanol (650 pi) was then added, after mixing, the samples were incubated at - 
20°C for at least 20 minutes, ideally 1 hour. The samples were then centrifuged for 5 
minutes at 14,000 xg to pellet the DNA. The supernatant was removed and 100 pi of 
70% ethanol was added followed by another 5 minute spin at 14,000 xg. The 
supernatant was removed, the pellet dessicated and subsequently resuspended in 15 
pi ddH20.
2.2.9 5 Transformation of Total Yeast DNA into E. coli
Samples of the extracted yeast DNA (7 pi) were used to transform 55 pi competent 
JM109 E. coli cells as in section 2.1.7. The cell suspension was plated onto 
Chloramphenicol LB-agar plates. Individual colonies containing pMyr clones were
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picked and grown in 5 ml LB+Chloramphenicol overnight at 37°C. The pMyr plasmid 
DNA was prepared and analysed using Xho\ and EcoRI (Promega) restriction 
enzymes as described in section 2.1.8. Plasmid DNA was used to re-transform 
cdc25-2 yeast cells to confirm the interaction was specific to RP2 and not due to 
phenotypic revertancy (Section 2.2.4). In addition yeast cells were re-transformed 
with pSos alone to check for binding to Sos and/or transactivating the system (e.g. a 
Ras related molecule acting as a false positive). Any putative interactor DNA was 
sequenced with pMyr primers to determine the indentity of the putative interactor and 
whether the clone was in frame as described in section 2.1.9. Plasmid DNA from 
putative interactors was also re-transformed into yeast with the RP2 bait plasmid and 
the empty pSos plasmid to check for specific binding to RP2.
2.2.9.6 Analysis for Revertants
In order to eliminate revertants from the time-consuming procedure of DNA extraction 
and sequencing, other methods were assessed. Due to the weak transactivation of 
the bait it was not possible to test for revertants as described in the published protocol 
(CytoTrap System, Stratagene). Instead, 10 ml of SD/glucose (-U) was inoculated 
with a portion of the yeast colony to be tested, and grown at 24°C with shaking until 
the culture was saturated, usually 2 days. A 200 pi aliquot of culture was then plated 
onto SD/glucose (-U) plates and grown at 24°C for 40 hours. The cultures were then 
replica plated onto SD/glucose (-L) plates to observe which colonies were cured of the 
bait plasmid. These colonies were then tested at the permissive (24°C) and restrictive 
temperatures (37°C). Revertants continue to grow at 37°C even with the loss of the 
bait, but interactors do not.
2.2.9.7 Yeast Spheroblast PCR
An alternative method to avoid the time consuming procedure of extracting DNA and 
sequencing for every putative interactor is to use PCR and sequence directly. A small 
amount of each colony was picked with a sterile loop into 10-20 pi incubation solution 
(1.2 M Sorbitol, 100 mM sodium phosphate pH 7.4, 2.5 mg/ml Lyticase). The 
resulting mixture was incubated at 37°C for 5 minutes. 1-3 pi was used as a template 
for PCR, the other PCR reagents used were as described in section 2.1.10. The 
cycles were 95°C for 10 minutes to break down the protein coat and denature the 
DNA, followed by 95°C for 30 s, 68°C for 30 s and 72°C for 1 minute (the average 
insert size of the library is 1.2 kb). This technique was not deemed to be reliable and 
therefore was not used to eliminate any putative interactors from being processed.
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2.2.10 Southern Blotting
Southern blotting was used as a technique to try to eliminate the processing of Arl2 
and Arl3 among putative interactors using bovine-specific Arl2 and Arl3 probes.
Putative positive yeast colonies were selected as described In section 2.2.9 and DNA 
from the yeast colonies was extracted as described in section 2.2.9.4. 5-7 pi of the 
total extracted yeast DNA was then separated on a 2% agarose gel by 
electrophoresis as described in section 2.1.5 and was run at 80 volts.
The gel was incubated in denaturation buffer for 30 minutes to denature the DNA to 
allow the probe to bind to ssDNA. The denatured gel was then used to set up the 
Southern blot overnight. A capillary blot was assembled using Whatman filter paper 
as a wick which was immersed in denauration buffer. The gel was placed on the wick 
with the Hybond N+ membrane on top of it, 3 sheets of Whatman filter paper were 
placed on top of the membrane and then paper towels were used for the final layer. 
The blot was then left overnight to allow transfer of the DNA from the gel to the 
membrane.
Arl2 and Arl3 specific probes were prepared using PCR as described in section 2.1.10 
and utilising primers designed for bovine Arl2 and Arl3. The primers were designed to 
a central part of the cDNA sequence as the 3’ and 5’ ends of the cDNA clones can 
exhibit variability. The resulting DNA amplicons were different sizes to allow 
differentiation between Arl2 and Arl3. After PCR the DNA was extracted from the gel 
and purified using the Qiagen Gel Extraction kit, according to the manufacturer’s 
instructions. The DNA was then quantified using a Spectrophotometer as described 
as in section 2 .1 .8 .1.
The blot was dismantled the following morning and the position of the wells was 
clearly marked. The membrane was then dried and then baked at 80°C for 2 hours. 
The membrane was then prepared for hybridisation by pre-wetting the membrane in 5 
X SSC. The membrane was then incubated with Hybridisation solution shaking for 1 
hour at 65°C. During this time the probe was prepared. The probe was denatured by 
incubation at 95°C for 5 minutes and then rapidly placing on ice. A total reaction 
volume of 50 pi was used with 5 pi of adCTP32P and 200ng probe to re-hydrate the 
Ready-to-go® bead (Amersham). The reaction was incubated at 37°C for 30 minutes
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and denatured for 5 minutes at 95°C. The denatured probe was then added to the 
hybridisation solution and incubated with the membrane overnight at 65°C.
The following morning the membrane was washed twice in 2 X SSC/0.1% SDS for 30 
minutes at room temperature, and then twice in 2 X SSC/0.1% SDS for 30 minutes at 
65°C. As background was still high a further wash using 1 x SSC/0.1% SDS at 65°C 
was also performed. The membrane was then exposed to film.
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2.3 CELL CULTURE AND IMMUNOCYTOCHEMISTRY
2.3.1 Cell Culture Maintenance (Adherent cells)
Chinese hamster ovary (CHO) cells, human neuroblastoma SK-N-SH cells, monkey 
African green kidney fibroblast (COS7) cells, and cervical adenocarcinoma cells 
(HeLa) were cultured in Dulbecco’s modified Eagle’s Medium (DMEM)/F12 (Gibco, 
UK). All cells were cultured in medium containing 10% fetal bovine serum and 100 
units/ml penicillin and 100 pg/ml streptomycin. Cells were maintained in an 
environment of 5% C 02 and 37°C.
Cells were passaged every 3-4 days or when they were approximately 90-95% 
confluent and were maintained in T75 flasks with 13 ml media per flask. When cells 
reached 95% confluency they were washed twice with 20 ml HBSS (Gibco, UK) 
before being incubated with 1 ml of trypsin (Gibco, UK) for up to 5 minutes until cells 
were no longer adherent, 9ml of DMEM/F12 media was then added to stop the action 
of the trypsin. Cells were then appropriately diluted in fresh DMEM/F12 media.
2.3.2 Liquid Nitrogen Storage of Cells
Approximately 2x105 cells were resuspended in 0.25 ml freezing media (20% foetal 
bovine serum, 72% DMEM/F12, 8% DMSO) and an alcohol bath (VWR) was used to 
slowly freeze the cells to -80°C over 24 hours. Cells requiring long term storage were 
then placed in liquid nitrogen.
2.3.3 Resuscitation of Cells from Liquid Nitrogen
Aliquots of cells were removed from liquid nitrogen and rapidly warmed to 37°C and 
added to pre-warmed media. The cells were then pelleted at 500 g and resuspended 
in fresh media to remove the DMSO.
2.3.4 Lipofectamine Transfection
Transient transfection of adherent cells with plasmid DNA was achieved using 
Lipofectamine reagent in combination with ‘Plus’ reagent (Invitrogen, UK).
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2.3.4.1 Transfection of eight-well chamber slides
In a typical transfection reaction using eight-well chamber slides, cells were seeded at 
a density of 20,000  cells/well and were left at 37°C for 24-48 hours until approximately 
60% (HeLa, COS7, SK-N-SH cells) or 70% (CHO and ARPE19 cells) confluent. The 
following solutions were then prepared for each transfection reaction: A: 100 ng 
plasmid DNA was mixed with 25 pi serum free DMEM/F12 media and 1 pi ‘Plus’ 
reagent and B: 100 pi serum free media mixed with 0.5 pi Lipofectamine reagent. 
Solutions A and B were then incubated at 22°C for 15 minutes, then mixed together 
and incubated for a further 15 minutes at 22°C to allow DNA-liposome complexes to 
form. At this point the cells to be transfected were washed twice with serum free 
media and then 100 pi of the DNA-liposome solution was added to the appropriate 
well and incubated for 3 hours at 37°C. After this incubation, 100 pi of serum 
containing 20% serum was added to the cells. The cells were then assayed 24 hours 
after transfection.
2.3.4.2 Transfection of six-well plates
Transfections of cells in six-well plates was done as described above but with 
variations in the quantities of solutions used and the number of cells seeded. In a well 
of a six-well plate 200,000 cells were seeded per well. Solution A: 25 pi serum free 
DMEM/F12 media was mixed with 800 ng plasmid DNA and 4 pi ‘Plus’ reagent, 
Solution B: 800 pi serum free media was mixed with 2 pi Lipofectamine reagent. After 
the two incubations 800 pi of the A+B solution was added to each well and 800 pi of 
media containing 20% serum was added after the 3 hour incubation.
2.3.4.3 Preparation of cell lysates
Cell lysates were prepared fresh when required from either T25 flasks or 6 well 
dishes. Lysates requiring transiently transfected cells were transfected in six-well 
plates as described in 2.3.4. 24 hours after transfection cells were washed twice in 
ice-cold PBS and then lysed in 300 pi lysis buffer per well (0.5% NP40, 5mM EDTA 
and 1% Protease Inhibitor Cocktail (Sigma) in PBS) for 15 minutes at 4°C. Cell 
lysates were then centrifuged at 13,000 g for 30 minutes at 4°C to obtain the 
supernantant fraction and 300 pi ice cold PBS was used to resuspend the pellet 
fraction when required. Untransfected cells were prepared in the same way but from 
T25 flasks.
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2.3.5 Immunocytochemistry
Cells were seeded in eight-well chamber slides at a density of approximately 20,000 
cells per well and allowed to grow for 24-48 hours. The cells were then washed twice 
in PBS and fixed in either 3.7% paraformaldehyde in PBS for 15 minutes or 100% ice- 
cold methanol for 5 minutes. Cells were permeabilised using 0.1%-0.2% Triton X-100 
for 15 minutes. Non-specific binding was prevented by incubation in Blocking Buffer 
(3% bovine serum albumin (BSA), 10% normal donkey serum in PBS) for 1 hour at 
22°C. Primary antisera were added at the appropriate titre (See Table 2.4) to 
Blocking Buffer and the cells were incubated with the primary antisera for 1 hour at 
22°C. After 5 washes in PBS the cells were incubated with the secondary antisera in 
3% BSA in PBS for 1 hour at 22 °C. The secondary antisera were cyanine- 
conjugated and used at the titres stated in Table 2.4. If needed, DAPI was used at 
1:10,000 (to a final concentration of 0.002 mg/ml) before the penultimate PBS wash 
and was incubated for 5 minutes at 22°C.
Name Specificity Raised In Supplier Titre Used
Arl3-854 Arl3 Rabbit Gift Nick Cowan 1:200-250
9E10 myc tag Mouse Sigma 1:1000
VSV VSV tag Mouse Gift Karl Matter 1:4
S974 RP2 Sheep Our own 1:100
TUB 2.1 (3-tubulin Mouse Sigma 1:500
Ca Inexin Calnexin Mouse StressGen, US 1:100
(3-COP maD clone Mouse Sigma, UK 1:40
EEA1 Early endosome 
antigen 1
Mouse Gift Clare Futter 1:100-1:200
3603 SPAG7 Rabbit Our lab 1:500
TNP03 Transports 3 Rabbit Gift W. Y. Tarn 1:500
RAN RAN Mouse Transduction 1:500
p27/Kip1 p27 Mouse Transduction 1:200
Table 2.4 Primary Antisera for mmunocytochemistry
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Specificity Raised In Conjugate Supplier Titre Used
Rabbit IgG Donkey Cy-3 Jackson 1:100
Sheep IgG Donkey Cy-2 Jackson 1:100
Mouse IgG Donkey Cy-3 Jackson 1:100
Sheep IgG Donkey Cy-3 Jackson 1:100
Rabbit IgG Donkey Cy-2 Jackson 1:100
Mouse IgG Donkey Cy-2 Jackson 1:100
Table 2.5 Secondary Antisera fo r Immunocytochemistry
2.3.6 Co-lmmunoprecipitations
Co-immunoprecipitations were performed on cells transiently co-transfected in six-well 
plates as described in 2.3.4. Each reaction was done in duplicate and cell lysates of 
the same transfection were pooled at the stage of adding the antibody. 24 hours after 
transfection cells were washed twice in ice-cold PBS and then lysed in 300 pi lysis 
buffer per well (0.5% NP40, 5 mM EDTA and 1% protease inhibitor cocktail (Sigma) in 
PBS) for 15 minutes at 4°C. Cell lysates were then centrifuged at 13,000 g for 30 
minutes at 4°C, and 500 pi of each lysate was used for the Co-IP while the rest was 
kept as ‘Input’ sample. 4 pi of 9E10 antibody (a-myc) was added to each 500 pi 
sample and this was incubated overnight at 4°C with rotation. 25 pi packed bed 
volume of protein G sepharose equilibriated in lysis buffer (without CPI) was added to 
each sample and incubated at 4°C for 3 hours with rotation. The sepharose was then 
washed five times with lysis buffer, pelleting beads in between at 500 g for 30 
seconds. The bound protein was eluted from the sepharose with 50 pi sample buffer. 
The sample was denatured at 96°C for 3 minutes and the beads were pelleted before 
loading on an SDS-PAGE gel (See section 2.2.7), 10 pi of the Co-IP sample was 
loaded onto the gel with 10 pi of the ‘Input’ in the adjacent lane and was resolved on 
an SDS gel. Bound protein was then detected by Western blotting with specific 
antibodies (See section 2.2.8 and Table 2.4).
2.3.7 GST-Pulldown Assay
RP2, Arl3-T31N and Arl3-Q71L were cloned into the pGEX-2T vector (by Dr Tatyana 
Novoselova) and transformed into Top 10 OneShot E.coli bacteria. Having checked 
for the presence of the plasmid in the bacteria (see sections 2.1.8, 2.1.2 and 2.1.5), 
the bacterium were used to inoculate an overnight 5 ml culture of L-Broth with
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Ampicilin (see Table 2.1). The following morning the overnight cultures were used to 
inoculate larger LB+Ampicilin cultures (RP2 -  1 litre cultures; Arl3 -  200 ml cultures) 
at a dilution of 1:100. The cultures were grown for 2 hours and then expression of the 
GST-fusion proteins were induced by addition of IPTG to a final concentration of 1 
mM. RP2 cultures were then grown for a further 4 hours while Arl3 cultures were 
grown for another 2 hours. In all experiments empty pGEX-2T was used as a control.
Bacteria were then centrifuged at 6,000 xg for 15 minutes at 4 °C. The resulting 
pellets were then resuspended in PBS with added bacterial cell protease inhibitor 
cocktail (Sigma, UK) (5 ml PBS for 200 ml original culture volume) and the cells were 
lysed by sonication on ice (5 x 30 sec pulses) using a 9mm probe on a Soniprep150 
(80% power). Lysates were centrifuged at 14,000 g for 30 minutes at 4°C and the 
supernatant was then passaged through a 0.45 pm filter. Small scale versions of this 
protocol were initially employed to check for optimum conditions for the expression of 
the fusion proteins, samples were resolved on SDS-PAGE and gels were stained with 
Coomassie stain to visualise proteins (see section 2.2.7).
1 ml of a 50% slurry of previously equilibriated glutathione sepharose 4B (Amersham 
Biosciences) was added and the lysates were then incubated with rotation for 1 hour 
at 4°C. After binding the GST-resin was washed with 10 x volume ice-cold PBS.
Cell lysates were prepared from confluent T75 flasks of cells (see section 2.3.1), after 
trypsin treatment cells were resuspended in 50 ml ice-cold PBS and centrifuged at 
800 g for 5 minutes, the wash was then repeated before cells were lysed in 1 ml of 
lysis buffer (50 mM Tris-HCI (pH8), 150 mM NaCI, 1% Triton, 1% protease inhibitor 
cocktail) at 4°C for 15 minutes. In cases where transfected cells were used the cells 
were seeded and transfected in 6 well dishes as described in section 2.3.4.2 and then 
trypsinised in 300 pi 1 x Trypsin, resuspended in 50 ml ice-cold PBS and centrifuged 
at 800 g for 5 minutes, the wash was then repeated before cells were subsequently 
lysed in 300 pi lysis buffer as described above.
Lysates were subsequently centrifuged at 14,000 g for 15 minutes at 4°C. Protein 
concentration was determined using the BCA assay (Novagen). Cell lyastes were 
pre-cleared on GST-bound glutathione sepharose 4B resin for 1 hour at 4°C with 
rotation (400 pg cell lysate, 50 pi glutathione sepharose 4B, 10 pi mammalian cell 
protease inhibitor cocktail (Sigma, UK), made up to 900 pi with PBS). Pre-cleared 
lysates were then incubated with the GST-fusion proteins bound to the resin overnight
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at 4°C with rotation (900 |jl pre-cleared lysate, 10 pi mammalian cell protease inhibitor 
cocktail, 50 pi GST-fusion resin, made up to 1 ml with PBS).
The following morning the GST resin was washed 5 x with PBS, the resin was 
centrifuged at 500 g for 30seconds between each wash, beads were then 
resuspended in 80 pi of 2 x sample buffer and incubated at 100°C for 5 minutes to 
elute bound proteins from the resin. Samples were then resolved using SDS-PAGE 
and coomassie staining and proteins were detected using Western blotting and 
specific antibodies (see sections 2.2.7 and 2.2.8).
2.3.8 Live Cell Imaging
Cells were seeded into 35mm dishes with a central glass coverslip (MatTek, USA) at 
density of 200,000 cells/dish and were transfected as described in 2.3.4.2. 24 hours 
after transfection the cells were observed using a Zeiss Axiovert M100 microscope 
and Improvison software, the GFP channel (excitatation at 488 nm) was used to 
visualise the transfected GFP protein. A program was set up to take a photo of the 
cells every 15 seconds for a duration of ten minutes. Single frames were then used to 
construct video files of the cells showing the movement of the GFP-tagged protein in 
that time.
2.3.8.1 Con focal scanning microscopy
For all other immunocytochemical imaging applications a Zeiss LSM 510UV confocal 
scanning microscope was used with LSM510 and Adobe Photoshop software. 
Excitation wavelengths were 354 nm (DAPI), 488 nm (Cy2/GFP) and 543 nm (Cy3).
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CHAPTER 3
IDENTIFICATION OF RP2 INTERACTING PROTEINS
3.1 Introduction
In order to investigate the putative pathways that RP2 may be involved in and how 
these may be important in retina a yeast two-hybrid approach was adopted to 
discover novel RP2 interacting partners. Yeast two-hybrid systems have been shown 
to successfully identify interacting partners for other retinal proteins, for example the 
delineation of the interaction between the nuclear receptor Nr2e3 and the 
transcription factor CRX (Peng et al., 2005). In the case of the Nr2e3-CRX 
interaction both the proteins are retina-specific, however yeast two-hybrid has also 
been used for ubiquitously expressed retinal disease proteins, such as RPGR. The 
RCC1 domain of RPGR was used as a bait in yeast two-hybrid which led to the 
identification of retina-specific RPGRIP1 as an interacting partner (Boylan et al., 
2000), RPGRIP1 was subsequently found to be a causative gene for LCA and as 
such the interaction enhanced the knowledge of RPGR’s role in retinal degeneration 
(Dryja et al., 2001).
3.1.1 Yeast two-hybrid
The yeast two-hybrid system was developed by Fields and Song (1989). The system 
was designed on the principle that the two functional domains (DNA binding domain 
and transcriptional activation domain) of a transcription factor (TF) are able to exist 
and fold independently as part of fusion proteins which can be functionally active 
when they are physically brought back together. The DNA binding domain of the 
yeast Gal4 TF was used as the ‘bait’ domain and the transcriptional activation domain 
was used as the ‘target’ or ‘prey’ domain in the system. The gene of interest is 
cloned into a vector that results in the protein of interest being fused to the Gal4 TF 
DNA binding domain, and a cDNA library cloned into a vector resulting in expression 
of the cDNA clones as fusion proteins with the Gal4 TF transcriptional activation 
domain. Thus the bait/DNA binding domain fusion protein binds to the reporter gene 
in the nucleus of the yeast. When there is an interaction between two proteins the
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transcriptional activation domain is brought together with the DNA binding domain to 
activate transcription of a |3-galactosidase reporter gene (Figure 3.1) (Fields and 
Song, 1989). The methodology provides a powerful system for screening a cDNA 
library for putative interactions with a protein of interest by co-transforming yeast cells 
with the ‘bait’ (gene of interest) and ‘target’ (cDNA library) plasmids and assaying for 
(3-galactosidase activity.
Figure 3.1 Schematic representation of the transcription-based yeast two- 
hybrid system
The schematic illustrates how the system operates in the yeast cell nucleus and how 
this translates into growth on HIS- media and the result of the (3-Galactosidase assay. 
Adapted from http://www1 .imperial.ac.uk/medicine/about/institutes/nhli/cardio/heart/ 
cellbio/myogene/. Dr Nigel Brand, National Heart and Lung Institute, Imperial 
College.
Variations on this methodology have been developed since the original system was 
published, such as the use of alternative transcription factors, for example the LexA
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TF, and the addition of dual reporter genes to allow increased stringency of testing for 
an interaction. For example the HIS3 gene is often used as an additional reporter 
gene. Thus putative interactors can be initially screened using HIS- growth media 
such that the number of colonies requiring screening with the p-galactosidase (X Gal) 
assay is much reduced (Miller and Stagljar, 2004).
There are potential problems to consider in the use of this system to identify 
protein:protein interactions: for example an artificial environment can lead to false 
positive interactions, possibly due to proteins that would never come into contact in a 
physiological environment interacting in a non-specific manner. On the other hand it 
has also proved to be a useful system for observing transient interactions that would 
perhaps otherwise have been difficult to identify; often proteins involved in these 
interactions are of low abundance or interact briefly while ‘in transit’ from one 
organelle to another. Yeast two-hybrid may be of limited use if the protein of interest 
used as the bait in the screen is able to activate the system independently of an 
interaction, termed transactivation, this problem usually occurs when the bait is a 
transcription factor (Causier and Davies, 2002). An alternative yeast two-hybrid 
system has been developed more recently in which the interaction does not occur in 
the nucleus of the yeast cell, this system, which is described below, enables a two- 
hybrid assay to be performed using bait proteins which are not amenable to the 
transcription-based system.
3.1.2 Son of Sevenless Recruitment System
The SOS (Son of Sevenless) recruitment system (SRS) is a modified yeast two- 
hybrid system that utilises a variation on the TF-based yeast two-hybrid principle to 
find potential interacting partners for a protein. The system uses a strain of yeast 
(cdc25-H) which contains a point mutation at position 1328 of the CDC25 gene, the 
human homolog of which is hSos. The mutation is temperature sensitive and so 
allows normal growth of the yeast at 22-25°C (permissive temperature) but prevents 
the cells from being able to grow at 37°C (restrictive temperature) (Aronheim et al., 
1994). The CDC25 and hSos gene products act as guanyl nucleotide exchange 
factors (GEFs) that are able to induce the Ras signalling cascade by directly 
activating Ras, which is required for yeast growth through the activation of the 
adenylyl cyclase pathway (Broder et al., 1998). The hSos protein which is expressed 
as a fusion protein with the gene of interest is able to complement this mutation at the 
restrictive temperature only when it is localised to the plasma membrane where yeast
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Ras is localised, and it is this principle that forms the basis of the system (Aronheim 
etal., 1994) (See Figure 3.2).
The cDNA library to be screened is cloned into a vector that tags each cDNA with a 
myristoylation signal at the N-terminus, thus targeting all the expressed proteins from 
the library to the plasma membrane. The expression of the cDNAs is under the 
control of the Gall promoter, such that expression is induced only in the presence of 
galactose in the media. The gene of interest is cloned into the pSos vector and is 
expressed as a fusion protein with hSos. Therefore, when yeast are grown at 37°C in 
the presence of galactose an interaction between ‘bait’ and ‘target’ proteins will result 
in the artificial recruitment of hSos to the membrane. This will complement the 
CDC25 mutation and activate Ras allowing growth at the restrictive temperature (See 
Figure 3.2).
This system does not rely on transcription and so does not have the problem of 
traditional transactivation. Another potential advantage is that the interaction occurs 
in the cytoplasm at the plasma membrane as opposed to the nucleus (see section 
3.1) and therefore can be used for larger proteins which may not easily translocate to 
the nucleus and also allows limited post-translational protein modifications that may 
occur in the cytoplasm which may be important for an interaction. This system can 
also be used for proteins which are themselves transcription factors and thus can 
cause transactivation of the traditional two-hybrid system. A further advantage of the 
SRS system is that it is capable of detecting weaker interactions due to the sensitivity 
and cascading nature of the Ras signalling pathway. It should be noted, however, 
that this system does still have the inherent problem of false positives and non­
specific interactions as do other yeast two-hybrid strategies (Huang et al., 2001).
A challenge with any yeast two-hybrid assay is the potential large number of false 
positives that are generated. For the SRS system this is due to the ability of 
mammalian Ras and Ras-related cDNAs from the cDNA library being able to 
complement the mutation without the need for hSos at the membrane. The hSos is 
able to stimulate the conversion of GDP-Ras to GTP-Ras and the cDNA 
myristoylation tag means the Ras is recruited to its site of action at the plasma 
membrane, for example p21-Ras has been a commonly reported false positive 
(Huang etal., 2001).
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Figure 3.2 Schematic showing how the SRS system is used to identify 
interacting proteins for a protein of interest
A At the permissive temperature the yeast are able to grow due to the mutation in 
CDC25 having no effect. B At the restrictive temperature when there is no interaction 
between the ‘bait’ and ‘target cDNA’ the mutation in CDC25 means the protein is 
unable to stimulate the conversion of Ras-GDP to Ras-GTP and thus the yeast do 
not grow. C At the permissive temperature the cells grow whether there is an 
interaction or not. D At the restrictive temperature if there is an interaction the loss of 
function of the CDC25 protein is compensated for by the recruitment of hSos to the 
plasma membrane which stimulates the conversion of Ras from GDP-bound to the 
active GTP-bound form. Modified from Evans et al (2006), Methods in Enzymology.
The SRS system relies on the temperature sensitive yeast strain cdc25-H, however, 
yeast are prone to mutation such that the cdc25-H mutant yeast strain may ‘revert 
back’ to the wildtype phenotype, and so grow at the restrictive temperature. As this is 
the phenotype used to select putative interactors it can be time consuming to 
distinguish a genuine interaction from a revertant colony. The SRS has been used
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successfully in identifying the GABApI interaction with cellular retinoic acid binding 
protein (CRABP), an interaction potentially important in retinal neuron signalling 
(Song et al., 2005). This suggests that the system is an effective method for the 
detection of novel interactions important to retinal biology.
The SRS yeast two-hybrid system was chosen as the most suitable for detecting 
potential physiologically relevant RP2 interactors. RP2 is dually aceylated and 
targeted to the cytosolic face of the plasma membrane (see section 1.4.2) in retina 
and all cell types tested (Chappie et al., 2000, Chappie et al., 2002). As such the 
localisation of the ‘prey’ to the cytosolic face of the plasma membrane of the yeast 
cell is closer to the normal physiological environment in which RP2-mediated 
interactions are likely to occur.
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3.2 Optimisation of CytoTrap for screening a retina cDNA library using RP2 as 
bait
The system used in this study is the CytoTrap® system, Stratagene’s version of the 
SRS system. Considerable optimisations of the standard protocols provided by 
Stratagene for CytoTrap were necessary in order to efficiently screen a bovine retina 
cDNA library (Stratagene) for RP2 interacting partners. The methods used are 
described in Chapter 2 but details of the strategies behind the final methodologies are 
described in this chapter.
3.3.1. Sub-cloning of RP2 into the pSos vector
The pSos plasmid is a relatively large plasmid at 11.3kb. RP2 was subcloned into 
the pSos vector as described in sections 2.1.2-8. The large size of the vector meant 
that bacterial transformation efficiency was low. Rearrangements and recombination 
events were observed with pSos and RP2 as shown in Figure 3.3.
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Figure 3.3 Rearrangements of pSos/RP2 plasmids
RP2/pSos plasmids from E.coli transformations of RP2/pSos ligations, DNA was 
digested with A/col and Not\. Lane 2 contains a correctly ligated RP2 insert in the 
pSos plasmid. Control pSos digested with A/col and Not\ is shown in Lane 7. Lanes 
1, 3, 4, and 6 show rearranged pSos plasmid. Lane 5 shows an apparently correctly 
ligated RP2 insert in the pSos vector which appears to be partially digested.
The pSos rearrangements were overcome by using SURE® 2 supercompetent E.coli 
cells (Stratagene). These bacteria have altered E.coli genes involved in DNA repair 
and recombination, thus reducing the likelihood that these events will occur and result 
in deletion and/or alteration of the plasmid construct. Homologous recombination 
events are reduced by the introduction of recB and recJ mutations which is similar to
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a mutation in the recA gene. Mutations in genes involved in DNA repair, specifically 
in the UV and SOS repair systems, allows the cloning of usually unstable DNA, for 
example DNA containing long inverted repeats. The manufacturer does not 
recommend using these cells for constructs larger than 10kb which may explain why 
there are still rearrangements (Figure 3.3) even when using cells intended to prevent 
such occurrences. All subsequent cloning into pSos was successful when this 
protocol was followed.
3.3.2 Functional analysis of pSos-RP2 in CytoTrap
It was necessary to establish if RP2 was functional in the SRS system and this was 
done as described in section 2.2.5. The expression level of the hSos-RP2 fusion 
protein was assessed as described in sections 2.2.4 and 2.2.6-8. The functionality of 
hSos-RP2 in CytoTrap was then analysed by co-transforming cdc25H yeast with 
pSos-RP2 and pMyr control plasmids (Table 2.1) and checking that they are able to 
grow as predicted. Figure 3.4 shows that hSos-RP2 expresses in the transformed 
cdc25-H yeast and that when co-transformed with the pMyr negative control plasmid 
(pMyrLaminC) there is minimal growth at the restrictive temperature and there is 
growth when co-transformed with the pMyr positive control (pMyrSB) plasmid (Figure 
3.4).
The RP2-hSos fusion protein was found to slightly transactivate the system; when 
hSos-RP2 is expressed alone or in combination with a negative control 
(pMyrLaminC) there was some growth at the restrictive temperature. This growth 
was minimal and was usually noticeable after approximately 6-7 days at the 
restrictive temperature (see Figure 3.4). Whenever a screen was performed, a 
negative control using pSos-RP2 and pMyrLaminC was included, which was used as 
a direct comparison to the library screen. As soon as any colonies became visible on 
the negative control plate no further colonies were selected from the screen.
3.3.3 Screening strategies
In order for any yeast two-hybrid method to be successful, efficient transformation 
with plasmid DNA is important. The recommended manufacturer’s protocol for 
transformation of the cdc25-Ha yeast were found to be insufficient (efficiency of 5- 
7x102/pg DNA) for large-scale library screening and so adjustments to the protocol 
were made, the final protocol used is described in sections 2.2.4 and 2.2.9.
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Figure 3.4 Functional analysis of the hSos-RP2 bait
A Yeast co-transformed with plasmid combinations as indicated and grown for 120 
hours at the permissive and restrictive temperatures. The hSos-RP2 ‘bait’ is able to 
grow to a limited degree at the restrictive temperature whereas when hSos is 
expressed without RP2 there is no growth at 37°C. The pMyrSB plasmid expresses 
Rit1 protein, which binds to hSos, pMyrLaminC expresses Lamin C which does not 
bind to either hSos or RP2. B Yeast co-transformed with pSos-RP2 and either pMyr- 
Arl3 or pMyr-LaminC after 96 hours, showing that the RP2-Arl3 interaction can be 
detected above the background transactivation. C Yeast protein extracts transformed 
with pSos-RP2 or pSos alone probed using an antibody to RP2 showing expression 
of the hSos-RP2 fusion protein.
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The method developed was based on the standard LiOAc method (Ito et al. 1983), as 
modified by Gietz et al. (1992). There were several adjustments made to this 
standard protocol in order to achieve the highest transformation efficiency of the 
cdc25H strain. Many protocols recommend vortexing the cells when mixing the cell 
suspension with the LiOAc/PEG mixture prior to heat shock to ensure adequate 
mixing of the suspension. It was determined, however, that vortexing at this stage 
decreased the transformation efficiency by up to 15% compared to using gentle 
pipetting to mix the cells. It is possible that due to the presence of 40% PEG in the 
cell suspension that the cells are in a fragile state and vortexing increases cell death 
rather than directly decreasing efficiency of DNA transformation. DNA purity was, as 
expected, a significant factor in obtaining optimal transformation efficiency. During 
the optimisation process the average transformation efficiency was approximately 
1x103/pg and with all the adjustments made the average transformation efficiency 
was increased to between 1-3x104/pg DNA.
Saccharomyces cerevisiae strains that are not temperature sensitive are usually 
grown at 30 °C and any incubation steps in a transformation protocol are performed 
at 30 °C. The yeast strain used in CytoTrap is temperature sensitive; the permissive 
temperature being 22-25 °C and the restrictive temperature being 37 °C. As 
previously mentioned there are problems with the strain’s ability to revert to a non­
temperature sensitive phenotype. Therefore the heat shock of 42 °C during the 
transformation protocol was shortened as much as possible to reduce the potential 
environmental pressure for the yeast to revert. The recommended length of heat 
shock for most published protocols is 15-20 minutes, it was determined empirically 
that a heat shock of 10 minutes resulted in an efficient transformation while reducing 
the environmental pressure on the yeast and hence reducing the likelihood of 
revertants.
There are two common approaches to transforming yeast for two-hybrid screening: 
co-transformation and sequential transformations. Sequential transformations involve 
first transforming the yeast with the bait plasmid and then to transform these yeast 
strains with the cDNA library plasmid. This is generally achieves high efficiency 
transformation to screen a library. Sequential transformations were less suitable for 
this yeast strain, partially due to the low level transactivation by hSos-RP2, so the 
approach taken in this study was co-transformation which also minimised revertancy 
events. In order to reduce the number of yeast able to revert to the non-temperature
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sensitive phenotype the amount of time the yeast were grown was kept to a 
minimum.
Two different conditions of screening were employed in this study. The different 
conditions had different limits of detection for interacting partners. The standard 
procedure of using replica plating onto SD/Galactose plates, as described in section 
2.2.9.2, after initially plating onto SD/Glucose plates, was used for 12 screens during 
optimisation and for 4 optimal screens (“normal stringency screens”). Unlike the 
transcription-based yeast two-hybrid system, CytoTrap requires the transformed 
yeast to be grown at the permissive temperature for up to 40 hours on SD/Glucose 
plates and then replica plated onto SD/Galactose plates and incubated at the 
permissive temperature. This procedure allows the yeast to grow before being 
subjected to selection at the restrictive temperature. The procedure of replica plating 
does however decrease the efficiency of the screen. It was calculated that replica 
plating led to a 3-5% loss in total colonies screened, probably due to the yeast 
colonies still being too small to be successfully picked up by the velvet, however the 
method was more likely to detect weaker interactors than the alternative condition 
described below (see table 3.1).
An alternative method was attempted to bias the detection parameters towards the 
identification of higher affinity interactors. The yeast was transformed with the RP2 
bait and cDNA library plasmids as described in section 2.2.9.1 but were plated 
directly onto SD/Galactose plates rather than SD/Glucose plates. The plates were 
incubated at 24 °C for 24 hours before being transferred to 37°C where they were 
incubated until colonies were visible, thus eliminating the need for replica plating. 
Due to there being no need for replica plating it was possible to plate colonies at a 
much higher density and there was no colony loss due to the replica plating 
procedure. Therefore, this method allowed a higher number of colonies to be 
screened in a single screen (see Table 3.1). This screening strategy (referred to as a 
“high stringency screen”) resulted in only revertants and strong interactors being 
detected (Table 3.1) and was not used for further screening as weaker interactors 
may be missed if this protocol was used exclusively for screening. Following the 
optimisation of the system for RP2, involving replica plating, it was possible to screen 
approximately 300,000 colonies in a single low stringency screen.
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Normal Stringency Screen High Stringency Screen
No Colonies Screened >1x10®
No Putative Interactors 87
No Revertants/False 
Positives
55
No. Interacting Clones 32
No Interactors 2
RP2 Interactors confirmed Arl3 (30). Arl2 (2)
% Putative Interactors that 
were false positives or 
revertants
63%
% Interactors that were Arl 
clones
100%
No. Colonies Screened 300.000
No Putative Interactors 82
No Revertants/False 
Positives
71
No Interacting Clones 11
No Interactors 5
RP2 Interactors confirmed Arl3 (6), Arl2 (1), RAN (2). 
CDKN1B (1), TNP03 (1),
% Putative Interactors that 
were false positives or 
revertants
87%
% Interactors that were Arl 
clones
64%
Table 3.1 A comparison of screening strategies
A comparison of the results of screening with RP2 bait using two different strategies 
illustrated by comparing a representative screen for each strategy.
Finally, adjustments to the recommended protocol for extracting the yeast DNA for 
transforming E.coli were necessary. The final protocol is described in section 2.2.9.4- 
5. The cell lysis method suggested by the manufacturer was relatively inefficient and 
inconsistent but using an adapted version of a phenol/chloroform/isoamyl alcohol- 
based extraction method provided sufficient amounts and quality of DNA to efficiently 
transform the E.coli.
3.3 Strategies to expedite processing of revertant and Arl clones
During the development of the system it became clear that a method to eliminate the 
large number of false positives (approximately 90% of an average screen) and known 
strong interactors (i.e. Arl3, see Chapter 4) was necessary. A method to determine 
whether or not a putative positive yeast colony was either a revertant or a positive
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was recommended by Dr Gina Scott, University of Leeds. This method was based 
on the yeast losing the RP2 bait plasmid through growth in non-selective media as 
described in section 2 .2 .9.6 and then testing the yeast for growth at the restrictive 
temperature. If the yeast has reverted to the non-temperature sensitive phenotype it 
would continue to grow at the restrictive temperature despite losing the bait plasmid. 
This method allowed the elimination of approximately 75% of the revertants without 
having to extract DNA from the yeast cells and the subsequent analyses required. 
Using this method, however, did not eliminate any false positives that may bind 
specifically to the hSos protein or any Ras false positives that require the hSos 
protein to stimulate the yeast growth.
Arl3 is an established RP2 interacting partner (Bartolini et al., 2002) (see section
1.6.1). During the screening process Arl3 was detected 45 times, and as such 
strategies to identify Arl3 at an earlier stage of screening were developed. The Arl3- 
RP2 interaction was relatively ‘strong’ and well above the background level of RP2 
transactivation (see Figure 3.4). Arl2 was also found to be a strong RP2 interactor in 
this system. These interactions will be discussed further in Chapter 4.
3.3.11dentifying Arl clones
Arl3 was the most common positive cDNA identified in this screen with Arl2 being the 
second most common (see section 3.4 and Table 3.1). In order to process and 
prioritise novel putative interactors more quickly, two methods were developed to 
detect the presence of Arl2 and Arl3 at an earlier stage in the processing of the 
screening.
The first method used to identify Arl clones was yeast colony PCR. Yeast 
spheroblast PCR (as described in 2.2.9.7) did successfully identify some Arl clones 
but was inconsistent, the positive control was not always successfully amplified. An 
alternative Southern blotting method was then used, as described in section 2.2.10. 
Southern blotting did not provide results as rapidly as PCR but appeared, initially, to 
be more consistent and therefore, more useful. Analysis of Southern blots of plasmid 
DNA extracted from potentially positive yeast colonies showed high background 
hybridisation, perhaps to yeast genomic DNA. However only 66% of the tested 
putative Arl cDNAs were subsequently confirmed Arl clones by sequence analysis. 
Therefore, this method was thought not reliable enough.
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The final approach to reducing the need to fully process Arl2 and Arl3 clones was 
colony PCR of bacterial colonies. E.coli were transformed with extracted yeast DNA 
as previously described in section 2.2.9.4-5 and then small portions of bacterial 
colonies were re-suspended in PCR MasterMix (Abgene, UK) with bovine-specific 
Arl2 or Arl3 primers. The primers were designed based on previously sequenced 
bovine Arl clones. The PCR reaction and conditions are as described in section 
2.2.10. The bovine Arl3 primers amplify a 201 bp region from base pair number 175 
to 376. This was the most reliable method used and was consistently able to detect 
Arl2 and Arl3 plasmids when they were present, as well as being able to distinguish 
between the two genes (see Arl3 in Figure 3.5). The disadvantage of the method 
was that it did not eliminate the need for DNA extraction and bacterial 
transformations; it did, however, prevent the need to re-transform yeast cells to check 
the specificity of the interaction as well as making it unnecessary to subsequently 
sequence the clone.
2kb
1kb
500bp
250bp
Figure 3.5 Bacterial colony PCR to detect Arl clones
Specific detection of an Arl3 plasmid from a putative interactor (Putative Interactor 2) 
by PCR was confirmed by sequencing. Putative interactor 1 was later confirmed to be 
RAN (see Chapter 5). The negative control was a bacterial colony known to contain 
bovine Arl2.
3.4 Overview of bovine retina cDNA library screening
The cDNA library from Stratagene was characterised both before and after in-house 
amplification as described in section 2.2.3. The titre of the library on delivery was 
calculated to be 5 x 108 cfu/ml. The average insert size pre-amplification was 
determined to be 1.23kb. Post-amplification the average insert size was found to be
\  a,
, /  /
\<  ^ #  ^  
v #  0 ° 0 °
«r3r qp ^
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1.34kb, indicating that the amplification process did not preferentially amplify the 
smaller cDNAs. The quality of library clones was also checked as described in 
section 2.2.3 and was found to contain known retinal genes such as rhodopsin and 
CRX, therefore the library was deemed to be representative enough for screening.
Overall approximately 2.6 million clones were screened, the majority of which were 
screened using the recommended replica plating strategy, only one screen was 
conducted using the ‘high stringency’ parameters which accounted for approximately 
1 million of the screened colonies. Screening 2.6 million colonies resulted in 564 
putative interactors of which 508 were false positives/revertants (90%) Of the 56 
interacting clones, 51 were Arl3 (45) or Arl2 (6 ), two thirds of the detected Arl3 clones 
were found in the single ‘high stringency screen’ (see Table 3.2). In total, six 
potential RP2 interactors were discovered using CytoTrap. Table 3.1 shows the 
differences in screening when using the two previously described strategies by 
comparing a representative screen from each, the clear difference being that the high 
stringency screen biased the screening process towards RP2’s higher affinity 
interactors, i.e. Arl3 and Arl2. There were also fewer false positives/revertants in the 
‘high stringency screen’.
3.5 Putative Interactors
The CytoTrap method resulted in confirmation of Arl3 as an RP2 interactor as well as 
the discovery of five potential new interactors (Table 3.2). Arl3 was the most 
common cDNA detected in the screen with 80% of the putative interacting clones 
being Arl3 clones. Arl2 was the second most common putative interactor discovered, 
six clones were identified which were all identical. Four other novel putative RP2 
interactors were also identified and will be discussed in the following chapters.
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Total for all screens
No. Colonies Screened -2,600,000
No. Putative Interactors 564
No. Revertants/False 
Positives
508
No. Interacting Clones 56
No. Interactors 6
RP2 Interactors confirmed Arl3 (45), Arl2 (6), RAN (2), 
CDKN1B (1), TNP03 (1), 
SPAG7 (1)
% Putative Interactors that 
were false positives or 
revertants
90%
% Interactors that were Arl 
clones
91%
Table 3.2 Summary of all screens for RP2 interactors
In total 17 screens were performed, 16 of these utilised the ‘normal stringency’ 
parameters, of these 4 were optimal screens and the other 12 were used to optimise 
the screening conditions. One screen was conducted using the ‘high stringency’ 
parameters.
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3.6 Discussion
The choice of method when investigating interacting partners for a given protein is 
very important. Most approaches have both advantages and disadvantages. The 
use of yeast two-hybrid may lead to the discovery of transient interactors, which can 
be hard to detect in cellular studies but can be key to a particular pathway in the cell. 
CytoTrap was utilised to investigate novel RP2 interactors due to the fact that RP2 
undergoes post-translational modifications and thus the SRS system reflects RP2’s 
endogenous localisation more accurately than a nuclear-based yeast two-hybrid 
assay, and it does appear to have been a suitable system for this purpose. The 
choice of cDNA library is also crucial to any investigation of this kind. One of the 
fundamental aims of this study is to explore why mutations in RP2 lead to the 
development of RP when the gene is expressed in every tissue tested (Schwahn et 
al., 1998, Chappie et al., 2000). The approach taken therefore was to use a retina 
cDNA library as potentially important retina-specific RP2 interactors will be well 
represented in the library as well as ensuring that any ubiquitously expressed RP2 
interactors are not ignored.
The use of a temperature sensitive yeast strain that has the inherent capability of 
reversion to the wild type genotype, and the resultant high number (90% of all 
putative positives) of revertants encountered in the CytoTrap system was the most 
significant disadvantage of the system. The dual reporter system utilised by 
transcription-based yeast two-hybrid tends to reduce the number of false positives, 
however the nuclear location of the interaction in this system has its own set of 
disadvantages as discussed in section 3.1.1. During the development of CytoTrap 
for screening a cDNA library, obtaining good transformation efficiency for the yeast 
was problematic. However, through optimisation of a LiOAc based method the 
efficiency was increased by at least ten-fold. Although a transformation efficiency of 
at least 1x106 colonies/pg DNA is ideal for such applications the lower efficiency was 
compensated for through increasing the amount of DNA and yeast cells used for 
each reaction, and as such was found to be sufficient for screening the cDNA library.
The use of different detection parameters through the exclusion of replica plating in 
the ‘high stringency’ screen biased the screen towards the detection of ‘stronger’ 
interactors. Although in the case of RP2 this meant that all the detected interactors 
were Arl2 or Arl3, the strategy was successful and has been used to screen other 
retinal disease genes in the lab (Hidalgo et al., submitted). In order to ensure that 
weaker interactors were not missed, the use of replica plating for the remainder of
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screening was employed. There appeared to be a higher percentage of putative 
positive yeast colonies subsequently determined as revertants when replica plating 
was used, which may be explained by the reduced number of generations of growth 
when replica plating is omitted from the protocol and so reducing the likelihood of 
revertancy.
As mentioned in section 3.1.2, CytoTrap has been successfully used to identify the 
interaction of GABA p1 with CRABP; this interaction was discovered using the same 
commercial bovine retina cDNA library (Stratagene) that was used in this project 
(Song et al. 2005). In this instance 1.3 million colonies were screened and of these 
200 colonies grew at the restrictive temperature, consequently 23 colonies were 
determined to contain CRABP cDNAs that were specifically interacting with the 
GABA p1 bait. Therefore 0.015% of colonies screened were putative positives and
11.5% turned out to be CRABP clones (Song et al., 2005). Using RP2 as bait to 
screen 2.6  million colonies 0 .02% of colonies screened were putative positives and of 
those 10% were specific interactors (8% were Arl3). The comparable level of 
revertants (90% in this screen and 88.5% in the screen by Song et al) and highest 
frequency interactors (8% Arl3 compared to 11.5% CRABP) indicates that the 
screening process was consistent with published studies using the same system and 
library.
Since the development of the SRS, a new Ras-based recruitment system has been 
developed (RRS). The principles are the same and the same cdc25H mutant yeast 
strain is used, however activated mammalian Ras lacking the prenylation CAAX motif 
is used for the fusion protein rather than hSos. The loss of the prenylation motif 
means that the active Ras cannot associate with the membrane unless recruited to 
the membrane through interaction with a myristoylated cDNA (Broder et al., 1998). 
This system addresses the problem of Ras false positives; the lack of hSos in the 
yeast prevents stimulation of the conversion of Ras cDNAs from Ras-GDP to Ras- 
GTP which occurs in SRS. As Ras is a smaller protein than hSos, some technical 
difficulties, which occur due to the large size of the hSos gene and hence protein, can 
be overcome (Broder et al., 1998). The RRS would be even better for screening for 
RP2 interactors than the SRS, however a suitable library would need to constructed.
SRS (CytoTrap) was chosen to investigate RP2 interacting partners for the reasons 
described previously (Section 3.1.2). There are however other approaches to the 
analysis of protein:protein interactions. Yeast-two hybrid systems are usually chosen
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for use as a screening method to discover new putative interactors, however, directed 
interactions can also be tested using a yeast-two hybrid approach. Yeast-two hybrid 
systems have many advantages and disadvantages as previously discussed (Section
3.1), the main problem being the detection of false positives. One of the fundamental 
advantages of SRS as a Yeast-two hybrid system is that the interactions occur in 
cytoplasm as opposed to the nucleus, allowing proteins such as transcription factors 
to be used. However, SRS is a lower throughput system than the traditional 
transcription-based system requiring more time and optimisation to achieve good 
results. Furthermore the design of the transcription-based system means that 
multiple reporter constructs are used which further reduces the processing of false 
positives. In the SRS system false positives can be generated due to the natural 
ability of yeast cells to revert to a preferable genotype. Despite the lower throughput 
and increased incidence of false positives, SRS was the system of choice as it 
reflects the physiological environment for RP2; RP2 is post-translationaly modified in 
the cytoplasm and localises to the plasma membrane and CytoTrap is not only 
cytoplasmic-based but also utilises a myristoylation signal to target prey proteins to 
the plasma membrane.
Another approach for identifying new interacting partners for a protein is pull down 
assays followed by mass spectrometrical analysis of the resulting proteins. The 
success of this approach relies heavily on the parameters set by the investigator and 
careful analysis of the raw data, for example low abundance proteins may be missed 
due to falling outside the set conditions. A further advantage of such an approach is 
the ability to generate interaction profiles by altering the tissue or cell type being used 
or to use different developmental time points to create a more detailed picture of how 
a proteins function may alter depending on the conditions. This can also be achieved 
through using different cDNA libraries for yeast-two hybrid, but library screening is a 
more time intensive process and so this approach may be more suited to a mass 
spectrometrical analysis method. A major disadvantage in using mass spectrometry 
is the lack of distinction between proteins which are direct interactors and those that 
form part of complex, therefore there is an additional consideration when analysing 
any results from this method.
Bioinformatics can also provide a starting point for a targeted search for potential 
interacting partners, using predicted domains and protein families established 
knowledge about a particular protein can guide a search for novel interacting 
partners.
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All novel interactors discovered through a screening method should be corroborated 
using a different assay such as a pull-down, yeast two-hybrid or co- 
immunoprecipitation. Co-immunoprecipitations using endogenous protein provide the 
most compelling evidence that an interaction is at the very least, physiological. This 
is not always possible however due to the requirement for specific antibodies and 
optimal cellular conditions for the interaction. If one of the proteins being investigated 
is of low abundance this may be a difficult approach, the interaction may also be 
transitory or may only occur at a very specific time or in response to a particular 
cellular event, therefore making it hard to detect. Co-immunoprecipitations or pull 
down assays using over-expressed tagged proteins can overcome these problems 
but do not provide such robust evidence for an interaction as the conditions are not 
as physiological and over-expression and tagging can alter the normal properties of a 
protein. Once identified it is then possible to use interaction assays to map 
interaction domains and identify important residues for the interaction, it is also 
important therefore to determine where and when the interaction may occur, usually 
through the use of co-localisation studies.
The process of optimising the CytoTrap system for the application of identifying RP2 
interactors has resulted in a system that has successfully identified RP2 interacting 
partners. The suitability of the system was confirmed when the previously described 
RP2 interactor, Arl3, was the most commonly detected cDNA in the screen. This 
indicates hSos-RP2 fusion protein is expressed, that RP2 is properly folded and that 
hSos does not occlude interaction sites. Arl3 can be regarded as a very strong 
interacting partner for RP2. In this system, growth of yeast can be seen as early as 
day 2 post-replica plating when this interaction occurs which is comparable, if not 
stronger, than the strong positive control of pSos and pMyrSB (hSos and Rit1). The 
system was also useful for mapping the RP2 interaction domain of the novel 
interactors which will be discussed in the next chapters.
The work described in this chapter has been published in part in Evans et al (2006).
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CHAPTER 4
CHARACTERISATION OF THE INTERACTION OF RP2 
AND ARL3
4.1 Introduction
The function of RP2 is still unknown, however, the acylation and localisation of RP2 
to the plasma membrane is necessary for the normal function of the protein (Chappie 
et al., 2000). RP2 was first shown to interact with Arl3 by Bartolini et al (2002) as 
described in section 1.6 , however little else was known about the function of Arl3 or 
the nature of the RP2-Arl3 interaction at the outset of this research. Arl3 remains the 
only currently published RP2 interacting protein. During the period of the research 
described here two important studies were published which have contributed to our 
understanding of the function of Arl3 and the importance of the RP2-Arl3 interaction. 
The crystal structure of RP2 has now been solved and the RP2-Arl3 interaction was 
further investigated by Kuhnel and colleagues (2006), and this will be discussed 
further in section 4.7 (Kuhnel etal., 2006).
Arl3 and RP2 are both ubiquitously expressed, which leaves the question as to how 
RP2 mutations exclusively cause RP unresolved. Importantly, Arl3 was recently 
implicated directly in photoreceptor function and maintenance in a report by Schrick 
and colleagues describing an Arl3 knockout mouse (Schrick et al., 2006). 
Homozygous mice lacking Arl3 were born at a sub-Mendelian ratio implying there is a 
degree of embryonic lethality associated with loss of Arl3 function. The surviving 
mice died within three weeks and exhibited multiple abnormalities. The abnormalities 
described in the mice were all cilia-associated defects: renal, hepatic and pancreatic 
epithelial tubule defects were present which mimicked the symptoms of polycystic 
kidney disease (PKD), the mice also suffered from retinal dystrophy. Abnormal 
retinal development was apparent from postnatal day 9. Knockout mice had under­
developed inner and outer segments when compared to wild type mice. By postnatal 
day 13 mice lacking Arl3 had many TUNEL positive cells in the outer nuclear layer 
(ONL), as well as impaired transport of rhodopsin to the outer segments indicating
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compromised photoreceptor development and cell death (Schrick et al., 2006). Arl3 
knockout mice have structurally normal cilia, including the photoreceptor connecting 
cilium, suggesting Arl3 is not important for the cilia structure per se but perhaps is 
important in cilia function or plays an alternative role such as a regulatory protein or 
as part of a signalling pathway. The mice also had abnormal cell proliferation 
patterns, for example with multiple renal cysts resulting from increased cell 
proliferation. These data implied a direct role for Arl3 in correct development and 
survival of the photoreceptor cells as well as a possible role in regulation of cell 
proliferation of other ciliated cells (Schrick et al., 2006). Dysfunction of essential cilia 
genes is recognised as a common mechanism leading to retinal degeneration 
(Sections 1.2.3.1, 1.3.3.1, 1.3.4.4). Therefore there is a possibility that the RP2-Arl3 
interaction plays a role in the integrity of the photoreceptor connecting cilium and that 
the progression of disease due to mutations in RP2 may be due to disruption of this 
function.
This chapter aims to investigate the nature of the RP2-Arl3 interaction and build on 
the previously known information regarding the interaction in order to elucidate the 
role of RP2 and Arl3 in the pathogenesis of RP resulting from mutations in RP2.
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4.2 Arl3 and Arl2
4.2.1 RP2 interacts with Ari3
Arl3 was the most commonly detected RP2 interactor in the yeast two-hybrid screen 
as described in Chapter 3. Several different Arl3 cDNAs were identified. Predicted 
amino acid sequences of three different clones are shown in Figure 4.1 A. These 
clones have different N-termini; cDNA 1 is missing the first 3 amino acids of the 
predicted sequence, cDNA 2 has an arginine codon prior to the methionine start 
codon, and cDNA 3 is missing the methionine start codon. This demonstrates that 
they originated from different cDNA clones. There was no evidence of alternatively 
spliced isoforms. The cDNAs express nearly full length Arl3, thus giving no indication 
of the RP2 binding site for Arl3 except that the first 3 amino acids of Arl3 are not 
necessary for RP2 binding as seen in ‘Arl3 cDNA T (Figure 4.1). Not all of the Arl3 
clones were sequenced as colony PCR was used to identify Arl3 clones during 
processing as described in sections 2.1.10 and 3.3.1. The predicted bovine Arl3 
amino acid sequence is 98.6% identical to human Arl3 with only three amino acid 
substitutions at positions 79, 152 and 178, two of which are conservative (79 Lysine 
to Arginine and 178 Asparagine to Serine) (Figure 4.1 A).
Arl3 is a member of the Ras superfamily of small GTPases and as such it was 
possible that it was acting as a false positive in this system. Yeast were re­
transformed with the pMyr-Arl3 plasmid and either pSos or pSos-RP2 to ensure that 
Arl3 was binding specifically to RP2 and not hSos, as described in section 2.2.4. Arl3 
was shown to bind specifically to RP2 as there was no growth at the restrictive 
temperature when hSos and Arl3 are co-expressed (Figure 4.1B).
In order to further test the interaction human Arl3 was cloned into pSos as described 
in 2 .1.2-9 by PCR amplification from an IMAGE clone (No. 3926032) (see section 
2.1.10-11). Cdc25-Ha yeast cells were transformed with pSos-Arl3 and grown at the 
restrictive and permissive temperatures for 10 days (as described in section 2.2.4). 
The hSos-Arl3 fusion protein appeared to transactivate the SRS system as 50% of 
the transformed yeast colonies were able to grow at the restrictive temperature in the 
absence of an interaction. In repeat experiments approximately 50% of pSos-Arl3 
transformants grew at 37°C, and 50% did not. Therefore pSos-Arl3 could not be 
used reliably in the CytoTrap system.
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Bovine Arl3 
Arl3 cDNA 1 
Arl3 cDNA 2 
Arl3 cDNA 3 
Human Arl3
-MGLLSILRKLKSAPDQEVRILLLGLDNAGKTTLLKQLASE
 LSILRKLKSAPDQEVRILLLGLDNAGKTTLLKQLASE
RMGLLSILRKLKSAPDQEVRILLLGLDNAGKTTLLKQLASE 
— GLLSILRKLKSAPDQEVRILLLGLDNAGKTTLLKQLASE 
-MGLLSILRKLKSAPDQEVRILLLGLDNAGKTTLLKQLASE
40
Bovine Arl3 
Arl3 cDNA 1 
Arl3 cDNA 2 
Arl3 cDNA 3 
Human Arl 3
DISHITPTQGFNIKSVQSQGFKLNVWDIGGQRKIRPYWRN 80 
DISHITPTQGFNIKSVQSQGFKLNVWDIGGQRKIRPYWRN 
DISHITPTQGFNIKSVQSQGFKLNVWDIGGQRKIRPYWRN 
DISHITPTQGFNIKSVQSQGFKLNVWDIGGQRKIRPYWRN 
DISHIT PTQGFNIKSVQSQG FKLNVWDIGGQRKIRPYWKN
Bovine Arl3 
Arl3 cDNA 1 
Arl3 cDNA 2 
Arl3 cDNA 3 
Human Arl3
YFENTDILIYVIDSADRKRFEETGQELAELLEEEKLSCVP 120 
YFENTDI LI YVIDSADRKRFEETGQELAELLEEEKLSCVP 
YFENTDILIYVIDSADRKRFEETGQELAELLEEEKLSCVP 
YFENTDILI YVI DSADRKRFEETGQELAELLEEEKLSCVP 
YFENTDILI YVI DSADRKRFEETGQELAELLEEEKLSCVP
Bovine Arl3 
Arl3 cDNA 1 
Arl3 cDNA 2 
Arl3 cDNA 3 
Human Arl3
VLIFANKQDLLTAAPASEIAEGLNLHTIRDRFWQIQSCSA 160
VLIFANKQDLLTAAPASEIAEGLNLHTIRDRFWQIQSCSA
VLIFANKQDLLTAAPASEIAEGLNLHTIRDRFWQIQSCSA
VLIFANKQDLLTAAPASEIAEGLNLHTIRDRFWQIQSCSA
VLIFANKQDLLTAAPASEIAEGLNLHTTRDRVWQIQSCSA
Bovine Arl3 
Arl3 cDNA 1 
Arl3 cDNA 2 
Arl3 cDNA 3 
Human Arl3
LTGEGVQDGMNWVCKNVSAKKK 182
LTGEGVQDGMNWVCKNVSAKKK
LTGEGVQDGMNWVCKNVSAKKK
LTGEGVQDGMNWVCKNVSAKKK
LTGEGVQDGMNWVCKNVNAKKK
B 24°C 37°C
pSos-RP2
pSos
pMyr-Arl3
Figure 4.1 Arl3 cDNAs that interacted with RP2
A Predicted amino acid sequences of three different Arl3 cDNAs detected as RP2 
interactors using CytoTrap. Residues coloured red indicate differences between the 
human and bovine Arl3 sequences. B Cdc25-Ha yeast transformed with pMyr-Arl3 
and pSos-RP2 or pSos showing no growth at 37°C with hSos, and specific growth 
with Arl3 and hSos-RP2.
96
Chapter 4 -  Characterisation of the interaction of RP2 and Ari3
4.2.2 RP2-A/12 interaction
Arl3’s closest phylogenetic relative is Arl2, they share 53% primary amino acid 
sequence identity and 63% similarity (Hillig et al., 2000, Hanzal-Bayer et al., 2002). It 
has been previously reported that Arl2 and Arl3 share some interacting partners, as 
described in section 1.6. Arl2 has not been previously reported to bind to RP2 (e.g. 
Bartolini et al., 2002). In this study, Arl2 was identified as an RP2 interacting partner 
with six clones isolated from library screening. Two of the Arl2 clones detected as 
RP2 interactors were sequenced as described in 2.1.9, and were identical in their 
nucleotide sequence. Other Arl2 clones detected in the screen were identified using 
bacterial colony PCR as described in 2.1.10 and 3.3.1. The predicted amino acid 
sequence translated from the Arl2 cDNA clones is shown in Figure 4.2, the 5’ 
sequence prior to the methionine start codon represents in-frame 5’UTR sequence. 
The predicted amino acid sequence for bovine Arl2 is 99% identical to human Arl2 
with amino acid substitutions at positions 108 and 182. There was a single residue in 
the bovine Arl2 cDNA clone at amino acid position 134 which differed from the 
predicted bovine Arl2 protein sequence on the UCSC database. UCSC and Genbank 
databases were used to search for bovine Arl2 cDNAs to compare predicted amino 
acid sequences. All mRNAs, cDNAs and ESTs on the database were S134, coded 
by TCC, whereas the two cDNAs isolated from the CytoTrap screen were F134, 
coded by TTC. This sequence variation may represent a rare polymorphism present 
in the library or may be due to a mistake in the reverse transcription reaction used to 
make the library. Human Arl2 (IMAGE clone no. 3140402) was cloned into pSos and 
used in parallel with the bovine Arl2 cDNA. There was no difference in behaviour 
when the 2 clones were compared, indicating that the S134F mutation made no 
difference to the ability of Arl2 to bind to RP2 in this system (data not shown).
All putative interactors were tested for their ability to bind specifically to RP2 by re­
transforming yeast with the pMyr clone and either pSos-RP2 or pSos as described in 
section 2.2.4. Figure 4.2 confirms that the Arl2 cDNA identified in the library screen 
is only able to stimulate growth of transformed yeast when hSos-RP2 is also present 
(Figure 4.2).
Having established that both Arl2 and Arl3 could interact with RP2, the relative affinity 
of each interaction was investigated further. Cdc25-Ha yeast were co-transformed 
with pSos-RP2 and either pMyr-Arl2 or pMyr-Arl3 as described in section 2.2.4. 
Tenfold serial dilutions were prepared and 5 pi of the cell suspensions were plated 
onto appropriate selective media in duplicate and incubated at 24°C and 37°C. Cells
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Bovine Arl2 
Arl2 cDNA 1 
Human Arl2
------- MGLLTILKKMKQKERELRLLMLGLDNAGKTTILKK 35
PGGGYRDMGLLTILKKMKQKERE LRLLMLGLDNAGKTTILKK 
--------MGLLTILKKMKQKERELRLLMLGLDNAGKTTILKK
Bovine Arl2 
Arl2 cDNA 1 
Human Arl2
FNGEDTDTISPTLGFNIKTLEHRGFKLNIWDVGGQKSLRSYW 77 
FNGEDIDTISPTLGFNIKTLEHRGFKLNIWDVGGQKSLRSYW 
FNGEDIDTISPTLGFNIKTLEHRGFKLNIWDVGGQKSLRSYW
Bovine Arl2 
Arl2 cDNA 1 
Human Arl2
RNY FE S T DG LIWVVDSADRQRMQDCQRELQNLLVEERLAGAT 119 
RNY FE S T DG LIWVVDSADRQRMQDCQRELQNLLVEERLAGAT 
RNYFESTDGLIWVVDSADRQRMQDCQRELQSLLVEERLAGAT
Bovine Arl2 
Arl2 cDNA 1 
Human Arl2
LLIFANKQDLPGALSSNAIREALELDSIRSHHWCIQGCSAVT 161
LLIFANKQDLPGALFSNA1REALELDSIRSHHWCIQGCSAVT
LLIFANKQDLPGALSSNAIREALELDSIRSHHWCTQGCSAVT
Bovine Arl2 
Arl2 cDNA 1 
Human Arl2
GENLLPGIDWLLDDIS SRIFMAD 184 
GENLLPGIDWLLDDISSRIFMAD 
GENLLPGIDWLLDDISSRIFTAD
B 24°C 37°C
pSos-RP2
pSos
pMyr-Ar!2
Figure 4.2 RP2-Arl2 interaction detected with CytoTrap
A Predicted amino acid sequence of Arl2 cDNA detected as an RP2 interactor using 
CytoTrap. Red residues show residues that differ between the bovine and human 
Arl2 sequences. The blue residue indicates a residue in the cDNA clone that differs 
from both the human and bovine Arl2 sequences on the database (UCSC). B Cdc25- 
Ha yeast cells transformed with pMyr-Arl2 and pSos-RP2 or pSos showing no growth 
at 37°C for hSos, and specific binding of Arl2 to RP2.
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transformed with pSos-RP2 and pMyr-Arl3 grew at a faster rate compared to RP2- 
Arl2 co-transformed cells. Figure 4.3A shows the difference observed. Although 
more yeast were plated in the Arl2 dilutions (as seen at 24°C), at 37°C yeast 
transformed with Arl3 exhibited more growth. This would indicate that the RP2-Arl3 
interaction was of a higher affinity than the RP2-Arl2 interaction.
4.2.3 Domain mapping
RP2 constructs were designed to map the interaction domain of RP2 for any 
interacting proteins identified. These constructs are shown in the schematic in Figure 
4.3B. The constructs were designed to maximise stability of the peptides based on a 
predicted structure (Evans et al., 2006). The RP2 constructs were designed to 
determine if the N-terminus (RP2 1-200) or C-terminus (RP2 190-350) contained the 
binding domain for the putative interacting partner. To further characterise potential 
binding domains two smaller constructs were designed to include the two known 
homology domains in RP2: the TBCC homology domain (RP2 41-200) and the NDK 
homology domain (RP2 238-350) as described in section 1.4.2. The domains were 
amplified by PCR and cloned into pSos as described in sections 2.1.10-11 and 2.1.2- 
9. The expression levels of all RP2-hSos constructs were investigated by Western 
blotting of transformed yeast protein extracts with an antibody to hSos (as described 
in 2.2.6-8). The expression level of the constructs was different (Figure 4.3C). The 
C-terminal fragment (RP2 190-350) expressed at a level comparable to full length 
RP2 (wtRP2), whereas the NDK homology domain (RP2 238-350) expressed at a 
lower level (see Figure 4.3C). The N-terminal domain (RP2 1-200) expressed at a 
slightly higher level than the TBCC domain (RP2 41-200), but both expressed at a 
higher level than the NDK domain (RP2 238-350) and less than full length RP2 
(Figure 4.3C).
Having established that the RP2 domain constructs were expressed in Cdc25-Ha 
cells at detectable levels, the yeast were co-transformed with the RP2-hSos 
constructs and either pMyr-Arl2 or pMyr-Arl3 (see section 2.2.4). Arl2 required full 
length RP2 to grow, while the Arl3 interaction was observed with the N-terminus of 
RP2 (RP2 1-200) (see Figure 4.3D). Yeast growth was also detected with the RP2 
41-200 construct co-expressed with Arl3, although less growth was observed 
compared to wild type RP2 or RP2 1-200. This may be because the RP2 41-200 
construct expressed at lower levels than RP2 1-200 (Figure 4.3C).
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Figure 4.3 Delineation of the Arl binding domain of RP2
A Cdc25-Ha yeast cells co-transformed with pSos-RP2 and pMyr-Arl2 or pMyr-Arl3 
grown for 70 hours at the restrictive and permissive temperatures as indicated. B 
Schematic showing RP2 homology domains and the constructs designed for mapping 
the interaction domain of RP2. C Western blot using an antibody to hSos showing 
the expression levels of RP2 constructs in Cdc25-Ha yeast. D Cdc25-Ha yeast co­
transformed and grown for 96 hours indicating that Arl3 interacts with the N-terminus 
of RP2 (1-200). RP2 41-200 was sufficient for growth. Arl2 required full length RP2 
for growth.
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4.2.4 RP2 interacts preferentially with GTP-bound Ar13
The optimal conditions for the RP2-Arl3 interaction have been described as Arl3 
being in the ‘active’ GTP-bound state and RP2 being non-myristoylated (Bartolini et 
al., 2002) described in section 1.6.1. In order to investigate the binding further, 
’locked’ forms that mimic GTP-bound (Q71L) and GDP-bound (T31N) conformations 
of Arl3 were created using site directed mutagenesis in pMyr-Arl3 as described in 
section 2.1.12 (Bourne etal., 1990).
Cdc25-Ha cells were co-transformed with pSos-RP2 constructs and each of the 
pMyr-Arl3 mutants as described in section 2.2.4. Figure 4.4A shows the differences 
between wtArl3, Arl3-T31N and Arl3-Q71L growth with full length RP2, RP2 1-200 
and RP2 41-200. As previously described (section 4.2.3) the Arl3-RP2 41-200 
growth was visibly weaker than RP2-Arl3 which provided conditions that allowed 
detection of a visible difference in growth between Arl3-T31N and Arl3-Q71L. The 
Arl3-Q71L mutant appeared to interact with a much higher affinity than Arl3-T31N 
(Figure 4.4A). wtArl3 behaved in a similar way to Arl3-T13N, suggesting that in this 
system the majority of wtArl3 is in the GDP-bound conformational state.
4.2.4.1 GST pulldown assays to confirm the RP2-Arl3 interaction
GST-Arl3 (T31N and Q71L) protein was purified as described in section 2.3.7 for use 
in pulldown assays. GST pulldown assays using GST-Arl3-T31N and GST-Arl3- 
Q71L (see section 2.3.7) demonstrated clear differentiation between the two Arl3 
mutants showing significantly stronger binding of endogenous RP2 with Arl3-Q71L 
using both HeLa and COS7 cell lysates (Figure 4.4B). No non-specific binding to 
GST was detected. These assays confirmed the differences in binding affinities 
detected with the CytoTrap assay. A GST-RP2 pulldown assay was also performed 
to investigate the binding of endogenous Arl3 to RP2 (Figure 4.4C). No clear, 
specific signal for endogenous Arl3 was detected as binding to GST-RP2 or to GST 
alone.
4.2.4.2 Co-immunoprecipitations to confirm an RP2-AM3 interaction 
Co-immunoprecipitations were performed to confirm RP2’s enhanced binding affinity 
for Arl3-GTP (Figure 4.5). Co-immunoprecipitations were performed as described in 
section 2.3.6 using myc-tagged Arl3 constructs and RP2-GFP. The optimal DNA 
ratios for transfection, in order to obtain good expression of both proteins, was 
determined to be 1:19 (RP2:Arl3). In control experiments with no RP2-GFP or no 
myc-Arl3-Q71L no non-specific immunoprecipitation was detected (Figure 4.5A).
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A 24°C 37°C
wtRP2
24°C 37°C 24°C 37°C
1-200
41-200
wtArl3 Arl3-T31 N Arl3-Q71L
B
36kDa—
HeLa Lysate 
COS7 Lysate
—  RP2
Input GST-Arl3-T31N GST-Arl3-Q71L GST
HeLa Lysate 
COS7 Lysate
28kDa
17kDa
Input GST-RP2 GST
Figure 4.4 RP2 preferentially interacts with Arl3-GTP
A Wild type Arl3 (wtArl3), Arl3-T31N, and Arl3-Q71L pMyr constructs in Cdc25-Ha 
yeast co-transformed with hSos-RP2 constructs grown at 24°C and 37°C for 72 
hours. Comparison of RP2 41-200 with the Arl3 mutants shows more growth with 
Arl3-GTP. B GST pull-down assay using GST-Arl3-T31N, GST-Arl3-Q71L and GST 
alone with HeLa or COS7 cell lysates. Endogenous RP2 bound to the GST-fusion 
proteins was detected using an RP2 antibody. C GST pull-down assay using GST- 
RP2 and GST alone with HeLa or COS7 cell lysates. Endogenous Arl3 was detected 
using an Arl3 antibody.
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Figure 4.5 Analysis of the RP2-Arl3 interaction using co-immunoprecipitation
A Co-immunoprecipitations of CHO cell lysates transfected with myc-Arl3-Q71 and 
RP2-GFP, immunoprecipitated with an anti-myc (9E10) antibody and immunoblotted 
with an antibody to GFP. B Analysis of the immunoprecipitated protein was 
performed using an antibody to myc (9E10). The antibody light chain (at 25kDa) 
prevented clear visualisation of the immunoprecipitated myc-Ar!3 proteins. C Co- 
immunoprecipitations of CHO cell lysates transfected with myc-Arl3 (wt, T31N, Q71L) 
constructs as indicated and RP2-GFP using the same antibodies as in A. * indicates 
the antibody heavy chain.
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There was only detectable co-precipitation of RP2-GFP in the presence of myc-Arl3- 
Q71L (Figure 4.5A). To determine any difference in binding affinity of RP2 for wtArl3, 
Arl3-T31N and Arl3-Q71L immunoprecipitations were performed as described 
previously but using myc-wtArl, myc-Arl3-T31N and myc-Arl3-Q71L. To ensure there 
was equal immunoprecipitation of the myc-Arl3 proteins the cell lysates were 
analysed using an antibody to myc (9E10). Due to the presence of the antibody light 
chain at a similar molecular weight as myc-Arl3 it was difficult to clearly visualise the 
immunoprecipitated myc-Arl3 (Figure 4.5B). Immunoprecipitation of myc-wtArl3 and 
myc-Arl3-T31N did not result in co-immunoprecipitation of RP2-GFP, only 
precipitation of myc-Arl3-Q71L led to the co-immunoprecipitation of RP2-GFP (Figure 
4.5C).
4.2.5 RP2 pathogenic mutants disrupt the RP2-Ar13 interaction 
To determine the significance of the RP2-Arl3 interaction in the context of the 
development of RP, the effect of several known RP2 pathogenic mutations on the 
interaction were investigated. Initially, four pathogenic mutations were chosen 
(Figure 4.6A); R118H is the most common missense mutation in RP2 RP patients 
(see Table 1.3), C67Y and C86Y have been predicted to destabilise the protein 
(Dodatko et al., 2004, Kuhnel et al., 2006), these three mutations are all found in the 
TBCC homology domain and are conserved between either TBCC or TBCCD1 
(Figure 1.4). The fourth mutation, L253R, is the only reported missense mutation 
which lies within the NDK homology domain and is conserved with NDK (see section 
1 .4.2.2).
RP2-hSos was engineered to contain the four pathogenic mutations (as previously 
described in 2.1.12) and these constructs were then used in the CytoTrap system to 
observe the effects of the mutations on the RP2-Arl3 interaction. The expression 
levels of the hSos-RP2 fusion proteins were checked, as described in sections 2.2.6- 
8 , and were observed to have different expression levels (Figure 4.6B). The C86Y 
mutant expressed at a comparatively very low level, with L253R also expressing well 
below wild type. C67Y and R118H appeared to express at a comparable level to wild 
type RP2. Each pSos-RP2 mutant was tested for their ability to allow growth at 37°C 
with pMyr-Arl3, pMyr-Arl3-T31N and pMyr-Arl3-Q71 L (Figure 4.6C). Again, wtArl3 
and Arl3-T31N behaved similarly while Arl3-Q71L appeared to bind to all the mutant 
RP2 proteins with a higher affinity. All the RP2 mutants were still able to stimulate 
growth with Arl3 except C86Y which was only able to grow with Arl3-Q71 L, albeit to a
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Figure 4.6 Effects of RP2 missense mutations on the affinity of the RP2-Arl3 
interaction
A RP2 schematic showing the position of the missense mutations studied. B 
Western blot using an antibody to hSos showing expression levels of the hSos-RP2 
mutants in Cdc25-Ha cells. C Cdc25-Ha yeast co-transformed with the pSos-RP2 
mutants and pMyr-Arl3, pMyr-Arl3-T31N or pMyr-Arl3-Q71L at the restrictive and 
permissive temperatures. Reduced growth was observed with RP2-C86Y. D Co- 
immunoprecipitations of myc-Arl3-Q71L and RP2-GFP mutants. myc-Arl3-Q71L was 
precipitated using an antibody to myc and bound RP2-GFP was detected using an 
antibody to GFP. * indicates the antibody IgG heavy chain.
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lesser degree than wild type RP2 (Figure 4.6C). A recently reported mutation 
(R211H) was made (see section 2.1.12) and has no effect on Arl3 binding (data not 
shown).
Site directed mutagenesis (see section 2.1.12) was used to engineer these mutations 
in RP2-GFP. CHO cells were transiently transfected with the constructs as described 
in section 2.3.4-5 and imaged using confocal microscopy to observe the cellular 
localisation of these mutants and how they may differ from wild type RP2 localisation. 
C67Y and C86Y both differed from the wild type RP2 protein localisation. Both 
mutant proteins appeared to form intracellular inclusions (Figure 4.7) and many of the 
transfected cells either died post-transfection or appeared to be amorphic. Both of 
these mutants therefore cause misfolding of the protein with the C86Y mutation 
resulting in more large intracellular inclusions and reduced plasma membrane 
localised RP2 when compared to C67Y. The R118H mutant localised predominantly 
to the plasma membrane (Figure 4.7) and was indistinguishable from wild type RP2 
as previously reported (Chappie et al., 2000). The L253R mutant protein formed 
many small inclusions throughout the cytoplasm of the cell indicating some misfolding 
of the protein although to a lesser extent or following a different processing pathway 
than C67Y or C86Y (Figure 4.7). This would appear to correlate with the apparent 
ability, or lack thereof, of each mutant to stimulate the growth of pMyr-Arl3/pSos-RP2 
co-transformed yeast at 37°C, as only C86Y appears to misfold to such an extent that 
there is severely reduced RP2 available on the plasma membrane, and in the 
cytoplasm. Although both C67Y and L253R misfold there is evidence of some RP2 
correctly folded and localised to the plasma membrane (Figure 4.7).
Co-immunoprecipitations were also used to analyse the binding of RP2 mutants to 
Arl3. This method had previously provided a complementary method to distinguish 
binding affinities (section 4.2.3.2). Co-immunoprecipitations were performed as 
previously described in 2.3.6 and are shown in Figure 4.6D. The ‘Inputs’ panel 
shows the amount of expressed and soluble RP2 and this appears to correlate with 
the immunocytochemistry (Figure 4.7) and hSos-RP2 expression levels (Figure 
4.6B). C86Y was expressed at the lowest level, most likely due to misfolding and 
subsequent degradation or insolubility. wtRP2 was expressed at the highest level 
and was immunoprecipitated with Arl3-Q71L. Longer exposures revealed both C67Y 
and L253R were co-immunoprecipitated, but at considerably lower levels than 
wtRP2. There was no evidence of C86Y being precipitated with Arl3-Q71L but this is 
most likely due to the low level of protein input in the assay, it could be predicted that
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Figure 4.7 Subcellular localisation of RP2 pathogenic mutants
Immunofluorescence confocal microscopy of CHO cells transfected with RP2-GFP 
mutant constructs, showing mis-localisation of RP2 for C67Y (small and large 
inclusions), C86Y (large inclusions) and L253R (small cytoplasmic inclusions) 
mutants. Plasma membrane staining was observed for wtRP2 and R118H-RP2. The 
larger peri-nuclear inclusions are marked by arrows and smaller inclusions are 
highlighted with arrowheads. Scale bars are 10 pm.
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if there was a comparable level of soluble protein as wild type, binding to Arl3-Q71L 
may have been detected. Interestingly, R118H was not immunoprecipitated despite 
being expressed at a level comparable to wild type RP2. Arl2 could not be co- 
immunoprecipitated with RP2 under any conditions (see Figure 4.6D negative 
control).
4.3 Arl6 does not interact with RP2
During the course of this study the first reported role in human disease for an Arl 
family member was published. Arl6 was found to be the causative gene for the BBS3 
locus as discussed in section 1.6.3 (Fan etal., 2004, Chiang et al., 2004). As one of 
the phenotypes of BBS is retinal dystrophy, and Arl6 is also involved in cilia function, 
Arl6 was tested for its ability to bind to RP2. Arl6 was amplified from an IMAGE clone 
as described in section 2.1.10-11 and cloned into the pMyr vector. Cdc25-Ha yeast 
cells were transformed with pSos-RP2 and either pMyr-Arl6 , pMyrSB (positive control 
plasmid) or pMyrLaminC (negative control plasmid) and tested for growth at the 
permissive and restrictive temperatures for 7 days (see section 2.2.4). As shown in 
Figure 4.8A, there was no growth observed for the RP2-Arl6 two-hybrid assay 
suggesting that Arl6 is not able to bind to RP2.
4.4 Cofactor C (TBCC) does not interact with any Arl proteins tested
As discussed in Chapter 1, RP2 shares both sequence and partial functional 
homology with TBCC which functions in the tubulin folding pathway (see 1.5.2). The 
involvement of Arl2 in the regulation of the tubulin GAP activity through TBCD and 
the ability of Arl3 to bind to RP2 through the TBCC homology domain of RP2 led to 
the question as to whether TBCC was able to bind to an Arl protein. TBCC was 
therefore cloned into the pSos vector (sections 2.1.10-11 and 2.1.2-9) and the 
expression level was analysed after transforming yeast with the plasmid as described 
in sections 2.2.6-8 (Figure 4.8B). The hSos-TBCC protein expressed at a level 
similar to wtRP2 as shown in Figure 4.8B and the hSos moiety was functional, as 
yeast growth was observed using the positive control pMyrSB plasmid (Figure 4.8C). 
Cdc25-Ha yeast were co-transformed with pSos-TBCC and pMyr-Arl2, wtArl3, Arl3- 
T31N, Arl3-Q71L, and Arl6  as described in section 2.2.4. After 10 days of 
observation at the restrictive and permissive temperatures there was no evidence of 
an interaction between TBCC and any of the Arl proteins tested (Figure 4.8C).
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Figure 4.8 Interaction of the Arl family of proteins with RP2 and its homolog 
TBCC
A Cdc25-Ha yeast co-transformed with pSos-RP2 and pMyr-Arl6 and control 
plasmids grown for 96 hours at the restrictive and permissive temperatures. B 
Western blot of co-transformed yeast total protein using an antibody to hSos shows 
that hSos-TBCC protein is expressed. C Cdc25-Ha yeast co-transformed with pSos- 
TBCC and various pMyr-Arl plasmids and grown for 120 hours at the restrictive and 
permissive temperatures. The positive control shows the hSos moiety of the hSos- 
TBCC fusion protein is functional in the system.
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TBCCD1 (described in section 1.4.2.1) was also cloned into the pSos vector as 
described in sections 2.1.10-11 and 2.1.2-9 and the expression level of the hSos- 
TBCCD1 protein was analysed (sections 2.2.6-8). However the hSos-TBCCD1 
protein was undetectable using western blotting, although hSos alone was detected 
(data not shown). Therefore TBCCD1 could not be used in this system to analyse 
binding to the Arl proteins. TBCCD1 was also cloned into the pCMV-Tag3b vector for 
use in mammalian cells (sections 2.1.10-11 and 2.1.2-9) and was not detectable in 
transfected cell lysates using western blotting or in transfected cells using 
immunocytochemistry (data not shown).
4.5 Cellular localisation of RP2 and Arl3
Arl3 and RP2 have both been reported to localise to different cellular compartments 
in cell lines and in retina. While RP2 is found predominantly on the plasma 
membrane in all retinal and non-retinal cell types tested (Chappie et al (2000), 
Chappie et al., (2002), Grayson et al. 2002), Arl3 appears to act as a microtubule 
associated protein (MAP) and was enriched in the connecting cilium in 
photoreceptors (Grayson et al., 2002) (see section 1.6.1). To date, there is no 
evidence of endogenous RP2 and Arl3 proteins co-localising, and as such the site of 
the RP2-Arl3 interaction within cells is unclear.
4.5.1 Cellular localisation of tagged Arl3 protein
In order to distinguish between the T31N and Q71L Arl3 mutants the proteins were 
expressed with a tag. Arl3 has a potential myristoylation signal at its N-terminus, 
although there is currently no evidence that Arl3 is myristoylated or targeted to 
membranes. However, the choice of tag for use with transfected protein may alter 
the potential for this post translational modification. The Arl3 mutant constructs 
(T31N and Q71L) were, therefore, cloned into vectors with N- and C-terminal tags 
and all experiments were performed with Arl3 tagged at both termini. myc-wtArl3, 
myc-Arl3-T31N, myc-Arl3-Q71L, wtArl3-VSV, Arl3-T31N-VSV, and Arl3-Q71L-VSV 
were transfected into CHO cells as described in section 2.3.4-5 and all had a similar 
subcellular localisation. The protein was observed diffusely throughout the cell, 
predominantly localised to the cytoplasm with some nuclear staining evident (Figure 
4.9).
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Figure 4.9 Subcellular localisation of tagged Arl3
A Immunofluorescence of CHO cells transiently transfected with myc-wtArl3, myc- 
Arl3-T31N, or myc-Arl3-Q71L. B Immunofluorescence microscopy of CHO cells 
transiently transfected with wtArl3-VSV, Arl3-T31 N-VSV or Arl3-Q71L-VSV. All scale 
bars are 10pm.
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4.5.2 Localisation of endogenous RP2 when Arl3 was over-expressed 
Endogenous RP2 localisation was investigated in HeLa cells (see sections 2.3.4-5) 
and was observed to localise predominantly to the plasma membrane and exhibited 
some cytoplasmic staining (Figure 4.10A) as previously reported (Chappie et al., 
2000, Chappie et al., 2002, Grayson et al., 2002). The effect of excess Arl3 on RP2 
localisation was investigated. HeLa cells were transiently transfected with myc-Arl3 
mutants and were stained for endogenous RP2 and the transfected Arl3 protein (see 
sections 2.3.4 and 2.3.5. Endogenous RP2 localisation did not appear to alter in the 
presence of myc-Arl3-T31N (Figure 4.10B). However, an increase in intracellular 
RP2 surrounding the nucleus was observed in the presence of myc-Arl3-Q71L in 
approximately 30% of transfected cells (see Figure 4.10C). This localisation pattern 
was also occasionally observed in cells lacking myc-Arl3-Q71L (approximately 10% 
of cells observed). The significance of this re-localisation of RP2, therefore, required 
further investigation.
4.5.3 Investigation of the co-localisation of RP2-GFP and myc-Ar13-Q71L
To further investigate the ability of Arl3-Q71L to promote the relocalisation of RP2 
and to determine if there was any co-localisation between RP2 and Arl3, the effect of 
co-expressing RP2-GFP and myc-Arl3 was investigated. RP2-GFP alone was 
transfected into CHO cells (see 2.3.4-5) and exhibited a predominantly plasma 
membrane localisation (Figure 4.11A). RP2-GFP was then co-transfected with either 
myc-Arl3-T31N or myc-Arl3-Q71L into CHO cells and the cells were stained with an 
antibody to the myc tag. When RP2-GFP and myc-Arl3-T31N were co-transfected 
there was no alteration in the localisation of either protein and no evidence of any co­
localisation (Figure 4.11B). Importantly, when RP2-GFP and myc-Arl3-Q71L were 
co-transfected both proteins exhibited an alteration in their localisation and apparent 
co-localisation (Figure 4.11C). RP2-GFP was enriched intracellularly, in particular 
there was enhanced staining for RP2-GFP around the nucleus in a triangular pattern, 
suggestive of Golgi staining. myc-Arl3-Q71L co-localised with RP2-GFP and was 
also enriched in an apparent Golgi-like pattern. Myc-Arl3-Q71L was also 
occasionally observed on the plasma membrane when co-transfected with RP2-GFP.
4.5.4 Characterisation of the RP2 and Ar13-Q71L interaction
To investigate the re-localisation of RP2-GFP and myc-Arl3-Q71 L a range of cellular 
markers were used for double labelling. CHO cells were transfected as described 
above but Arl3 was not stained and instead antibodies to resident proteins of the ER 
and Golgi were used. Calnexin was chosen as an ER marker as, it is an ER
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Figure 4.10 Localisation of endogenous RP2 with Arl3 over-expression
A Immunofluorescence of HeLa cells stained with an anti-sheep RP2 antibody. 
Endogenous RP2 was localised to the cytoplasm and the plasma membrane (arrows 
highlight plasma membrane staining). B Transient transfection with myc-Arl3-T31N 
and stained for endogenous RP2 and myc-tagged Arl3 in HeLa cells. C Transient 
transfection with myc-Arl3-Q71L and stained for endogenous RP2 and myc-tagged 
protein. Arrowhead highlights intracellular RP2. All scale bars are 10 pm.
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Figure 4.11 RP2-GFP co-localised with myc-Arl3-Q71L
A Immunofluorescence of CHO cells transfected with RP2-GFP showed predominant 
plasma membrane localisation. Arrows highlight plasma membrane staining. B CHO 
cells transfected with RP2-GFP and myc-Arl3-T31 N and stained with an antibody to 
myc. There was no evidence of co-localisation between RP2-GFP and myc-Arl3- 
T31N. C CHO cells transfected with RP2-GFP and myc-Arl3-Q71L and stained using 
an antibody to myc showing extensive co-localisation between RP2-GFP and myc- 
Arl3-Q71L, highlighted by the arrowhead. All scale bars are 10 pm.
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resident chaperone. No co-localisation was observed between the intracellular RP2- 
GFP and calnexin (see Figure 4.12A). (3-COP was used as a Golgi marker and in 
this case co-localisation between intracellular RP2-GFP and (3-COP was observed, 
suggesting the intracellular re-localisation pattern is consistent with Golgi staining 
(Figure 4.12B). In cells transfected with RP2-GFP alone, RP2-GFP was not 
observed to co-localise with (3-COP (Figure 4.12C). These data show that the 
intracellular RP2 observed in the presence of myc-Arl3-Q71L is Golgi associated and 
in the absence of Arl3-Q71L is not Golgi localised but may correspond to an inclusion 
from over-expression.
Further investigation of the increased intracellular staining pattern of RP2-GFP was 
done using a vesicular marker. Early endosome antigen 1 (EEA1) is a marker for 
early endosomes. CHO cells were transfected with RP2-GFP and myc-Arl3-Q71L 
and then stained for EEA1 as described in 2.3.4-5. Figure 4.13 shows that there was 
no evidence of co-localisation between the two proteins and it is unlikely that RP2 is 
involved in early endosome vesicle trafficking.
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Figure 4.12 RP2-GFP co-localised with p-COP in the presence of Arl3-GTP
A Immunofluorescence of CHO cells transfected with RP2-GFP and myc-Arl3-Q71L 
and stained with calnexin showed no co-localisation between intracellular RP2-GFP 
and calnexin. B CHO cells transfected with RP2-GFP and myc-Arl3-Q71L and 
stained with p-COP showed co-localisation between intracellular RP2-GFP and p- 
COP. C CHO cells transfected with RP2-GFP alone and stained with p-COP showed 
no co-localisation between intracellular RP2-GFP and p-COP. All scale bars are 10 
pm.
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Figure 4.13 RP2-GFP did not co-localise with EEA1
A Immunofluorescence of CHO cells transfected with RP2-GFP and myc-Arl3-Q71L 
and stained with EEA1. B Zoom of panel A showed no evidence of extensive co­
localisation between RP2-GFP and EEA1. Arrow highlights a region of potential co­
localisation. All scale bars are 10 pm.
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4.6 Live imaging of RP2-GFP
The data from the study described above showed a possible site of interaction for 
RP2 and Arl3 at the Golgi. Interestingly other studies show that Arl proteins are 
involved in protein trafficking at the Golgi (Zhou et al., 2006, van Valkenburgh et al., 
2001). These data suggest that RP2 may have a novel role in the regulation of, or a 
direct involvement in, protein trafficking to or from the Golgi. To investigate this 
hypothesis further and to visualise the normal movement of RP2 in the cell, live 
imaging of RP2-GFP was performed.
CHO cells were transfected with RP2-GFP and myc-Arl3 constructs and the cells 
were then imaged in real time using a Zeiss Axiovert 100M microscope and 
Improvision software for ten minutes as described in section 2.3.8. RP2-GFP alone 
exhibited the expected predominant plasma membrane staining with some protein 
visible in small vesicles moving intracellularly (Figure 4.14B). Because RP2 
decorates the plasma membrane, it was also possible to visualise the considerable 
movement of the membrane itself (Figure 4.14A and Film 1 on enclosed CD). A 
similar localisation and movement was seen when RP2-GFP was co-transfected with 
myc-Arl3-T31N (Figure 4.15 and Film 2). However, a significant difference in RP2- 
GFP cellular localisation was observed when co-transfected with myc-Arl3-Q71L 
(Figure 4.16 and Film 3).
The previously observed altered localisation with an increase in intracellular RP2 in a 
Golgi-like staining pattern (section 4.5) was noted in these imaging experiments 
(Figure 4.11C and 4.12B). There was also a change in behaviour of the RP2-GFP. 
In the presence of myc-Arl3-Q71L the RP2-GFP became more dynamic and there 
appeared to be more intracellular vesicles containing RP2 in the cell (Figure 4.16).
In order to ensure the change in RP2 behaviour was specific and due to the RP2-Arl3 
interaction and not an indirect effect of Arl3-Q71L on membrane traffic, a severely 
truncated RP2-GFP construct was used. The first 15 amino acids of RP2 fused to 
GFP (Chappie et al., 2002) is sufficient for the construct to be localised to the plasma 
membrane and as Arl3 was not able to interact with RP2 through the first 15 amino 
acids (see section 4.2.3) this acts as an RP2 control which should not be directly 
affected by the presence of myc-Arl3-Q71L. The truncated-RP2-GFP when co­
transfected with myc-Arl3-Q71L, did not exhibit the intracellular staining observed 
with wtRP2 but did localise to the membrane (Figure 4.17A and Film 4).
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Figure 4.14 Live imaging of RP2-GFP
A CHO cells transfected with RP2-GFP and imaged in real time using a Zeiss 
Axiovert 100M microscope and Improvision software. The majority of movement 
seen is due to RP2-GFP highlighting the movement of the plasma membrane, an 
example is highlighted with the yellow arrow. B CHO cells treated as in A, the stills 
are taken over a one minute period and show an example of a vesicle moving to the 
plasma membrane, highlighted with the red arrow.
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Figure 4.15 Live imaging of RP2-GFP co-expressed with myc-Arl3-T31N
CHO cells transfected with RP2-GFP and myc-Arl3-T31N and imaged in real time 
using a Zeiss Axiovert 100M microscope and Improvision software. The yellow arrow 
indicates an area of plasma membrane ‘blebbing’. There is relatively little 
intracellular movement of RP2-GFP.
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Figure 4.16 Live imaging of RP2-GFP co-expressed with myc-Arl3-Q71L
A CHO cells transfected with RP2-GFP and myc-Arl3-Q71L and imaged in real time 
using a Zeiss Axiovert 100M microscope and Improvision software. The pink arrow 
shows an example of a vesicle moving toward the Golgi. The yellow arrow shows 
where vesicles appear to bud out from the Golgi. B CHO cells treated as in A, the 
stills are taken over a one minute period and show an example of a vesicle moving to 
the plasma membrane, highlighted by the red arrow.
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RP2-R118H-GFP was co-transfected into CHO cells with myc-Arl3-Q71 L and the 
RP2-GFP was observed as described above (section 2.3.8). The RP2-R118H-GFP 
did not show altered localisation and increased vesicle movement in the presence of 
Arl3-GTP (Figure 4.17B and Film 5) but was visualised predominantly at the plasma 
membrane. The R118H mutant was used in these experiments because as 
previously shown the R118H is not able to interact with Arl3 (section 4.2.4).
Some preliminary analysis of the intracellular movement of RP2-GFP was performed 
by counting vesicles and measuring their rates of movement. When RP2-GFP was 
transfected alone or in the presence of myc-Arl3-T31N there were notably fewer 
intracellular vesicles than with Arl3-Q71L. For example, in one cell co-transfected 
with RP2-GFP and myc-Arl3-Q71L alone there were 23 clearly identifiable vesicles, 
whilst in a cell transfected with RP2-GFP alone it was only possible to visualize 5 
vesicles. Counting vesicles from a number of different movies it was noted that for 
RP2-GFP alone 66% of the vesicles were seen to be moving towards the membrane, 
while the other 34% appeared to be moving randomly. When cells were co­
transfected with RP2-GFP and myc-Arl3-Q71L 65% of the vesicles were seen to be 
moving towards the membrane, 25% towards the Golgi and 10% apparently 
randomly.
The rate of movement of the RP2-GFP vesicles in the presence of Arl3-Q71L was 
estimated by measuring the distance travelled over time. However the estimate 
obtained may be inaccurate due to the difficulty in precisely following a single vesicle. 
An estimation for the rate of movement of a single vesicle (for an example see Figure 
4.16B) was 4 pm/minute or 0.06 pm/s.
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Figure 4.17 Live imaging of a truncated RP2-GFP construct and RP2-R118H- 
GFP co-expressed with myc-Arl3-T31N
A CHO cells transfected with truncated RP2-GFP and myc-Arl3-Q71L and imaged in 
real time using a Zeiss Axiovert 100M microscope and Improvision software. B CHO 
cells transfected with RP2-R118H-GFP myc-Arl3-Q71L and imaged in real time using 
a Zeiss Axiovert 100M microscope and Improvision software. All the RP-GFP 
movement appears to occur at the membrane.
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4.7 Discussion
The data presented in this chapter illustrates the suitability of CytoTrap as a tool to 
investigate RP2’s protein-protein interactions. CytoTrap was used to independently 
confirm the known RP2-Arl3 interaction and identified a novel putative RP2 interactor; 
Arl2. Library screening resulted in detection of 45 Arl3 clones as RP2 interactors, 
and the interaction was characterised further using RP2 domain constructs and 
pathogenic mutants (Section 4.2.3). RP2 has high affinity for Arl3 in the CytoTrap 
system as shown by the faster growth of yeast co-transformed with pSosRP2 and 
pMyrArl3 than the positive control (Figure 3.4). The RP2-Arl3 interaction was then 
further characterised using co-immunoprecipitations and GST pulldown assays which 
showed that the proteins do interact biochemically. Studies from Bartolini et al and 
Kuhnel et al also corroborated these data, confirming the TBCC-homology domain of 
RP2 acts as the interaction domain for Arl3 (Bartolini et al., 2002, Kuhnel et al., 
2006). Detection and characterisation of the RP2-Arl3 interaction provided 
confidence in the CytoTrap system as an appropriate method to investigate novel 
RP2 interacting partners.
Some differences in binding affinities were observed between data obtained using 
CytoTrap and data from alternative binding assays and published studies (Bartolini et 
al., 2002, Kuhnel et al., 2006). However, this may be explained through the 
differences in methodologies employed. CytoTrap by its design provides one of the 
optimum conditions for this interaction; RP2 is fused to the hSos protein and 
therefore is not myristoylated which reportedly enhances the affinity of interaction 
(Bartolini et al., 2002).
Yeast two-hybrid methods can generate false positive data through detection of 
interactions mediated by common domains, or proteins from the same family which 
exhibit similar structure, or through natural yeast mutations causing the yeast to 
behave as if an interaction was detected. It is possible that Arl2 is a false positive 
given the sequence and structural similarity with Arl3, which may account for the 6 
Arl2 clones detected. The interaction was not confirmed using co- 
immunoprecipitation or GST pulldowns and it was not possible to map the RP2 
interaction domain. Other reports also have not been successful in showing an Arl2- 
RP2 interaction (Bartolini et al. 2002, Kuhnel et al., 2006). Hence, the physiological 
relevance of this interaction is not clear.
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It was unclear why hSos-Arl3 resulted in growth of yeast at the restrictive 
temperature, but only 50% of the time. It is possible Arl3 causes transactivation 
possibly through direct activation of the Ras pathway, or that the hSos-Arl3 is 
expressed at such a high level that some protein reaches the plasma membrane 
even in the absence of an interacting partner.
During the progress of this study, a paper was published defining the crystal structure 
of RP2 and examining the interaction with Arl3 (Kuhnel et al., 2006). Kuhnel et al 
(2006) confirmed the previously published work by Dodatko et al (2004) and Evans et 
al (2006) in which the TBCC homology domain of RP2 was predicted to be a p-helix 
based on the C-terminal actin binding domain of cyclase associated protein (C-CAP) 
(Dodatko et al., 2004, Evans et al., 2006). Kuhnel and colleagues determined that 
the N-terminus of RP2 had a right-handed p-helical structure, with seven coils. The 
C-terminus of RP2 contained a ferredoxin-like a/p domain which was structurally 
related to NDK. The first 33 amino acids of the structure were not visible and 
therefore it is not known how they fit into the overall structure. The ability of RP2 to 
bind to Arl2 and Arl3 was analysed using a quantitative fluorescence polarization 
assay and it was concluded that RP2 only binds to Arl3 and not to Arl2. Although 
these data conflict with the CytoTrap data presented here, the two systems used to 
analyse binding are different and it is likely they have very different detection levels in 
regard to relative interaction affinities.
Kuhnel and colleagues also used fluorescence polarization assays to analyse the 
binding of Arl3 to either the N-terminus (1-230) or the C-terminus (229-350) of RP2. 
Arl3 was only able to bind to the N-terminal domain of RP2, and when a deletion 
mutant missing the first 34 amino acids was also used in this assay it was found that 
this deletion mutant had an affinity for Arl3 300 times lower than full length RP2, 
leading to the authors suggesting that the first 34 amino acids were necessary for 
Arl3 binding.
The data presented in this chapter also show that Arl3 bound to the N-terminus of 
RP2 and, furthermore, that the TBCC-homology domain was sufficient for binding (aa 
41-200). These data conflict slightly with data from Kuhnel et al, in which it was 
suggested that the first 34 amino acids of RP2 are necessary for Arl3 binding. 
However the CytoTrap system is very sensitive to any interaction due to the 
cascading nature of the Ras signalling pathway which the system exploits. The RP2- 
Arl3 interaction is strong in this system, comparable, if not stronger, than the positive
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control (hSos and Rit1). The growth of yeast with pMyr-Arl3 and pSos-RP2 41-200 
was weaker however than wtRP2 and RP2 1-200 which agrees with Kuhnel et al 
(2006), however it is not accurate to directly compare the yeast growth due to the 
lower expression level of the RP2 41-200 construct compared to the wt RP2 or RP2 
1-200 constructs.
Comparison of yeast growth rates between Arl3-T31N and Arl3-Q71L with the RP2 
41-200 domain indicated that RP2 preferentially binds to Arl3-Q71L. These 
observations corroborate the binding assays used by Kuhnel and colleagues which 
state that the binding affinity of RP2 for Arl3-GDP is 400 times lower than for Arl3- 
GTP. Kuhnel et al also found that RP2 has the ability to act as a guanine nucleotide 
dissociation inhibitor (GDI) for GTP-bound Arl3 (Kuhnel et al., 2006). It was not 
possible to detect endogenous Arl3 bound to GST-RP2 in a GST pulldown assay, 
however, this may reflect the guanine nucleotide-bound state of endogenous Arl3. 
As RP2 preferentially binds to GST-Arl3, it is likely that endogenous Arl3 is 
predominantly GDP-bound making it difficult to detect the small proportion of GTP- 
bound Arl3 that may bind to RP2 (Figure 4.6B).
Using CytoTrap to study pathogenic RP2 mutations it was not clear whether the lack 
of interaction between RP2-C86Y and Arl3 was due to the low expression level of the 
hSos-RP2-C86Y (the ability to bind to Ar!3-Q71L would suggest not) or whether this 
mutation affects RP2’s ability to interact with Arl3. The lack of interaction may be 
non-specific as the misfolded protein may not be able to interact with any potential 
interacting partners. Co-immunoprecipitation assays indicated the misfolding 
mutations (C67Y and C86Y) no longer interacted due to there being insufficient 
correctly folded protein. Immunocytochemical analysis showed the misfolded protein 
appears to form inclusions suggesting it was not available for binding to Arl3. The 
L253R mutation would be predicted not to directly affect the interaction with Arl3 as 
the residue is outside the interaction domain. Thus, one would predict that the 
mutation may affect the interaction with Arl3 through a global misfolding effect. The 
R118H mutation, despite being expressed at a level comparable to wild type and 
being correctly localised did not appear to be able to bind to the Arl3-Q71L, which 
suggests the Arginine 118 residue is important for the functionality of the RP2-Arl3 
interaction.
The data presented in this Chapter investigating pathogenic RP2 mutants and their 
ability to bind to Arl3 were in general agreement with the structure published in the
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Kuhnel study (Kuhnel et al., 2006) and predictions based on this structure. Firstly, 
the C67 and C86 residues lie along the ‘backbone’ of the N-terminal helix and their 
substitution to tyrosine residues could result in the destabilisation of the hydrophobic 
core set around these amino acids. The L253R mutation would also be predicted to 
destabilise the protein due to clashes between residues in the hydrophobic core of 
the C-terminal domain (Kuhnel et al., 2006). However, RP2-L253R was able to bind 
to Arl3. The R118H mutation, in contrast, has been predicted to be catalytically 
important, as discussed in Chapter 1, and does not lead to an incorrectly folded 
protein. In their study, Kuhnel et al analysed the effect of the R118H mutation on the 
ability of RP2 to bind to Arl3. They found that this mutation led to an 800 fold 
decrease in affinity for Arl3, this was determined to be below physiological relevance 
leading to the conclusion that the R118H mutation would most likely in vivo result in 
an inability of RP2-R118H to bind to Arl3 which was reflected in the co- 
immunoprecipitation experiments (described in this chapter).
CytoTrap was uniquely sensitive to the RP2-Arl3 interaction which meant that a range 
of affinities were detectable, for example according to Kuhnel et al the interaction 
between Arl3 and RP2-R118H is of an affinity 800 times lower than for wtRP2 and yet 
it was still detectable using CytoTrap, suggesting the method is suitable for detecting 
interactions with a wide range of affinities from low to high. The data obtained from 
CytoTrap, GST pulldown assays and co-immunoprecipitations illustrated the 
importance of using several different types of binding assay when analysing 
interactions and also their individual limitations. The GST-RP2 pulldown for example 
did not detect endogenous Arl3 binding to GST-RP2 due to the low levels Arl3-GTP 
found endogenously.
Prior to the study described in this chapter, there was no strong evidence of where in 
the cell the RP2-Arl3 interaction may occur, the proteins appeared to be expressed in 
a different pattern in the retina (Grayson et al., 2002). When excess RP2 and Arl3- 
GTP were expressed there was a distinctive shift in the localisation of both proteins 
(Figure 4.11C) to the Golgi (Figure 4.12B) which offers a potential cellular interaction 
site. The preference of RP2 to bind to GTP-bound Arl3 and then to prevent the 
dissociation of GTP suggests that the RP2-Arl3 interaction plays an important role in 
stabilising Arl3 in the GTP-bound state which goes against the natural nucleotide 
binding affinity of the protein (Kuhnel et al., 2006). RP2’s ability to act as a GDI and 
the re-localisation of RP2 and Arl3-GTP shown in this chapter suggests that RP2 may
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play an important role in keeping Arl3 in the active GTP-bound form, suggesting RP2 
is an Arl3 effector.
The data obtained using live imaging of RP2 has also provided novel data on RP2’s 
dynamic nature as well as showing a potential role for RP2 and Arl3 in vesicular 
trafficking. Live imaging also clarified that RP2-GFP was not being retained in the 
Golgi in the presence of Arl3-GTP. The presence of Arl3-GTP appears to increase 
the movement of RP2-GFP towards the plasma membrane and also towards the 
Golgi, overall an estimated 5-10 fold increase in intracellular RP2-GFP content was 
observed. The vesicles often move in and out of focus and it is only possible to 
follow them for short periods of time, therefore making accurate rate estimations 
difficult. More accurate calculations of the rate of movement of the RP2-GFP 
vesicles would assist in elucidating the protein trafficking pathway they may be 
involved in.
Table 4.1 Estimated rates for components of the axonal transport system
Adapted from Brady (1991).
The rate of movement for kinesin has been calculated to be 2 pm/sec in an in vitro 
study using purified microtubules (Alberts, 1994), the direction of movement has been 
shown to be toward the microtubule plus end, therefore kinesin motors transport in an 
anterograde direction. The kinesin Ned motor moves cargo in the opposite direction 
at a slower rate of 0.1 pm/sec (Alberts, 1994). The estimated rate of RP2 vesicles 
movement was 0.06 pm/sec, which is slower than that reported for kinesin. The
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kinesin calculation was generated using purified components in vitro and as such is 
likely to be an over-estimation of the true rate in vivo. An accurate estimation of the 
rate of movement of RP2-GFP vesicles would allow a more accurate preposition as 
to the transport mechanism being utilised, and thus more specific experiments to 
determine the nature of the transport.
The possibility of elucidating potential RP2 roles in trafficking and signalling is 
significant when using the technique of live imaging. Fluorescent markers could be 
used to characterise the vesicle-like bodies that contain RP2 which would provide 
clues as to the pathway that RP2 plays a role in. Alternative markers for late 
endosomes (e.g. Lampl) or other vesicle markers, and vesicle coat markers (e.g. 
clathrin) and using fluorescent transferrin receptor in live imaging may provide more 
information on the nature of the RP2 trafficking in the cell and whether it is itself 
involved in the processing and trafficking of proteins.
The use of drugs to disrupt various pathways is possible in live imaging and the cells 
can be directly observed to directly see the effect on the RP2 protein. A potentially 
interesting drug to use would be Brefeldin A which causes disruption of the Golgi 
through inhibiting the action of Arf1. As the likely site of interaction for RP2 and Arl3 
is the Golgi, it would be interesting to see what the effects of fragmenting the Golgi 
would be on RP2 and whether Arl3-GTP still alters the cellular localisation of RP2. It 
would also be interesting to disrupt exocytosis and endocytosis and observe whether 
there is a change in the vesiclular-like movement of RP2. The data from the live 
imaging experiments presented here, combined with an investigation by Yoon et al 
showing that RP2 can translocate to the nucleus under DNA damaging conditions 
indicates that RP2 has the potential to move throughout the cell and is not restricted 
to a plasma membrane association.
Currently the guanine nucleotide exchange factor (GEF) for Arl3 is unknown, thus 
there is relatively little known about the regulatory pathways involved in controlling 
the nucleotide binding state of Arl3. Similarly, the GAP for Arl3 is not known and the 
regulation of the conversion of Arl3-GTP back to Arl3-GDP is unresolved. 
Considering the ability of RP2 to act as a GDI for GTP-bound Arl3 it would be 
interesting to investigate the potential effect of GEFs and GAPs for Arl3 on RP2 
function.
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Live imaging could also be used as a tool to alter the cellular environment to induce 
an increase in endogenous GTP-bound Arl3. RP2-GFP was observed to behave 
differently in the presence of GDP- or GTP-bound Arl3. RP2-GFP could be used as a 
surrogate marker for the levels of GTP/GDP-bound Arl3 in the cell. Using various 
drugs and treatments, RP2-GFP localisation could be observed to investigate the 
conditions which lead to increases in Golgi associated RP2. This could provide 
insight into the cellular circumstances in which the RP2-Arl3 interaction may occur or 
in which pathway it is important.
The elucidation of a potential interaction site at the Golgi and a mutual role in 
vesicular trafficking indicates that the RP2-Arl3 interaction has physiological 
significance. The role of Arl3 in cilia (Schrick et al., 2006, Lai et al., 2007) and the 
importance of the connecting cilium and I FT in photoreceptor function also imply that 
the RP2-Arl3 interaction may have an important role in cilia function. Furthermore 
data from this chapter shows that pathogenic mutations in RP2 appear to disrupt the 
RP2-Arl3 interaction. It could be hypothesised that RP2 and Arl3 act together to 
regulate or utilise vesicular transport to and from the Golgi, perhaps through 
exploiting the microtubule network and as such link the membrane and the 
cytoskeleton through vesicular trafficking.
The data in this chapter has highlighted further the importance and location of the 
RP2-Arl3 interaction, however there is still a considerable amount to discover to 
understand the specific role this interaction plays in the development of RP.
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CHAPTER 5
CHARACTERISATION OF NOVEL PUTATIVE RP2 INTERACTORS
5.1 RAN
5.1.1 Introduction
RAN is a Ras-related small GTPase that localises predominantly to the nucleus and 
has multiple cellular roles. RAN has been shown to be involved in nucleo- 
cytoplasmic transport (Macara, 2001), as well as mitosis, nuclear assembly and cell 
cycle progression (Kornbluth et al., 1994). Although RAN is a member of the Ras 
superfamily it differs from other family members in that it is not prenylated through its 
C-terminus. RAN exists in either a GTP- or GDP-bound form, which is a feature of 
the Ras-related small GTPases. The cellular localisation of RAN is altered 
accordingly, GDP-bound RAN is found in the cytoplasm and the cytoplasmic face of 
the nuclear pore complex (NPC) (Weis et al., 1996, Lounsbury et al., 1996), whilst 
GTP-bound RAN localises to the nucleus and nuclear envelope (Carazo-Salas et al., 
1999). The subcellular localisation of RAN is key to its function and is maintained by 
specific exchange and activating factors. RAN’s nucleotide exchange factor (GEF) 
RCC1 is a chromatin-bound protein thus maintaining GTP-bound RAN in the nucleus 
while RAN’s GTPase activating protein, RanGAPI, is found predominantly in the 
cytoplasm (Figure 5.1 and 5.2) (Matunis etal., 1996).
Interestingly, RanGAPI does not act though an arginine finger, as suggested for 
TBCC and RP2 for the stimulation of the GAP activity of tubulin, and as reported for 
other small GTPases (e.g. Ras and Rho) (Scheffzek etal., 1997, Rittinger et al. 1997, 
Bartolini et al., 2002) (see section 1.5.2). Instead the machinery for GTP hydrolysis 
comes from RAN’s intrinsic ability to correctly position the catalytic glutamine residue 
(Q69) for the hydrolysis to occur (Seewald et al., 2002).
RAN-GTP is involved in the formation of the bipolar mitotic spindle and has been 
shown by Kalab et al (2002) and Caudron et al (2005) to achieve this by establishing 
a spatial concentration gradient of RAN-GTP. As RCC1 is a nuclear protein which is
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chromatin-bound, a high concentration of RAN-GTP is found surrounding the 
chromosomes which consequently facilitates microtubule nucleation and stabilisation 
around the chromosomes which is necessary for the organisation of the microtubules 
into a mitotic spindle (Kalab et al., 2002, Caudron et al., 2005).
RAN also plays a key role in bidirectional transport across the nuclear envelope. 
Figure 5.1 shows the role that RAN plays in nuclear import. A protein with a nuclear 
localisation signal (NLS) binds to Importin-a which in turn binds to Importin-p and the 
complex is relocalised to the nucleus. In the nucleus RAN-GTP binds to Importin-p 
which causes the Importin/NLS complex to dissociate resulting in the nuclear import 
of the target protein. RAN-GTP bound to Importin-p is transported into the cytoplasm 
where RanGAPI converts RAN-GTP to RAN-GDP following GTP hydrolysis. 
Importin-p is released and able to bind to another NLS-protein-lmportin-a complex. 
This process reduces the concentration of RAN-GTP in the nucleus. Levels of RAN- 
GTP in the nucleus are thought to be restored by RAN-GDP binding to nuclear 
transport factor 2 (NTF2), which transports RAN back into the nucleus where it can 
be converted to RAN-GTP by RCC1 (Ribbeck etal., 1998).
RAN is also involved in nuclear export and Figure 5.2 illustrates the proposed 
mechanism for RAN function in nuclear export. The binding of RAN to Exportin 1 is 
the key interaction in the process. Exportin 1 binds to the protein to be exported 
through its nuclear export signal (NES) and RAN-GTP then binds to this complex and 
is exported through the nuclear pore. Once in the cytoplasm the NES-protein is 
released by the conversion of RAN-GTP to RAN-GDP by RanGAPI. Exportin 1 and 
RAN then translocate back to the nucleus, where RAN can then be converted back to 
RAN-GTP by RCC1.
RAN has also been implicated in nuclear envelope assembly. A model for the 
involvement of RAN in this process proposes that due to the high RAN-GTP 
concentration near the chromosomes, RAN-GTP is able to bind to the chromosomal 
histones and recruit nuclear pore complex (NPC) proteins in vesicles, as well as 
Importin-p. Fusion of the vesicles and formation of the nuclear envelope occurs 
following GTP hydrolysis of RAN (Hetzer et al., 2000 and Zhang and Clarke, 2001).
RAN was identified as a putative RP2 interaction partner using CytoTrap and the 
following section describes the identification and characterisation of the interaction.
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Figure 5.1 RAN is involved in nuclear import
Schematic diagram showing the role that RAN plays in nuclear import. The binding 
of RAN-GTP to the nuclear import cargo through Importin-p (Imp-p) causes the 
complex to dissociate thus releasing the nuclear protein in the nucleoplasm. The 
RAN-GTP-lmportin-p complex is then exported through the nuclear pore to the 
cytoplasm where the conversion of RAN-GTP to RAN-GDP by RanGAPI releases 
Importin-p ready to bind to Importin-a. Adapted from Joseph (2006).
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Figure 5.2 RAN is involved in nuclear export as well as nuclear import
Schematic showing the role RAN plays in nuclear export. Exportin 1 binds to the 
target protein through its nuclear export signal, RAN-GTP then binds to Exportinl and 
the complex is exported through the nuclear pore complex. The conversion of RAN- 
GTP to RAN-GDP by RanGAPI causes the complex to dissociate thus releasing the 
cargo. RAN-GDP then binds Exportinl and the complex is imported through the 
nuclear pore into the nucleoplasm where RCC1 converts the RAN-GDP back to RAN- 
GTP. Adapted from Joseph (2006) and Ohno et al., (1998).
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5.1.2 Characterisation of the RP2-RAN interaction
RAN was detected as an RP2 interactor using CytoTrap. Two clones were 
independently identified as interacting clones as described in section 2.2.9. cDNA 
clones were processed and sequenced as described in sections 2 .2 .9.4-5 and 2 .1.9 
and both clones contained the complete open reading frame of RAN (Figure 5.3A). 
The two clones identified contained different lengths of in-frame 5’UTR sequence 
indicating they were amplified from different original cDNAs. Bovine RAN protein 
sequence is 100% identical to human RAN (Figure 5.3A). Cdc25-Ha yeast were co­
transformed with pSos-RP2 or pSos and pMyr-RAN as described in section 2.2.4 and 
grown at the restrictive and permissive temperatures for up to 7 days. Figure 5.3B 
shows that RAN interacts specifically with RP2 and there was no evidence of growth 
at 37°C for the pSos and pMyr-RAN co-transformants
5.1.2.1 RAN interacts with the C-terminal domain of RP2
Cdc25-Ha yeast were co-transformed with deletion and pathogenic missense pSos- 
RP2 constructs (Figure 4.3B) and pMyr-RAN as described in section 2.2.4. 
Transformed yeast were diluted and spotted onto appropriate selective media and 
grown at 24°C and 37°C for up to 7 days. pMyr-RAN was only able to induce growth 
at the restrictive temperature with either wild type RP2 or the C-terminal domain 
construct of RP2 (190-350) indicating that RP2 interacts with RAN through its C- 
terminus (Figure 5.4A). No growth was observed with the N-terminal 1-200 or 41-200 
RP2 constructs. No growth was detected using the shorter C-terminal domain of RP2 
(RP2 238-350). However, it is possible that the shorter C-terminal fragment of RP2 
(RP2 238-350) did not express at sufficient levels to allow an interaction to be 
detected.
The RP2-RAN interaction was characterised further by observing the effect of 
pathogenic RP2 mutations on the ability of RP2 to bind to RAN. Cdc25-Ha yeast 
were co-transformed with various pSos-RP2 mutants (Figure 4.5A) and pMyr-RAN. 
hSos-RP2-R118H was the only mutant for which growth was observed in a manner 
comparable to wild type. hSos-RP2-C67Y was still able to stimulate growth of yeast 
at 37°C but growth was reduced which is most likely explained by the reduced 
expression level compared to wild type. No growth was observed with the hSos- 
RP2-C86Y mutant which is again most likely explained by the low expression level of 
this mutant and the previously characterised misfolding of the protein (section 4.2.4).
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H um an RAN------------- -------- MAAOGEPOVOFKLVLVGDGGTGKTTFVKRHLTGE 34
RAN cD N A l DASGSNIAMAAQGEPQVQFKLVLVGDGGTGKTTFVKRHLTGE
RAN CDNA2 -ASGSNIAMAAQGEPQVQFKLVLVGDGGTGKTTFVKRHLTGE
B o v in e  RAN ------- MAAQGEPQVQFKLVLVGDGGTGKTTFVKRHLTGE
H um an RAN FEKKYVATLGVEVHPLVFHTNRGPIKFNVWDTAGOEKFGGLR 76
RAN cO NA l FEKKYVATLGVEVHPLVFHTNRGPIKFNVWDTAGQEKFGGLR
RAN CDNA2 FEKKYVATLGVEVHPLVFHTNRGPIKFNVWDTAGQEKFGGLR
B o v in e  RAN FEKKYVATLGVEVHPLVFHTNRGPIKFNVWDTAGQEKFGGLR
H um an RAN DGYYIQAQCA1IMFDVTSRVTYKNVPNWHRDLVRVCENIPIV 118
RAN cD N A l DGYYIQAQCAIIMFDVTSRVTYKNVPNWHRDLVRVCENIPIV
RAN CDNA2 DGYYIQAQCAIIMFDVTSRVTYKNVPNWHRDLVRVCENIPIV
B o v in e  RAN DGYYIQAQCAIIMFDVTSRVTYKNVPNWHRDLVRVCENIPIV
H um an RAN LCGNKVDIKDRKVKAKSIVFHRKKNLQYYDISAKSNYNFEKP 160
RAN cD N A l LCGNKVDIKDRKVKAKSIVFHRKKNLQYYDISAKSNYNFEKP
RAN CDNA2 LCGNKVDIKDRKVKAKSIVFHRKKNLQYYDISAKSNYNFEKP
B o v in e  RAN LCGNKVDIKDRKVKAKSIVFHRKKNLQYYDISAKSNYNFEKP
Hum an RAN FLWLARKLIGDPNLEFVAMPALAPPEWMDPALAAQYEHDLE 202
RAN cD N A l FLWLARKLIGDPNLEFVAMPALAPPEWMDPALAAQYEHDLE
RAN CDNA2 FLWLARKLIGDPNLEFVAMPALAPPEVVMDPALAAQYEHDLE
B o v in e  RAN FLWLARKLIGDPNLEFVAMPALAPPEWMDPALAAQYEHDLE
Hum an RAN 
RAN cD N A l 
RAN CDNA2 
B o v in e  RAN
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Figure 5.3 RAN interacts with RP2
A Alignment of the predicted amino acid sequence of two different RAN cDNAs 
detected as RP2 interactors using CytoTrap. Different N-terminal ends show they 
were derived from different cDNA clones. The predicted amino acid sequence is 
100% conserved between human and bovine. Putative GTP-binding motifs are 
underlined. The catalytically important T24, L43 and Q69 residues are highlighted in 
red, green and blue respectively. B Cdc25-Ha yeast transformed with pMyr-RAN and 
either pSos-RP2 or pSos alone grown for 96 hours showing specific binding to RP2. 
C Schematic of RAN showing the predicted GTP-binding motifs and the Ras domain.
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Figure 5.4 Characterisation of the RP2-RAN interaction
A Cdc25-Ha yeast co-transformed with various pSos-RP2 constructs and pMyr-RAN 
showing that RP2 and RAN interact, and that RP2 interacts with RAN through its C- 
terminus (RP2 190-350). The L253R mutation which is located in the C-terminal 
domain of RP2 disrupts the interaction. Yeast were grown for 96 hours. B Yeast co­
transformed with pSos-RP2 and GDP- and GTP-locked conformations of pMyr-RAN, 
grown for 96 hours, indicated that the RP2-RAN interaction was enhanced when RAN 
was in a GDP-locked (T24N) rather than GTP-locked conformation (L43E and Q69L).
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Importantly, the only pathogenic mutation in the C-terminal domain of RP2 tested 
(L253R) caused disruption of the RP2-RAN interaction. This highlights the 
importance of this residue for the function of the C-terminal domain, but it may also 
be possible that the mutant expresses at an insufficient level for this interaction to 
occur (Figure 5.4A).
5.1.2.2 GDP-bound RAN preferentially interacts with RP2
As RAN is known to exist in either a GTP- or GDP-bound form, mutants which lock 
the protein into both conformations were engineered in pMyr using site directed 
mutagenesis (see section 2.1.12). The mutants generated were based on well 
characterized Ras mutants: T24N locks RAN in a GDP conformation and Q69L locks 
RAN in a GTP conformation (Palacios et al., 1996) (Figure 5.3A). An additional 
mutation in the effector domain of RAN which mimics a GTP-bound state was created 
(L43E) (Lounsbury etal., 1996).
Yeast were co-transformed with pSos-RP2 and the GDP and GTP ‘locked’ 
conformations of pMyr-RAN as described in section 2.2.4 and observed for up to 7 
days. Figure 5.4B shows that there was a faster rate of growth between RP2 and 
RAN-T24N compared to L43E or Q69L which suggests that the RP2-RAN interaction 
is enhanced when RAN is in the GDP conformational state.
5.1.2.3 Pulldown assays for the RP2-RAN interaction
In order to corroborate the RP2-RAN interaction a GST-pulldown assay was utilised 
as described in section 2.3.7. Initially, using GST-RP2 as the bait, pulldown of 
endogenous RAN from HeLa cell lysates was investigated. RAN migrated at 
approximately 25kDa as expected. Figure 5.5A shows that RAN was detected as 
being bound to GST-RP2. However, due to the molecular weight of RAN being 
similar to that of GST, it was not possible to determine whether there was any RAN 
bound to the GST control and as such whether the binding to GST-RP2 was specific 
or not. Further resolution of the samples was attempted, but unfortunately it was not 
possible to separate the RAN and GST sufficiently for a definitive answer.
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Figure 5.5 RP2-GST pulldown assays using RAN as a target
A GST pulldown assays were performed using HeLa cell lysates to test if 
endogenous RAN was able to specifically bind to RP2. The presence of GST protein 
at a similar molecular weight to RAN masked the negative control. B Pulldown 
assays using CHO cell lysates transfected with myc-RAN and subsequently blotted 
with anti-myc. RAN bound to RP2-GST was detected. C GST pulldown assays to 
investigate whether RP2 preferentially bound to GDP-locked myc-RAN (T24N) using 
CHO cell lysates transfected with myc-RAN mutants and blotted for myc. Non­
specific binding of myc-RAN to the GST control was detected in this assay.
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RAN was sub-cloned from the pMyr vector into the pCMV-Tag3b vector (see sections 
2.1.2, 2.16-8) to facilitate expression of N-terminally myc-tagged RAN. Transfection 
of this construct allowed over-expression of myc-RAN and investigation of GDP/GTP 
forms of RAN, rather than relying on endogenous levels. Furthermore, the tagged- 
RAN could be resolved from the GST protein allowing more accurate analysis of the 
GST pulldown control. The GST pulldown was carried out as previously described 
but using CHO cell lysates transfected with myc-RAN. RAN bound to GST-RP2 and 
none was detectable in the GST control (Figure 5.5B) indicating that RP2 can bind to 
myc-RAN in this assay. The myc-RAN used in this assay is different from the 
endogenous RAN detected in the HeLa cell lysates which appears to bind to RP2 
with a higher affinity, as it has the additional in-frame 5’UTR sequence of bovine 
cDNA clone 2 (Figure 5.3), as well as a myc tag at the N-terminus. As the 
mechanism of this interaction and the RP2 interaction domain of RAN is not known, 
the effect of this additional N-terminal sequence on the interaction affinity is also not 
known and may explain the apparently reduced amount of RAN detected as binding 
to RP2.
As described in section 5.1.2.2, RP2 preferentially bound to RAN in the GDP-locked 
conformation (RAN-T24N mutant), therefore RAN mutants were also sub-cloned into 
the pCMV-Tag3b vector and were used in a GST pulldown assay with the 
expectation that RP2 would bind to the T24N mutant with a higher affinity. Figure 
5.5C shows the results of the assay. In this experiment all the RAN mutants bound to 
GST-RP2 but also bound to GST. It was not possible to distinguish between RP2 
and GST binding in this assay.
5.1.2.4 Subcellular localisation of RAN
In order to investigate the subcellular location of the RP2-RAN interaction 
immunocytochemical studies were performed to observe the localisation of 
endogenous and over-expressed RAN with RP2-GFP. RAN’s subcellular localisation 
in SK-N-SH cells was detected using a commercial antibody to RAN as described in 
section 2.3.5. As previously reported, RAN was observed to be predominantly 
nuclear but was also detected in the cytoplasm of the cell (see Figure 5.6A) (Macara 
et al., 2001). To investigate potential co-localisation between RP2 and RAN and 
therefore a subcellular site of interaction, SK-N-SH cells were transfected with RP2- 
GFP and stained for RAN as described in section 2.3.4.1-2.3.5. Apart from some 
distribution of both proteins in the cytoplasm, no subcellular co-localisation was 
observed.
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RAN
RAN RP2-GFP Merge
A
B
Figure 5.6 Subcellular localisation of endogenous RAN and RP2-GFP
A Immunofluorescence of SK-N-SH cells stained for endogenous RAN showing a 
predominantly nuclear (see arrowheads) localisation pattern with evidence of 
cytoplasmic RAN (see arrows). B Immunofluorescence of SK-N-SH cells transfected 
with RP2-GFP and stained for endogenous RAN. RAN and RP2-GFP did not appear 
to co-localise. All scale bars are 10 pm.
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There was also no obvious change in the localisation of endogenous RAN in the 
presence of RP2 (Figure 5.6A). RAN predominantly localised to the nucleus while 
RP2-GFP was predominantly localised to the plasma membrane (Figure 5.6B).
Further subcellular localisation experiments were performed with RAN expression 
constructs, rather than observing endogenous RAN. CHO cells were transfected with 
myc-wtRAN, with and without RP2-GFP (see section 2.3.4-5) and subsequently 
stained using an anti-myc antibody. The myc-wtRAN had a predominantly cytosolic 
localisation pattern with some nuclear staining (Figure 5.7A) but not to the degree 
seen with endogenous RAN in SK-N-SH cells (Figure 5.6). Importantly, when RP2- 
GFP was co-expressed with myc-wtRAN there was a shift in the localisation of the 
myc-wtRAN from the cytoplasm to the nucleus (Figure 5.7). Cells were counted and 
categorised according to the localisation of the myc-wtRAN; nuclear, cytoplasmic, or 
amorphic (in which case the cells were rounded up with an abnormal morphology). 
The cell counts corroborated the immunocytochemistry imaging suggesting RP2-GFP 
promotes myc-wtRAN shuttling to the nucleus (Figure 5.7C).
To further investigate this interesting change in RAN’s subcellular localisation, CHO 
cells were transfected with myc-tagged GDP and GTP locked RAN mutants T24N 
and Q69L and co-transfected with RP2-GFP. Figure 5.8 shows that the RAN-Q69L 
mutant is predominantly nuclear as expected and there was no evidence of any co­
localisation between RP2 and the GTP conformation of RAN (RAN-Q69L). This 
subcellular localisation did not alter when RP2 was co-expressed (Figure 5.8). CHO 
cells transfected with the myc-RAN-T24N mutant appeared extremely sick after 
transfection, both with and without RP2-GFP. The morphology of the cells was 
abnormal; they were rounded up and dying. Careful titration of the amount of 
transfected DNA and shorter time points post-transfection may help to resolve the 
issue and allow more detailed examination of the co-expression of RP2-GFP and 
myc-RAN-T24N.
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Figure 5.7 Altered localisation of myc-RAN in the presence of RP2-GFP
A Immunofluorescence of CHO cells transfected with myc-wtRAN stained with an 
antibody to myc showing a cytoplasmic distribution of myc-RAN. B 
Immunofluorescence of CHO cells transfected with myc-wtRAN and RP2-GFP and 
stained with an antibody to myc indicating that the myc-wtRAN is localised 
predominantly in the nucleus and on the nuclear envelope in the presence of RP2- 
GFP. All scale bars are 10 pm. C Cell counts of CHO cells transfected with myc- 
wtRAN with and without RP2-GFP showing that there is a shift in localisation of myc- 
wtRAN in the presence of RP2-GFP.
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m yc-R A N -Q 69L
Figure 5.8 Cellular localisation of myc-RAN-Q69L mutant
A Immunofluorescence of CHO cells 24 hours after transfection with myc-RAN-Q69L 
stained with anti-myc indicating a nuclear and nuclear envelope staining pattern for 
RAN-Q69L. B Immunofluorescence of CHO cells 24 hours after transfection with 
myc-RAN-Q69L and RP2-GFP stained with anti-myc. No co-localisation was 
observed between RP2-GFP and myc-Ran-Q69L. The presence of RP2-GFP did not 
alter the localisation of RAN nor did the RP2-GFP appear any different to the plasma 
membrane staining pattern seen previously. All scale bars are 10pm.
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5.1.3 Discussion
RAN was detected as an interactor of RP2, and it was shown that RP2 preferentially 
interacts with RAN when in the GDP-bound conformation. Over-expressed RP2 was 
able to alter the subcellular localisation of RAN from a predominantly cytoplasmic 
distribution to a more nuclear distribution. Two independent cDNA clones were 
isolated, which strengthens the likelihood that RAN is a genuine RP2 interactor. As 
described in Chapter 4, Arl3 was found to interact with the N-terminus of RP2, 
interestingly RAN interacts with the C-terminus of RP2. This is the first description of 
an interactor for the C-terminal domain of RP2. RP2 therefore functions in different 
pathways, mediated by the different functional domains it contains. The only reported 
missense mutation in the NDK-homology domain of RP2 (L253R) perturbed the 
ability of pSos-RP2 and pMyr-RAN to stimulate growth of yeast at 37°C. As 
described in Chapter 4 (section 4.8) the pathogenic L253R mutation is thought to 
destabilise the protein by causing clashes in the hydrophobic core. The same L253R 
mutation in RP2 did not perturb the interaction between RP2 and Arl3, which was 
mediated through the N-terminus of RP2, suggesting that the mutation is important 
for the structure and function of the C-terminus of RP2, and thus any interactions that 
may occur through the C-terminus. The interaction between RAN and RP2 needs 
further confirmation. The GST pulldown assay shows promising results and with 
optimisation may provide the required corroboration.
Recently the potential function of the C-terminus of RP2 has been investigated by 
Yoon and colleagues. Yoon et al investigated whether the NDK homology domain of 
RP2 exhibited any functional properties of human or E.coli NDK proteins (Yoon et al., 
2006). The study showed that RP2 did not exhibit any residual NDK function but 
revealed the ability of RP2 to act as a 3’ to 5’ exonuclease, as has been observed for 
human NDK1 (Yoon et al., 2006). RP2 was also shown to be able to localise to the 
nucleus under certain conditions. RP2 was reported to translocate to the nucleus 
upon DNA damage. Solar light and UVA radiation were found to be the most potent 
inducers of this effect (Yoon et al., 2006). These data provide evidence that RP2 
may not be required exclusively at the plasma membrane and cytoplasm and 
highlights the potential for RP2 to act in other cellular compartments perhaps with as 
yet undescribed functions.
RP2 was shown to preferentially interact with GDP-form of RAN in yeast two-hybrid. 
RAN-GDP has been localised to the cytoplasm and the cytoplasmic side of the 
nuclear pore complex (NPC) (Weis et al., 1996, Lounsbury et al., 1996). Therefore,
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the likely site of interaction for RP2 and RAN is in the cytoplasm. A change in the 
cellular localisation of myc-wtRAN was observed in the presence of RP2-GFP, from a 
cytoplasmic to nuclear staining pattern (see Figure 5.7). The mechanism for this is 
unclear, however it is possible that RP2 is stimulating GEF activity for wtRAN, which 
explains the re-localisation to the nucleus. This would not be possible using the 
T24N mutant as it is incapable of exchanging GDP for GTP.
It is likely there is a considerable amount of RAN-GDP in the nucleus as RAN’s GEF, 
RCC1, is localised to the nucleus. Lounsbury et al show that a T24N RAN mutant 
localises to the nucleus in BHK21 cells (Lounsbury et al., 1996) which indicates GDP- 
bound RAN is also found in the nucleus. It is possible, therefore, that the RP2-RAN 
interaction may also occur in the nucleus or at the nuclear envelope. Considering the 
data from Yoon et al showing RP2 has the ability to translocate to the nucleus, RP2 
may have a role in the regulation of RAN’s guanine nucleotide bound state by 
modulating RAN’s movement between its GEF in the nucleus and GAP protein in the 
cytoplasm. It is interesting to note that RP2’s preference for RAN-GDP is in contrast 
to RP2’s preference for Arl3-GTP (described in Chapter 4).
The retinal localisation of RAN was investigated by Mavlyutov et al (2002) using 
bovine retinal sections. RAN was described as being localised to the nucleus and 
nuclear envelopes of all retinal cell bodies and was localised to the inner segments of 
photoreceptors but appeared to be excluded from the outer segments, as well as 
being localised to the synaptic endings of cells in the outer plexiform layer (OPL) and 
nerve fibre layer (NFL). RAN was highly expressed in ganglion cell neurons and in 
these cells formed a continuous nuclear rim, which the authors speculate is due to 
the high abundance of nuclear pore complexes at the nuclear envelope (Mavlyutov et 
al., 2002). It is clear that RAN is extensively expressed in retina and may have a key 
role in normal retinal function. Although RP2’s retinal localisation is distinct, i.e. 
predominantly plasma membrane and cytoplasmic, RP2 is also found throughout the 
retina (see Figure 1.7). Co-staining retina sections with both RP2 and RAN 
antibodies may reveal any co-localisation.
The possibility that RAN was a false positive interacting partner for RP2 must be 
considered, however this seems unlikely as two different RAN clones were identified 
in different screens. Importantly, data presented in this chapter shows a clear 
difference in the interaction affinities with RP2 detected between the GDP- and GTP- 
locked conformations of RAN. There also appears to be a functional consequence of
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over-expressing RP2 and RAN; RP2 was able to alter the predominantly cytoplasmic 
distribution of myc-RAN to the nucleus. The mechanism of this sub-cellular re­
localisation and the physiological relevance remains unclear, however it is interesting 
to speculate that RP2 has the potential to assist in the sub-cellular localisation of 
RAN, and that this may support the hypothesis proposed in Chapter 4 that RP2 has a 
role in protein trafficking (Section 4.6). As described previously, Arl3 has been shown 
to have an important role in ciliated tissues, and interestingly RAN has been shown to 
localise to the centrosome (Nakamura et al., 1998), therefore it is possible that RP2 
has a cilia function role mediated through its interacting partners.
The identification of RAN as an RP2 interacting protein is particularly interesting 
when considering the broader spectrum of RP related genes and pathways. As 
previously described, RAN’s GEF is RCC1 which shares homology with RPGR (see 
section 1.3.3.3). Many of the RP-associated mutations in RPGR occur in the RCC1- 
homology domain which suggests the domain is important for RPGR’s normal retinal 
function. It is possible to speculate, therefore, that RP2 may act as an adaptor 
protein for RAN in an important retinal pathway, and that RPGR is a potential GEF for 
RAN, such that RP2 and RPGR act in the same retinal pathway.
It will be important to confirm the RP2-RAN interaction and that this interaction is 
mediated through the C-terminus of RP2, as well as corroborating RP2’s preference 
to bind to GDP-bound RAN. Having confirmed these aspects of the interaction it will 
be necessary to determine how and where in the cell the interaction takes place and 
more specifically where in the retina the interaction occurs. It would be interesting to 
utilise live cell imaging to analyse the effects of RP2 on key nucleo-cytoplasmic 
trafficking pathways (see Figure 5.1 and 5.2) in which RAN plays a role. It would also 
be interesting to investigate further the conditions in which RP2 translocates to the 
nucleus (Yoon et al, 2006) and determine whether this enhances the RP2-RAN 
interaction using treated cell lysates or immunocytochemistry. The RP2-RAN 
interaction warrants considerable investigation, as the implications of this interaction 
are very exciting, potentially linking RP2 with novel pathways and functions, including 
other known retina degeneration proteins.
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5.2 Cyclin dependent kinase inhibitor 1B
5.2.1 Introduction
Cyclin dependent kinase (CDK) inhibitors block the kinase activity of cyclin-CDK 
complexes. Cyclin dependent kinase inhibitor 1B (also known as CDKN1B, p27Kip1, 
CDKN4, KIP1) is involved in the control of the cell cycle and the progression from G1 
to S phase. The regulation of CDKN1B levels in the cell controls cell cycle 
progression (Figure 5.9). When CDKN1B levels are high it binds to Cyclin D-Cdk4 
and prevents these proteins from phosphorylating Retinoblastoma (Rb), which results 
in upregulation of Cyclin E. As Cyclin E is able to phosphorylate CDK2, keeping the 
levels of Cyclin E low results in low levels of phosphorlyated-CDK2. Phosphorylated 
CDK2-Cyclin E is able to bind to and phosphorylate CDKN1B, thus targeting it for 
degradation and continuing the cycle to deplete the cell of CDKN1B. At this point, the 
cell is able to progress into S phase (Figure 5.9) (Caldon et al., 2006). The 
recognition of phosphorylated CDKN1B is thought to occur by SKP2 which is able to 
recognise phosphorylated CDKN1B predominantly in S-phase and acts as the 
ubiquitin-protein ligase needed for CDKN1B to be correctly targeted for ubiquitination 
and eventual degradation by the 26S proteasome (Carrano et al., 1999).
5.2.2 Characterisation of the RP2-CDKN1B interaction
CDKN1B was detected as a novel RP2 interacting partner using CytoTrap; a single 
cDNA clone was identified. The cDNA clone was processed and sequenced as 
described in sections 2.2.9.4-5 and 2.1.9 and was found to be lacking the first 54 
amino acids of the predicted amino acid sequence of full length CDKN1B (Figure 
5.10A). The CDKN1B clone was tested for specific binding to RP2 by co­
transforming yeast with the pMyr-CDKN1B cDNA clone and either pSos-RP2 or pSos 
alone. This experiment confirmed that CDKN1B only stimulated growth of yeast at 
37°C with hSos-RP2 not hSos alone (Figure 5.1 OB). The interaction of CDKN1B with 
RP2 did not require the first phosphorylation site and N-terminal sequence (Figure 
5.10C).
5.2.2.1 The RP2-CDKN1B interaction is mediated through the C-terminus of RP2 
In order to ascertain whether CDKN1B interacted with RP2 through the C- or N- 
terminus of RP2, yeast were co-transformed with various deletion and pathogenic 
missense mutation pSos-RP2 constructs and pMyr-CDKN1B (see section 2.2.4) and 
growth was observed under the permissive and restrictive conditions for up to 7 days.
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Figure 5.9 CDKN1B is involved in cell cycle control
CDKN1B acts in concert with a number of other proteins to allow exit from the cell 
cycle. During G1 CDKN1B is not phosphorylated and is able to bind to Cyclin D1 and 
Cdk4 which prevents Cyclin D1 phosphorylating Rb which results in upregulation of 
E2F and subsequently Cyclin E upregulation. Cyclin E phosphorylates Cdk2 and 
when these two proteins form a complex with CDKN1B, CDKN1B becomes 
phosphorylated and is targeted for ubiquitination and degradation. Thus by binding to 
Cyclin D1 and Cdk4, CDKN1B prevents its own degradation and by blocking this 
interaction the cell is able to progress to S-phase through the depletion of CDKN1B. 
Adapted from Caldon et al (2006).
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Human CDKN1B 
CDKN1B cDNA 
Bovine CDKN1B
MSNVRVSNGSPSLERMDARQAE11PKPSACRNLFGPVDHEELT 42 
MSNVRVSNGSPSLERMDARQAEYPKPSACRNLFGPVNHEELT
Human CDKN1B RDLEKHCRDMEEASQRKWNFDFQNHKPLEGKYEWQEVEKGSL 84
CDKN1B cDNA ----------MEEASQRKWNFDFKNHKPLEGKYEWQEVEKGSL
Bovine CDKN1B RDLEKHCRDMEEASQRKWNFDFKNHKPLEGKYEWQEVEKGSL
Human CDKN1B 
CDKN1B cDNA 
Bovine CDKN1B
PEFYYRPPRPPKGACKVPAQESQDVSGSRPAAPLIGAPANSE 126
PEFYHRPPRPPKGACKVPAQEGQDASGARPAVPLLGSQANPE
PEFYHRPPRPPKGACKVPAQEGQDASGARPAVPLLGSQANPE
Human CDKN1B DTHLVDPKTDPSDSQTGLAEQCAGIRKRPATDDSSTQNKRAN 168 
CDKN1B cDNA DTHLVDQKTDAPDSQTGLAEQCPGIRKRPAADDSSPQNKRAN 
Bovine CDKN1B DTHLVDQKTDAPDSQTGLAEQCPGIRKRPAADDSSPQNKRAN
Human CDKN1B RTEENVSDGSPNAGSVEQTPKKPGLRRRQT 198 
CDKN1B cDNA RTEENVSDGSPNAGSVEQTPKKPGLRRRQT 
Bovine CDKNlB RTEENVSDGSPNAGSVEQTPKKPGLRRRQT
B 24° C 37°C
pSos-RP2
pSos
pMyr-CDKN1B
Putative NLS
Figure 5.10 CDKN1B interacts with RP2
A Alignment of predicted amino acid sequences of human CDKN1B, bovine 
CDKN1B, and the cDNA clone of CDKN1B detected as an RP2 interactor. The first 
54 amino acids of CDKN1B are missing from the cDNA clone. Red residues are 
those that differ between bovine and human sequences. B Yeast Cdc25-Ha co­
transformed with pMyr-CDKN1B and either pSos-RP2 or pSos after 96 hours growth 
indicating that RP2 and CDKN1B interact specifically. C Schematic of CDKN1B 
showing the putative nuclear localisation signal in the C-terminus of the protein and 
the three known phosphorylation sites (Ser10, Thr157 and Thr187) in CDKN1B.
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The interaction between RP2 and CDKN1B occurred through the C-terminus of RP2 
(Figure 5.11A). When RP2 pathogenic mutants were used as bait for the interaction 
there was loss of the ability to stimulate yeast growth between CDKN1B and RP2 
with the RP2-L253R mutation (Figure 5.11 A) as well as with the RP2-C86Y mutation. 
Although the RP2-C67Y mutation appeared to grow at a slower rate than wild type 
RP2, the interaction was evidently still detectable. RP2-R118H had no effect on 
RP2’s ability to interact with CDKN1B in this system (Figure 5.11A).
5 2.2.2 Cellular localisation studies of CDKN1B and RP2
Immunocytochemistry and confocal microscopy were used to analyse the subcellular 
localisation of CDKN1B and co-localisation between RP2 and CDKN1B. 
Endogenous CDKN1B was examined in SK-N-SH cells which were transfected with 
RP2-GFP and then stained using an antibody to CDKN1B (described in 2.3.4.1 and 
2.3.5). CDKNIB’s subcellular localisation in SK-N-SH cells was detected using a 
commercial antibody to CDKN1B as described in section 2.3.5. Figure 5.12A shows 
that CDKN1B was detected predominantly in the nucleus but also in the cytoplasm. 
To investigate potential co-localisation between RP2 and CDKN1B and therefore a 
potential subcellular site of interaction, SK-N-SH cells were transfected with RP2- 
GFP and stained for CDKN1B as described in section 2.3.4.1-2.3.5. Despite some 
distribution of both proteins in the cytoplasm, no subcellular co-localisation was 
observed (Figure 5.12B).
5.2.3 Discussion
The identification of CDKN1B as a putative RP2 interactor provides further evidence 
that the C-terminus of RP2 may have a novel role. As CDKN1B is involved directly in 
the regulation of the cell cycle it will be important to try and establish at which point 
during the cell cycle the RP2-CDKN1B interaction occurs. CDKN1B is localised to 
the nucleus when the cell is in a state of quiescence (e.g. due to contact inhibition) 
(Wang et al., 1999). Although RP2 may be able to translocate to the nucleus it is 
possible that the interaction occurs in the cytoplasm during S phase when CDKN1B 
moves to the cytoplasm to be degraded by the 26S proteasome. Co-localisation 
between RP2 and CDKN1B was not detected in the immunocytochemical 
experiments performed, however it is possible that the interaction occurs at a specific 
point in the cell cycle and some further investigations involving examination of RP2 
and CDKN1B expression at specific points of the cell cycle would be necessary to 
determine whether the interaction is cell cycle dependent.
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Figure 5.11 CDKN1B interacts with RP2 through the C-terminus of RP2
Yeast Cdc25-Ha co-transformed with various pSos-RP2 constructs show that 
CDKN1B interacts through the C-terminus of RP2 (190-350) and that the pathogenic 
mutation L253R in that domain perturbs the interaction. Yeast were grown for 96 
hours.
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Figure 5.12 Cellular localisation of endogenous CDKN1B
A Immunofluorescence of SK-N-SH cells stained for endogenous CDKN1B showing 
a cytoplasmic and predominant nuclear staining pattern. B SK-N-SH cells 
transfected with RP2-GFP and stained for CDKN1B 24 hours after transfection. No 
specific co-localisation between CDKN1B and RP2-GFP was detected and the 
presence of excess RP2 appeared to have no effect on CDKN1B localisation. All 
scale bars are 10pm.
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It is also possible that the interaction is transitory and so would be hard to detect.
There is evidence that CDKN1B is important for normal retina function as well as for 
correct development of other organs. Nakayama et al show that mice without 
CDKN1B have multiple abnormalities including retinal dysplasia (Nakayama et al., 
1996). These knockout mice are larger than their wild type litter mates but were born 
at the expected Mendelian ratios indicating there is no embryonic lethality associated 
with loss of CDKN1B. The larger size of the mice was not attributable to obesity but 
there was evidence of enlarged organs such as the thymus, spleen, testes and 
pituitary glands thus indicating abnormal cell proliferation. The mice also 
spontaneously developed pituitary tumours further supporting a role for CDKN1B in 
the control of cell replication in a variety of cell types (Nakayama et al., 1996).
Mice lacking CDKN1B also exhibited disorganised retinas; the cellular layers of the 
retina were perturbed. On closer examination it was noted that the outer nuclear 
layer, where the photoreceptor nuclei are located, had entered the retinal layer below 
the outer limiting membrane pointing to a role in correct cell proliferation for CDKN1B 
in retinal development (See Figure 1.2 for the normal retinal structure). During 
development, CDKN1B is expressed in various retinal progenitor cells in mice and is 
not restricted to a photoreceptor-specific pattern (Dyer and Cepko, 2001). 
Immunohistochemistry investigations of retina by Nakayama and colleagues show 
that in wild type adult mice CDKN1B is expressed exclusively in the photoreceptors 
suggestive of an important role for CDKN1B in adult mouse photoreceptor function 
beyond its role in retinal development (Nakayama et al., 1996). The retinal pigment 
epithelial (RPE) cells have also been shown to be affected by the loss of CDKN1B, 
the cells exhibit increased levels of nuclear division but without a corresponding 
increase in cell division suggesting a defect in mitosis (Defoe et al., 2007). As 
CDKN1B is expressed exclusively in the photoreceptors in adult mice it can be 
speculated that an alteration of the normal function of CDKN1B may indeed result in 
RP.
Interestingly, RAN has been directly implicated in the regulation of CDKN1B levels in 
the cell. As described in section 5.2.1 the levels of CDKN1B in the cell are crucial to 
this feedback-based mechanism of cell cycle control. A study investigating how 
these levels were regulated found that RAN-GTP was directly involved in the 
transport of CDKN1B from the nucleus to the cytoplasm and that this resulted in the 
proteolysis of CDKN1B (Connor et al., 2003). When the proteasome was inhibited it
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was found that CDKN1B accumulated in the cytoplasm and, therefore, that the 
transport of CDKN1B out of the nucleus occurred before degradation, implicating 
RAN in the regulation of CDKN1B and thus the cell cycle. This most likely occurs 
through the model proposed in Figure 5.2 as CDKN1B has been shown to interact 
with Exportin 1 (Connor et al., 2003).
CDKN1B was identified as a putative RP2 interacting partner using CytoTrap and 
was shown to interact with RP2 through the C-terminus of RP2. This putative 
interaction requires confirmation using different methodology in order to further 
understand the relevance of the interaction both in the retina and other tissues. It is 
possible that, if physiologically important, the RP2-CDKN1B interaction may have a 
role divergent, but related, to the cell cycle, especially as the photoreceptors are post­
mitotic cells. For example, in its role as a cell cycle regulator, CDKN1B also plays an 
important role in centrosome replication (Hinchcliffe et al., 1999) which potentially ties 
RAN, CDKN1B and RP2 into a regulatory function at the centrosome.
CDKN1B may represent a false positive, as the interaction has not yet been 
corroborated and only one clone was identified in the CytoTrap screen. This potential 
interaction merits further investigation as the CDKN1B knock out mouse shows that 
CDKN1B is important for normal retinal function and development, and therefore the 
RP2-CDKN1B interaction may indeed play an important role in normal retinal 
function.
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5.3 Transportin 3
5.3.11ntroduction
Transportin 3 (TNP03) is a member of the human lmportin-p family of proteins. It is 
involved in the transport of proteins into the nucleus. TNP03 was originally 
described as being the nuclear import receptor for a group of proteins known as SR 
proteins. SR proteins are relatively abundant and are rich in arginine/serine (RS) 
dipeptides (RS domain). They are involved in pre-mRNA splicing and alternative 
splicing regulation. SR proteins are localised to the nucleus through their RS domain 
acting as a nuclear localisation signal (Graveley, 2000). TNP03 binds to the RS 
domain of these proteins and transports them to the nucleus in a similar mechanism 
as shown in Figure 5.1. The interaction between TNP03 and the SR proteins is 
perturbed by RAN-GTP, indicating that RAN-GTP causes the dissociation of the 
TNP03-SR protein complex once in the nucleus (Kataoka etal., 1999).
A study by Lai et al described an alternatively spliced form of TNP03, specifically 
Isoform 2 (see Figure 5.13), which appears to interact exclusively with 
phosphorylated SR proteins (Lai et al., 2000), suggesting that Isoform 1 and Isoform 
2 of TNP03 have differing roles. Further investigations led to the observation that 
TNP03 is localised in the nucleus and the nuclear membrane, facilitated by its ability 
to bind to a nucleoporin (p62). A TNP03 mutant defective in RAN binding (AN281, 
deletion of the N-terminal 281 amino acids) co-localises with an anti-SC35 antibody 
which indicates that TNP03 can localise to nuclear speckles due to the TNP03-SR 
protein interaction not being disrupted by RAN (Lai et al., 2000). Nuclear speckles 
are a nuclear compartment thought to be storage sites for pre-mRNA splicing factors 
(Lamond and Spector, 2003, Lai et al., 2000). This suggests that TNP03 not only 
targets SR splicing factors to the nucleus but may also be involved in correctly 
localising them to the subcellular compartment in which they are stored, thus acting 
as an import receptor for phosphorylated SR proteins (Lai etal. 2000).
It has also been shown that TNP03 is able to import a non-SR protein to the nucleus 
using the same pathway it uses for SR proteins (Lai et al., 2003). RNA-binding motif 
protein 4 (RBM4) is a splicing regulator with antagonistic actions to SR splicing 
factors and yet through its interaction with TNP03 utilises the same pathway to 
translocate to the nucleus. This interaction is also RAN-dependent. These data 
show that TNP03 is not restricted to binding and importing only SR proteins but may 
also recognise alternative proteins (Lai et al., 2003). All the interactions between 
TNP03 and the splicing factors described occur through the C-terminus of TNP03.
156
Chapter 5  -  Characterisation of novel putative RP2 interactors
The N-terminus of the protein appears to be important for mediating binding to RAN- 
GTP (Lai et al. 2000).
TNP03 clearly has an important role in assisting splicing factors in reaching their 
correct cellular compartment, but whether it has any other functions either in the 
nucleus or the cytoplasm remains to be elucidated.
5.3.2 Characterisation of the RP2-TNP03 interaction
TNP03 was detected as an RP2 interactor using CytoTrap (as described in section 
2.2.9). The cDNA was sequenced as described in section 2.1.9. Database searches 
and bioinformatic analysis were performed following identification of the TNP03 clone 
to further understand the potential expression patterns (UCSC, ExPasy, NCBI). 
TNP03 was found to be alternatively spliced and potentially codes for at least five 
different protein isoforms (Figure 5.13). Two of the five isoforms have been 
described by Kataoka et al (Isoform 1) and Lai et al (Isoform 2), Isoforms 3 and 4 are 
annotated on the ExPasy database and Isoform 5 is not currently annotated on the 
databases (Kataoka et al., 1999, Lai et al., 2000). The gene contains 22 exons and 
has two potential methionine ‘start’ codons, the first in exon 1 and the second in exon 
2 (see Figure 5.13). The gene also appears to contain a cryptic splice site in exon 11 
resulting in a loss of 32 amino acids from Isoforms 2 and 4. Isoforms 3 and 4 also 
have an alternative C-terminus due to the final exon 22 being spliced out. The gene 
appears to be ubiquitously expressed based on EST expression data (NCBI, 
Unigene).
The TNP03 clone detected was found to be a cDNA originating from an Isoform 2 
mRNA (see Figure 5.13). The TNP03 cDNA is predicted to express full length in­
frame TNP03 and was also found to have in-frame 5’UTR sequence at the N- 
terminus (Figure 5.14A). Yeast were co-transformed with pMyr-TNP03 and pSos- 
RP2 or pSos, and TNP03 was found to only stimulate growth of yeast with hSos- 
RP2, not hSos alone (Figure 5.14B).
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Figure 5.13 Alternative splicing of the TNP03 gene
A schematic of the gene structure of TNP03 showing the different isoforms that may result from alternative splicing of the gene. Isoforms 2, 4 
and 5 contain a smaller spliced exon 11 (coloured in red). Isoform 5 has an alternative Methionine start codon in exon 2 and exon 22 is spliced 
out in isoforms 3 and 4 resulting in a different C-terminus to the protein.
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Human TNPG3 ------------------------------------MEGAKPiLQLVYQAVQALYliDPDPSGKEKASF 3?.
TNF03 cDNA RCSGBGRSRHSEEARGRSNRRSLGRRARTVAAATTATKEGAKPTLQLVYQAVQALYHDPDPSSKERASF
Bovine TNP03 ----------------------------------- MEGAKKIL0LVYQAVQALYEDRDP3GKEKASF
Human TN?03 WLGELCRSVHA»EI3DQHLQ1RCDVE3CYFAA0"MKMKIGTSFYELPTD3HA3HRDSI.^THIQNLKDLS 101
TNP03 cDNA WLGELQRSVHAWEISDQ1LGIRGDVESCY?AAQTMKMK:GT3FYELPTDSHAS1RDSLHTHIQNLKDL£
Bovine TNP03 WLGELCRSVHAtfEISDQLLQIRCDVESCYFAAQTMXMKICTSFYELPTDSHASLRDSLI/rHIONLKDLG
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Figure 5.14 Transportin 3 interacts with RP2
A Alignment of the predicted amino acid sequences of the TNP03 cDNA clone 
detected as an RP2 interactor with the predicted amino acid sequences of bovine and 
human isoform 2 of TNP03. Red residues indicate amino acids that differ between 
the human and bovine sequences. B Yeast co-transformed with pSos-RP2 or pSos 
alone and pMyr-TNP03 showing a specific interaction between RP2 and TNP03 in 
this system. Yeast were grown for 96 hours. C Schematic of TNP03 isoform 2 
protein structure showing functional domains and putative phosphorylation sites at 
T578 and S586.
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5.3.2.1 TNP03 interacts with the C-terminal domain of RP2
TNP03 was tested to determine which RP2 domain mediated the interaction. Cdc25- 
Ha yeast were co-transformed with various deletion and pathogenic missense 
mutation pSos-RP2 constructs and pMyr-TNP03 (see section 2.2.4) and growth was 
observed at 24°C and 37°C for up to 7 days. RP2 was also found to bind to TNP03 
through its C-terminal domain due to only being able to stimulate growth of yeast at 
the restrictive temperature with full length RP2 or the RP2 190-350 domain (Figure 
5.15A). The RP2-TNP03 interaction, therefore, occurs in the same RP2 domain as 
the potential RAN and CDKN1B interactions. TNP03 was able to induce growth with 
C67Y-RP2 and RP2-R118H mutations; however the interaction was perturbed by the 
RP2-L253R and RP2-C86Y mutations (Figure 5.15A).
A GST-RP2 pulldown assay was used to test the RP2-TNP03 interaction detected 
using CytoTrap. The assay was conducted as described in section 2.3.7 using a 
GST-RP2 bait and HeLa cell lysates to investigate binding of endogenous TNP03 to 
GST-RP2. A TNP03 antibody was provided as a gift from W.Y.Tarn (Institute of 
Biomedical Sciences, Academia Sinica, Taipei, Taiwan). An immunoreactive band 
running at approximately 100kDa was detectable in the HeLa lysates using the 
TNP03 antibody which is likely to be endogenous TNP03, but there appeared to be 
no endogenous TNP03 bound to RP2-GST or to the GST control (Figure 5.15B) and 
there was considerable background and non-specific immunoreactivity from the 
antibody. To test whether there was a complex of Arl3 with RP2 and TNP03 the 
assay was also conducted using GST-Arl3 mutants as baits and there was no 
evidence of TNP03 binding to GST-Arl3 either (Figure 5.15B).
5.3.2.2 Immunocytochemical analysis of the RP2-TNP03 interaction
TNP03 expression was studied in SK-N-SH cells using an antibody to TNP03 as 
described in 2.3.4.1-2.3.5 (Figure 5.16A). TNP03 was observed to be predominantly 
localised to the nucleus however plasma membrane staining was also observed in a 
few cells (Figure 5.16A). SK-N-SH cells were transfected with RP2-GFP (as 
described in section 2.3.4.1) and stained for TNP03 (Figure 5.16B). Despite TNP03 
being observed to occasionally localise to the plasma membrane in untransfected 
cells there was no evidence of extensive co-localisation between RP2-GFP and 
TNP03 (Figure 5.16B). The cellular localisation of TNP03 appeared unchanged 
when cells with and without RP2-GFP were compared, the majority of TNP03 was 
still observed to localise to the nucleus (Figure 5.16B).
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Figure 5.15 TNP03 interacts with the C-terminus of RP2
A Cdc25-Ha yeast co-transformed with various pSos-RP2 constructs and mutants 
and pMyr-TNP03 grown at the permissive and restrictive temperature showing 
TNP03 interacts with RP2 through the C-terminus of RP2 (190-350) and that the 
L253R mutation perturbs the interaction. B GST pulldown assays to corroborate the 
interaction, however no endogenous TNP03 was detected as binding to GST-RP2 or 
GST-Arl3.
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Figure 5.16 Cellular localisation of endogenous TNP03
A Immunofluorescence of SK-N-SH cells stained for endogenous TNP03 showing 
that the protein is localised predominantly in the nucleus, although some localisation 
of TNP03 was detected at the plasma membrane (marked by the white arrow). B 
SK-N-SH cells transfected with RP2-GFP and stained for endogenous TNP03. No 
co-localisation was observed between TNP03 and RP2-GFP, there was no alteration 
in the localisation of either TNP03 or RP2-GFP. All scale bars are 10pm.
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5.3.3 Discussion
TNP03 interacts with RP2 through the C-terminus of RP2 and was detected through 
the use of the CytoTrap yeast-two hybrid system. The interaction requires 
confirmation, possibly utilising an alternative interaction assay such as co- 
immunoprecipitation. Further investigation of the alternative splicing of TNP03 would 
also be interesting as there is comparatively little experimental data on this subject so 
far. It would be particularly interesting to investigate whether there is a dominant 
isoform expressed in retina (Figure 5.13). Recently, TNP03 has been independently 
detected as a putative RP2 interacting partner by Dr Tatiana Novoselova in the lab 
using CytoTrap. Having sequenced the second cDNA clone it was determined to be 
amplified from a different original mRNA than the clone described here, but was also 
found to be an isoform 2 TNP03 cDNA. Although the kind gift of an antibody aliquot 
from Dr WY Tarn was used for these initial experiments evidently the antibody was 
raised against a GST-fusion protein as it shows strong immunoreactivity with GST. 
The antibody for TNP03 is now being purified for further characterisation of the RP2- 
TNP03 interaction.
The localisation of TNP03 in retina has not been investigated and so a potential 
retinal role for TNP03 has yet to be elucidated. Ubiquitously expressed splicing 
factors have been implicated in retinal disease, e.g. PRPF31, PRPC8, PAP1 and 
HPRP3 are all splicing factors in which mutations cause RP (McKie et al., 2001, 
Vithana et al., 2001, Chakarova et al., 2002, Martinez-Gimeno et al., 2003, Maita et 
al., 2004). Therefore there is substantial evidence that the seemingly non-retinal- 
specific function of splicing, when perturbed, can result in retinal degeneration, 
implying TNP03 may have a vital role in retinal function. The mechanism of disease 
pathogenesis for splicing factor mutations remains to be elucidated but represents 
another group of proteins known to be ubiquitously expressed that cause a retina- 
specific phenotype.
As with all putative interacting partners detected in yeast-two hybrid screens there is 
a possibility that TNP03 represents a false positive interactor. However, the protein 
has been independently detected twice, with both proteins originating from different 
cDNA clones, thus strengthening the likelihood that TNP03 is a real interactor. The 
importance of splicing in RP has already been highlighted (Section 1.3.4.2) which 
further supports a role for an RP2-TNP03 interaction in retina function.
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Both TNP03 and CDKN1B interact with GTP-bound RAN. As described previously, 
TNP03 is involved in the transport of SR splicing factors to the nucleus. However, it 
has been shown that in the presence of GTP-bound RAN the interaction between 
TNP03 and its client SR protein is disrupted implying RAN is involved in the 
regulation of the importation of these SR proteins. As with CDKN1B, the regulation of 
TNP03 by RAN may be independent from the role RAN has in regard to RP2, but it 
also suggests that there is a novel pathway being unravelled by the data presented in 
this thesis involving RP2 and these novel interacting proteins.
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5.4 Sperm associated antigen 7
5.4.11ntroduction
There is comparatively little known about the function of Sperm associated antigen 7 
(SPAG7). The protein was first isolated from the acrosome of Vulpes vulpes sperm 
using a monoclonal antibody and was named fox sperm antigen 1 (FSA-1) (Beaton et 
al., 1994), and was subsequently renamed SPAG7. It was reported that FSA- 
1/SPAG7 was expressed in the acrosomal region of the sperm; more specifically it 
was found within the inner acrosomal compartment and only in developing or 
elongating spermatids, and the authors suggested FSA-1/SPAG7 may play a 
structural role in the developing acrosome. It was also shown that in fox, the FSA- 
1/SPAG7 RNA transcript was also expressed in heart (Beaton et al., 1994). SPAG7 
has been reported to interact with HLA-B-Associated transcript 5 (BAT5) (Lehner et 
al., 2004) a protein thought to be involved in the major histocompatability complex 
and immunity. SPAG7 has been reported as a housekeeping gene by Eisenberg and 
Levanon (2003) indicating it is ubiquitously expressed (Eisenberg and Levanon, 
2003).
Human SPAG7 is a 32kDa protein and has a putative R3H domain spanning amino 
acids 31-109. R3H domains are thought to mediate binding to single stranded 
nucleic acids. The major feature of the domain is an invariant arginine (at position 78 
in SPAG7) and a highly conserved histidine located three residues away (position 82 
in SPAG7) (see Figure 5.17C). SPAG7 also contains a bipartite nuclear localisation 
signal and so it may be involved in a nuclear function, for example in DNA repair. 
SPAG7 also has a putative phosphorylation site at residue S161 (Figure 5.17C).
5.4.2 Characterisation of the RP2-SPAG7 interaction
SPAG7 was detected as an RP2 interacting partner using CytoTrap. The cDNA was 
sequenced (as described in 2.1.9) and it was revealed that the clone was lacking the 
N-terminal 45 amino acids of the predicted amino acid sequence of the full length 
amino acid sequence of SPAG7 (Figure 5.17A) indicating the N-terminus and the first 
nuclear localisation signal of SPAG7 were not required for this interaction. Cdc25-Ha 
yeast were co-transformed with pMyr-SPAG7 and either pSos or pSos-RP2 as 
described in section 2.2.4. After 7 days growth at the permissive and restrictive 
temperatures there was no growth of cells lacking RP2, indicating that SPAG7 
specifically requires RP2 to stimulate growth at the restrictive temperature (Figure 
5.17B).
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Figure 5.17 SPAG7 interacts with RP2
A Alignment of the predicted amino acid sequences of the SPAG7 cDNA clone with 
human and bovine SPAG7 sequences, the N-terminal 45 amino acids are missing 
from the cDNA. Red residues denote residues that differ between the human and 
bovine sequences. B Cdc25-Ha yeast transformed with pMyr-SPAG7 and either 
pSos-RP2 or pSos alone indicating that SPAG7 specifically binds to RP2. Yeast 
were grown for 96 hours C Schematic of human SPAG7 showing putative nuclear 
localisation signals, the R3H domain and a putative phosphorylation site at S161. * 
marks where the detected cDNA sequence starts.
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5.4.2.1 SPAG7 interacts with the C-terminus of RP2
Cdc25-Ha were co-transformed with deletion and pathogenic missense mutation 
pSos-RP2 constructs and pMyr-SPAG7 (as described in section 2.2.4). SPAG7 
interacts with RP2 with a relatively low affinity when compared to the previously 
described interactors in this system. Yeast co-transformed with pMyr-SPAG7 and 
pSos-RP2 constructs were observed for up to 9 days to ensure slow growth was not 
over-looked. Figure 5.18A shows that despite the weaker interaction affinity, it is still 
possible to observe that SPAG7 interacted with RP2 through the C-terminus of RP2 
(Figure 5.18A) and that this interaction is abolished by the RP2-C86Y and RP2- 
L253R mutations (Figure 5.18A). Interestingly, the interaction between RP2 and 
SPAG7 was enhanced when the RP2-R118H mutant was tested; yeast co­
transformed with pMyr-SPAG7 and pSos-RP2-R118H grew quicker than cells 
transformed with pSos-RP2.
The SPAG7 cDNA clone identified from CytoTrap screening was cloned directly into 
pCMV-Tag3b (see section 2.1.2 and 2.1.6-8) to provide an N-terminally myc-tagged 
SPAG7 protein for expression in mammalian cells. The myc-SPAG7 clone was 
missing the first 45 amino acids of wild type SPAG7 and will be referred to as myc- 
SPAG7 (45-227). Co-immunoprecipitations were attempted using myc-SPAG7(42- 
227) and RP2-GFP or R118H-RP2-GFP as described in section 2.3.6 using a myc 
antibody to immunoprecipitate protein and an antibody to GFP to detect any bound 
RP2. To ensure that the myc-tagged proteins were immunoprecipitated successfully 
lysates were probed with an anti-myc antibody (9E10), however the antibody light 
chain prevented visualisation of the levels of immunoprecipitated protein (Figure 
5.18B bottom panel). R118H-RP2 was used in the assay as it appeared to have a 
higher affinity of interaction for SPAG7 than wild type RP2 in CytoTrap. No RP2- 
GFP, either wild type or R118H, was detected as being bound to SPAG7 in this 
assay (Figure 5.18B top panel).
5.4.3 Characterisation of a SPAG7 antibody
An anti-peptide antibody for SPAG7 was designed to the C-terminus of SPAG7 and 
was synthesised conjugated to KLH by Sigma Genosys. The peptide chosen for the 
antibody production was the final 13 amino acids of SPAG7 (see Figure 5.17A 
RLRQSEGEELPPTS). The proline residue (amino acid 225) marked in bold above 
exhibits species variation, in human and dog the residue is proline, while in mouse 
and rat it is a threonine and in cow it is a serine (Figure 5.17).
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Figure 5.18 SPAG7 interacts with the C-terminus of RP2
A Cdc25-Ha yeast co-transformed with various pSos-RP2 constructs and mutants 
and pMyr-SPAG7 indicating that SPAG7 interacts with RP2 through RP2’s C-terminal 
domain (190-350) and the L253R mutation abolishes this interaction. Yeast were 
grown for 96 hours. B Co-immunoprecipitations of myc-tagged SPAG7 or Arl3-Q71L 
and RP2-GFP constructs, an antibody to myc was used to immunoprecipitate. The 
top panel shows no RP2-GFP was detected as being bound to SPAG7 but was 
observed to bind to myc-Arl3-Q71L. To check that the myc-tagged proteins were 
immunoprecipitated lysates were probed with an anti-myc antibody (9E10), the 
antibody light chain prevented accurate determination of the levels of 
immunoprecipitated protein.
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The specificity of the immunoreactive antisera was tested using total cell lysates 
prepared from a variety of human cell lines (as described in section 2.3.4.3) as well 
as CHO cell lysates that had been transfected with myc-SPAG7(45-227) and 
untransfected CHO cell lysates. Endogenous SPAG7 is predicted to be 
approximately 32kDa. Initially, the antibody was compared directly with the pre- 
immune serum to investigate whether there was any pre-existing immunoreactivity by 
Western blotting as described in section 2.2.7-8. Figure 5.19A shows the SPAG7 
antibody (3603) was able to detect a band of approximately 27kDa which 
corresponds to the myc-tagged SPAG7 protein in transfected CHO lysates and a 
band of 32kDa which corresponds to endogenous SPAG7 in HeLa cell lysates and 
did not exhibit cross reactivity with other CHO cell proteins (see Figure 5.19A). Very 
low levels of endogenous SPAG7 were detected in SK-N-SH cell lysates at higher 
exposures. SK-N-SH cell lysates do not have detectable levels of endogenous RP2 
(data not shown). To ensure antibody specificity, a peptide competition assay was 
conducted utilising the peptide antigen (as described in section 2.2.8.1). After 
peptide competition, the SPAG7 antibody (3603) was not able to detect endogenous 
SPAG7 immunoreactivity in any of the human cell lysates tested (BE - colon 
carcinoma cells, 293T - embryonic kidney cells and HeLa - cervical carcinoma cells), 
immunoreactivity of the the myc-SPAG7(45-227) expressed protein was also greatly 
reduced (Figure 5.19B). Therefore the antibody could detect bovine, hamster and 
human SPAG7 protein and did not appear to exhibit species specificity.
CHO cells were transfected with myc-SPAG7(45-227) and were stained using anti- 
myc and SPAG7 antibody (3603). Myc-tagged SPAG7 localised to the nucleus and 
was detected by both the myc and SPAG7 antibodies, indicating the SPAG7 antibody 
worked efficiently for immunocytochemistry (Figure 5.19C). The SPAG7 antibody 
was, therefore, used to stain for endogenous SPAG7 in HeLa cells, where it was 
observed to be predominantly nuclear with some protein localised throughout the 
cytoplasm (Figure 5.19D).
5.4.2.3 Immunocytochemical analysis of SPAG7 and its interaction with RP2 
SK-N-SH cells were stained using SPAG7 (3603) antibody as previously described in 
section 2.3.5, predominant localisation of SPAG7 was detected in the nucleus despite 
low levels of endogenous SPAG7 being detected from SK-N-SH cell lysates (Figure 
5.20A and Figure 5.19A).
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Figure 5.19 Characterisation of an antibody to SPAG7
A Western blots using an antibody to SPAG7 showing that the pre-immune sera does 
not exhibit any immunoreactivity. The antibody detects myc-SPAG7(45-227) and 
endogenous SPAG7 in HeLa cell lysates. B Western blots using SPAG7 (3603) 
antibody with and without peptide block (10pg/ml peptide in block) showing specific 
detection of SPAG7. C Immunofluorescence of CHO cells transfected with myc- 
SPAG7(45-227) construct and stained for myc and SPAG7 (3603) showing extensive 
overlapping signals. D Detection of endogenous SPAG7 in HeLa cells indicating 
SPAG7 was predominantly nuclear. All scale bars are 10pm. Antibody titres are 
stated in Tables 2.5 and 2.6.
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When SK-N-SH cells were transfected with RP2-GFP (see sections 2.3.4.1-2.3.5) 
there was no evidence of co-localisation of RP2-GFP and endogenous SPAG7. 
There was also no apparent alteration in the cellular localisation of SPAG7 (Figure 
5.20B).
5.4.3 Discussion
SPAG7 was detected as a putative RP2 interacting partner using the CytoTrap yeast 
two-hybrid system. Despite being the weakest interaction detected, it was still 
possible to map the interaction domain to the C-terminus of RP2 and show that the 
pathogenic L253R mutation in that domain abolished the interaction. Co-localisation 
between RP2 and SPAG7 was not observed, however it may be that the interaction is 
transitory. It is also possible that the interaction between RP2 and SPAG7 only 
occurs after DNA damage when RP2’s localisation potentially changes (Yoon et al.,
2006). The retinal localisation of SPAG7 is currently unknown and as such it is not 
clear whether it may have a key function in retina. It would be interesting to 
determine whether there was any overlap in the retinal expression profile of SPAG7 
and RP2.
It is possible that SPAG7 is not a bona fide interacting partner for RP2 but represents 
a false positive from the yeast-two hybrid screen. As SPAG7 was only detected 
once, and has not been corroborated through any other method, the physiological 
relevance of the interaction remains unclear.
Interestingly all the novel RP2 interactors are localised predominantly to the nucleus 
which was unexpected. The prediction prior to the start of two-hybrid screening was 
that most of RP2’s interacting partners would be cytosolic or membrane-associated. 
However, the data from Yoon et al shows that RP2 is able to translocate to the 
nucleus and data shown in Chapter 4 shows that RP2 is not static. The reported 
conditions for RP2 to translocate to the nucleus involve DNA damaging agents. 
Interestingly, SPAG7 contains an R3H domain which is believed to be a single 
stranded nucleic acid binding domain and as such has the potential to bind to single 
stranded damaged DNA. This suggests that RP2 may have a novel function 
involving SPAG7 in the nucleus in the mediation of some aspect of DNA repair.
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SPAG7A
B
Figure 5.20 SPAG7 is localised predominantly in the nucleus
A Immunofluorescence of SK-N-SH cells stained with an antibody to SPAG7 (3603) 
showing that endogenous SPAG7 was localised predominantly to the nucleus in SK- 
N-SH cells but was also detected in the cytoplasm. B SK-N-SH cells transfected with 
RP2-GFP and stained for SPAG7. There is no evidence of co-localisation of SPAG7 
and RP2-GFP. All scale bars are 10pm. SPAG7 (3603) antibody was used at a titre 
of 1:500.
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5.5 Discussion
The data presented in this thesis show that the CytoTrap method of yeast two-hybrid 
for detection of RP2 interactors was successful as five novel putative interactors have 
been identified and a known interactor has been independently confirmed. All the 
novel interactors discussed in this chapter appear to interact with RP2 through its C- 
terminus (RP2 190-350) which provides new information on the potential functions of 
the C-terminal domain of RP2. This is the first report of protein interactions with the 
C-terminus of RP2.
The novel interactors identified using CytoTrap have diverse functions and are all 
ubiquitously expressed, and interestingly are all localised to the nucleus. If the 
interaction between RP2 and these proteins is implicated in the development of RP 
still needs to be elucidated. Interestingly, all the novel interactors described in this 
chapter were not able to interact with RP2 when the L253 residue, which is 
conserved with NDK, was mutated to an arginine residue. The L253R mutation in 
RP2 is a reported pathogenic mutation (Table 1.3) and was predicted by Kuhnel eta l
(2006) to cause destabilisation of the protein (Kuhnel et al., 2006). It is notable 
therefore that the presence of this mutation leads to the abolishment of interaction 
with all the interactors that bind to RP2 through the C-terminal domain (RP2 190- 
350), but not with Arl3 which binds to RP2 through the N-terminal domain (RP2 41- 
200). In order to further define the interaction domain for each of the novel 
interactors it would be interesting to mutate other residues conserved with the NDK 
domain, as it can be predicted they will be important functionally or structurally, to 
delineate the binding domain in RP2 more concisely. If it was found that more than 
one of the interactors utilised the same binding site with RP2 it would be interesting to 
use a competition assay to determine the circumstances in which RP2 would bind to 
one or the other. Therefore, just as the AS6 and R118H pathogenic mutations have 
been shown to have functional consequences (Chappie et al., 2000, Bartolini et al., 
2002, Kuhnel et al., 2006 and Chapter 4) (see sections 1.4.3 and 1.5.2), the 
functional consequence of the L253R mutation may be the loss of the ability of RP2 
to interact with these novel interactors.
CytoTrap reflects the reportedly ideal conditions for the RP2-Arl3 interaction (Bartolini 
et al. 2002). It may be therefore that these novel interactors would not have been 
detected using the transcription-based yeast-two hybrid systems that tag the bait 
protein at the C-terminus as RP2 would potentially be myristoylated. None of the 
novel putative interacting partners appear to localise to the plasma membrane and
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therefore the function of the plasma membrane localisation of RP2 remains unclear, 
although it is known to be important in the development of RP (Chappie et al., 2000, 
Chappie et al., 2002). It is possible that the RP2 involved in these interactions 
comprises a small portion of the total RP2 pool, i.e the non-myristoylated RP2, or that 
the interaction is transient yet physiologically significant. Therefore, in order to 
confirm these interactors it would be necessary to optimise co-immunoprecipitation 
assays to reflect the likely physiological conditions of these novel interactions, 
possibly by using an RP2 myristoylation mutant to shift the subcellular pool of RP2 
away from plasma membrane localised RP2.
GST pulldown assays proved inconclusive. These techniques were optimised for 
characterising the RP2-Arl3 interaction and as such the assay may require further 
optimisation for each of the putative interactors as, for example, expression levels of 
the each protein will vary. This approach could be complemented by cellular and 
subcellular localisation studies and observing the effects, on RP2 and cell viability 
and function, of depleting cells of the protein partners (and vice versa).
The ability of RP2 to bind to these novel interactors through its C-terminus illustrates 
the importance of the C-terminal domain and highlights the fact that RP2 is a 
multifunctional protein potentially involved in pathways mediated through different 
domains of the protein. The interactions could be important for regulating a common 
convergent pathway in retina. Surprisingly, none of the putative RP2 interactors 
described are retina-specific, however potential convergent pathways with other 
retinal disease genes are emerging, for example the RCC1-homology domain in 
RPGR and potential interaction between RAN and RP2, and the RP2-TNP03 
interaction and its potential link with the splicing factors that are known to cause RP. 
Further work to delineate these putative retinal pathways could unravel the disease 
pathogenesis of RP2 mutations in RP.
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CHAPTER 6
DISCUSSION
6.1 Discussion and future work
Inherited retinal dystrophies are a major cause of blindness, of which retinitis 
pigmentosa (RP) is the most common form. Although many of the causative genes 
for RP have been identified the pathogenesis of disease remains unclear. RP2 was 
identified by Schwahn (1998) as the causative gene for the RP2 locus on the X 
chromosome and was found to encode a ubiquitously expressed protein (Schwahn et 
al., 1998, Chappie et al., 2000). RP2 has been shown to localise to the plasma 
membrane in cultured cells and in all cells throughout the retina through dual 
acylation (Chappie et al., 2000, Chappie et al., 2002, Grayson et al., 2002). The only 
known interacting partner for RP2 at the start of this thesis was ADP ribosylation 
factor (Art)—like 3 (Arl3), which was shown to interact with RP2 in a myristoylation and 
nucleotide-dependent manner (Bartolini et al., 2002). However, the mechanism by 
which mutations in the ubiquitously expressed RP2 result in a retinal phenotype is still 
to be elucidated.
The aim of this thesis was to use yeast-two hybrid to investigate the role RP2 plays in 
the retina and how this can lead to the development of RP when perturbed. The use 
of CytoTrap to find novel interacting partners for RP2 was successful, a previously 
known interaction (Arl3) was confirmed and characterised further and putative novel 
interactors were also identified. The data presented has confirmed the significance of 
the RP2-Arl3 interaction by showing a functional consequence of the interaction, as 
well as a potential cellular interaction site at the Golgi. Arl3 was determined to 
interact with RP2 through the TBCC homology domain at the N-terminus of RP2 and 
the interaction was disrupted by pathogenic mutations in RP2. Novel putative 
interacting partners for RP2 were also been identified: RAN, CDKN1B, TNP03 and 
SPAG7. All these novel putative interacting partners were shown to interact with RP2 
through the C-terminus of RP2, potentially under competition with each other. It was 
also found that the only currently reported missense mutation in the NDK homology
175
Chapter 6 - Discussion
domain of RP2 perturbed RP2’s interaction with all the novel interactors, 
strengthening the significance of these proteins as bona fide protein partners and 
their potential role in RP. The diverse functions of these putative interactors provide 
further insight into the multiple roles RP2 may have, and tentatively link RP2 with 
other known retinal degeneration proteins.
The identification of Arl2 as a putative RP2 interacting partner led to further 
investigation as to whether Arl3 was in fact the major interactor for RP2 from the Arl 
family. The growth of yeast co-transformed with RP2 and Arl3 was faster than for 
yeast transformed with Arl2 suggesting that the affinity of interaction between RP2 
and Arl2 was lower than for RP2 and Arl3. Furthermore, Arl2 needed full length RP2 
to interact whereas using Arl3 it was possible to define the interaction domain, again 
suggesting the Arl2 interaction may be non-physiological. Arl3 has been shown to be 
a microtubule associated protein (MAP) and to localise to the connecting cilium in 
photoreceptors (Grayson et al. 2002), it has also been detected in a cilia proteomic 
screen (Liu et al., 2007), and the phenotype of the Arl3 knock out mouse further 
supports its role in cilia function and retinal degeneration (Schrick et al., 2006). It is 
interesting to note that there is currently not an RP2 animal model available, however 
studies using the Arl3 knock out mouse may provide further information on the RP2- 
Arl3 interaction. Grayson et al (2002b) reported that in RP2-Arg120Stop patient 
lymphoblastoid cells there was no effect on the expression level of Arl3, therefore it 
would be interesting to investigate the effect on RP2 retinal localisation and 
expression in the absence of Arl3 by using the Arl3 knock out mouse (Grayson et al., 
2002b, Schrick et al., 2006).
Data from Bartolini and colleagues (2002) suggesting the RP2-Arl3 interaction is 
enhanced when Arl3 is GTP-bound was corroborated in this study (Bartolini et al. 
2002). Furthermore, the data from Kuhnel et al (2006) implying that RP2 is able to 
act as a GDI for Arl3 was supported by this study showing the relocalisation of RP2 
and Arl3-GTP to the Golgi (Kuhnel et al., 2006). Data presented in this thesis also 
suggest that RP2 may be involved in vesicular trafficking in the cell in the presence of 
Arl3-GTP.
Further investigation into this aspect of the interaction is required but it would also be 
interesting to examine whether this trafficking may be related to the intraflagellar 
transport (IFT) in cilia. Studies have shown that rates of movement along sensory 
cilia are approximately 0.65 pm/sec in the anterograde direction and approximately
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1.08 pm/sec in the retrograde direction (Orozco et al., 1999, Signor et al., 1999). 
After more detailed determination of the rate of movement of RP2-GFP it may be 
interesting to observe RP2 and Arl3-GTP in ciliated cells and to investigate any 
potential role in IFT. There is also the possibility that RP2 may be utilising the actin 
network for the intracellular movement described in Chapter 4. Actin-based transport 
is believed to be slower and occurs over shorter distances than microtubule-based 
transport (Apodaca, 2001). In contrast to microtubule-based transport which utilises 
dynein and kinesin motors (Brady, 1991), actin-based transport involves myosin 
motors. The speed of actin-based transport has been estimated to be approximately 
0.1 pm/sec (Apodaca, 2001) which is close to the 0.06 pm/sec estimation for RP2- 
GFP rates (section 4.6). The ability of RP2 to bind to actin has not been investigated 
but the presence of the two CARP domains in the TBCC homology domain suggests 
it is possible RP2 may have some association with actin. Interestingly, one of the 
myosin motors implicated in actin-based transport which is localised to the 
connecting cilium in photoreceptors, Myosin Vila is the most common gene mutated 
in Usher syndrome one of the phenotypes of which is RP (Weil et al., 1995, Liu et al., 
1997, Jaijo et al., 2007). Therefore, further investigation of the exact mechanism of 
the vesicular transport system that RP2 may be involved in is an interesting avenue 
to explore.
The homology between RP2 and TBCC has been investigated (Bartolini et al., 2002, 
Grayson et al., 2002) revealing that RP2 and TBCC do share some functions 
(Bartolini et al., 2002). There is no experimental evidence currently available 
however as to the potential function of TBCCD1. Bartolini (2005) and colleagues 
reported the tubulin destabilising properties of another protein homologous to another 
tubulin-specific cofactor, TBCE, called E-like (Bartolini et al., 2005). It is possible, 
therefore, that studies involving TBCCD1 and other potential cofactor homologs may 
reveal the fine control and regulation of the microtubule cytoskeleton.
The Sos recruitment system (SRS) was used to identify five novel putative interacting 
partners for RP2. The use of domain constructs and pathogenic mutants was used to 
define the RP2 interaction domain. Interestingly, all the novel interactors identified, 
except Arl2, interact with RP2 through the C-terminus and were all nuclear proteins. 
This data suggests that RP2 is a multifunctional protein and may have a role in the 
nucleus or nuclear envelope perhaps by transporting proteins to the nucleus through 
interactions mediated by its C-terminus. The missense mutations found in both 
domains suggest that the potential differential functions mediated by the two
177
Chapter 6 - Discussion
homologous domains in RP2 are both important for RP2’s function in retina. It is also 
interesting to speculate as to how RP2 differentiates between the C-terminal 
interacting partners, it is possible for example that they compete for binding to RP2. 
It was not possible to detect TNP03, SPAG7, RAN or CDKN1B bound to RP2 in 
alternative binding assays but the optimum conditions for each interaction are 
unknown and it is possible that there was no binding detected due to competition 
from the other interactors. Competition assays could be performed to test this 
hypothesis. Also, it is possible that the interactions occur in different cellular 
compartments or under different cellular conditions. The use of site directed 
mutagenesis (SDM) could define the interaction domain for each protein more 
precisely, for example by mutating residues conserved in the NDK-homology domain 
between E.coli NDK, human NDK 1 and 2 and RP2, and as such assist in 
understanding the mechanisms by which RP2 is able to differentiate between the 
interactors.
As described in Chapter 1 RP causative mutations in RP2 and RPGR result in 
indistinguishable phenotypes. RCC1 is the only currently reported GEF for RAN, but 
it is possible that there are alternative GEFs for RAN. The RCC1 domain of RPGR 
suggests that RPGR could have some GEF activity towards RAN. There are no 
reports of RPGR having any GEF activity for RAN but it may be that this function of 
RPGR is dependent on an adaptor protein or very particular cellular conditions which 
are not yet defined. RPGR and Arl3 also have a mutual interacting partner in PDE5 
(Linari et al. 1999a, Linari et al., 1999b). Thus a putative pathway involving both 
RPGR and RP2 appears to be emerging.
The investigation of the RP2-RAN interaction led to an interesting observation 
regarding the effect that RP2-GFP appeared to exert over myc-RAN. Expression of 
myc-tagged wild type RAN resulted in myc-RAN expression in the cytoplasm and 
amorphic cells rather than the expected nuclear distribution (Figure 5.7). However in 
the presence of RP2-GFP there was a reduction in the number of amorphic cells and 
a significant number of cells were now observed to have myc-RAN localised in the 
nucleus. It is possible that RP2 is acting as a GEF for RAN or recruiting a GEF, such 
as RPGR, to facilitate the conversion of RAN-GDP to RAN-GTP which localises to 
the nucleus. A further possibility is that RP2 has a chaperone function for RAN. As 
RP2 has homology to TBCC it has been speculated that RP2 may also have some 
chaperone activity. Whether RP2 functions as a chaperone for RAN or is involved in 
the recruitment of other proteins involved in the targeting of RAN to the nucleus and
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hence to RCC1 remains to be investigated but the data does provide another 
interesting potential link to RPGR. RPGR has been shown to interact with 
Nucelophosmin 1, which is a nuclear chaperone (Frehlick et al., 2006), through the 
retinal-dominant ORF15 isoform (Shu et al., 2005). Since there is potential of RPGR 
to act as a GEF for RAN it is possible that RP2 and RPGR act in concert to initiate 
the localisation of RAN to the nucleus possibly through Nucleophosmin 1 (Figures 5.7 
and 5.8).
The potential link between RP2 and RPGR could be investigated further through the 
study of RPGR animal models. There are canine and murine models for RPGR 
mutations which could be utilised to observe expression and localisation changes in 
key proteins in the predicted pathway such as HRG4, PDE5, RAN, Nucleophosmin 1, 
Arl3, and RPGRIP1 (Hong etal., 2000, Beltran e ta i, 2006).
The importance of ubiquitously expressed splicing factors in normal retinal function is 
apparent due to identification of pathogenic mutations in four such genes that result 
in autosomal dominant retinitis pigmentosa (Sullivan et al., 2006, McKie et al., 2001, 
Chakarova et al., 2002, Maita etal., 2004). The identification of TNP03 as a putative 
interacting partner for RP2 further suggests that splicing is an important aspect of 
normal retinal function. TNP03 is involved in the transport of SR splicing factors to 
the nucleus (Lai etal., 2000, Lai etal., 2001) as well as being shown to interact with a 
non-SR splicing factor (Lai et al., 2003). Interestingly, a study in Drosophila 
melanogaster using co-immunoprecipitations and microarray screening techniques 
identified groups of mRNAs that were regulated by specific SR proteins (Gabut et al.,
2007). One of the SR proteins studied by Gabut et al (2007) was dASF/SF2, the
D.melanogaster homolog of ASF/SF2, which was one of the SR proteins Lai et al 
(2000) showed interacted with TNP03 (Gabut et al., 2007, Lai et al., 2000). 
dASF/SF2 was also shown to be important for the regulation of splicing of a number 
of genes involved in eye development (Gabut et al., 2007). A hypothesis for the 
reason that mutations in splicing factors may cause RP is that alteration in their 
activity may result in aberrant splicing, which is supported by the work by Mordes and 
colleagues (2007) showing reduced expression of the retinal-specific gene RDS 
when the splicing factor PRPF31 was mutated (Mordes etal., 2007).
The RP2-TNP03 interaction may be important for the downstream effects of TNP03, 
in that if the interaction between RP2 and TNP03 is disrupted by mutations in RP2, 
TNP03 may not be able to bind to the SR splicing factors (e.g. ASF/SF2) and as
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such they would not be transported to the nucleus where they are able to regulate the 
splicing of important retinal genes. Furthermore, it has been shown that murine 
RPGR, which undergoes alternative splicing, has purine-rich exonic splicing 
enhancers (ESEs) in the sequence, elements that have been shown to interact with 
SR splicing factors (Lavigueur etal., 1993, Hong and Li, 2002). The authors suggest 
that the alternative splicing of RPGR may indeed be regulated by SR proteins binding 
to these ESEs and affecting the alternative splicing of the ORF15 exon shown to 
contain RP-causing mutations (Hong and Li, 2002).
CDKN1B has been shown to be important in both the development and function of 
the retina through studies using retinal progenitor cells (Dyer and Cepko, 2001) and a 
knock out mouse model (Nakayama et al., 1996). Furthermore there is evidence that 
CDKN1B acts as a modifier for the Chx10 null mutation, a homeobox gene which 
acts to regulate the proliferation of retinal progenitor cells (Liang et al., 2007). As 
such the murine model, a knock out of Chx10, has been described as having a 
reduced number of retinal cells which may be explained by the loss of repression of 
CDKN1B which is normally mediated by Chx10 (Liang et al., 2007). These data 
clearly implicate the correct regulation and function of CDKN1B is vital to normal 
retinal function. If, therefore, the RP2-CDKN1B interaction was important for the 
regulation of CDKN1B then disruption of the interaction may indeed have implications 
for the retina.
CDKN1B has three potential phosphorylation sites (Figure 5.10), the phosphorylation 
at each residue has been shown to have different effects on the CDKNIB’s 
localisation (Lee et al. 2007) and that there are different mechanisms involved in the 
phosphorylation of CDKN1B at the Ser10 and Thr187 residues (Lee et al. 2007). 
Therefore, the possibility that there are at least two different populations of CDKN1B 
(Lee etal., 2007) leads to the question whether RP2 would preferentially interact with 
differently phosphorylated forms of CDKN1B.
The physiological significance of the interaction between RP2 and SPAG7 still 
remains to be elucidated but does provide a link with data published by Yoon et al
(2006) indicating that RP2 has the ability to translocate to the nucleus under DNA 
damaging conditions (Yoon et al., 2006). As with all the novel interactors that are 
nuclear proteins the reported ability of RP2 to translocate to the nucleus offers the 
possibility that the interactions occur in the nucleus or on the nuclear envelope. For 
SPAG7, however, this is more likely due to the R3H domain in SPAG7 potentially
180
Chapter 6 - Discussion
mediating the ability of SPAG7 to bind to ssDNA, thus it is possible that the RP2- 
SPAG7 interaction only occurs when RP2 translocates to the nucleus upon DNA 
damage in which instance it may facilitate the binding of SPAG7 to the damaged 
ssDNA. The potential phosphorylation of SPAG7 may also potentially shed further 
light on the optimal conditions for the RP2-SPAG7 interaction as RP2 may 
preferentially bind to SPAG7 if it is phosphorylated.
There are links emerging not only between RP2 and other retinal disease proteins but 
also between the novel interactors themselves. CDKN1B and TNP03 have both 
been shown to interact with RAN (Lai et al., 2000, Connor et al., 2003). Although 
whether the interaction with RAN is simply due to the proteins’ nuclear targeting 
being mediated by RAN, or whether it may be more complex and related to the 
putative interaction with RP2 remains to be seen.
The use of yeast two-hybrid to discover new interacting partners and delineate 
pathways is a widely used approach and more recently large scale screening has 
become possible leading to the generation of large scale interactome maps. Using 
such screens and other published interactors it has been possible to create a putative 
RP2 interactome (Figure 6.1) (Stelzl et al., 2005, Colland et al., 2004). This approach 
highlights the potential links RP2 has to other retinal disease proteins, for example 
there are several proteins that link RP2 to HRG4 as well as the links between RP2 
and RPGR and hence RPGRIP1 and RPGRIP1L. A clearly important emerging 
theme appears to be the importance of cilia in the pathogenesis of retinal disease, a 
link already clearly established, and although RP2 has not been detected in a recent 
cilia proteome screen (Liu etal., 2007) it may be that RP2 plays a role in signalling or 
at the cilia base rather than within the cilia itself.
The importance of RAN in retinal degeneration also requires further investigation. 
RAN has been shown to interact with the nucleoporin RanBP2 (Nup358) (Yokoyama 
et al., 1995) and RanBP2 has been shown to associate with RPGRIP1 in amacrine 
cells in retina (Castagnet et al. 2003) (Figure 6.1). Another of RPGR’s interacting 
partners, Nucleophosmin 1, has also been shown to be regulated by RAN and 
Exportin 1 (Wang et al., 2005), further strengthening the connection between RAN 
and RPGR (Figure 6.1). In a similar way it is possible to see connections between 
HRG4 and PDE 5 and Centrin 3, a protein thought to be involved in transducin 
regulation in the photoreceptor connecting cilium (Friedberg, 2006) (Figure 6.1).
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Putative 
candidate gene
Genomic
position
Disease loci ?
Arl2 11 q13 Outside the SPOAN (spastic paraplegia, optic atrophy and 
neuropathy) region (Macedo-Souza et al., 2005, personal 
communication)
Arl3 10q23.3 No
BAT5 6p21.3 No
BTBD2 19p13.3 No
CDKN1B 12p13 Within region for DFNB62 (ar deafness) (Ali et al., 2006)
CDKN2C 1p32 No
Centrin 3 5q14.3 No
Exportin 1 2p16 Just outside the RP28 locus
Golgin-245 3p22-p21.3 Outside a vascular retinopathy locus on Chr3
Nucleophosmin 1 5q35 No
Prefoldin 1
Prefoldin 2 
Prefoldin 3
Prefoldin 4 
Prefoldin 5 
Prefoldin 6
5q31
1q23.3
Xq28
20q13.2 
12q12 
6p21.3
Within the critical region for autosomal dominant butterfly 
shaped macular dystrophy on 5q21,2-q33.2. (den Hollander 
et al., 2004)
Within the critical region for CORD8 (Ismail et al., 2006) 
Within the critical region for RP34 (Melamud et al., 2006) 
and COD2 (Bergen eta l., 1997)
No
No
No
RAN 12q24.3 Within region for DFNA41 (ad nonsyndromic sensorineural 
deafness) (Yan et al., 2005)
RanBP2 2q12.3 No
Rif1 1p13.3 No
SMURF2 17q22-q23 No
SPAG7 17p13.2 No
TLE1 9q21.32 No
Transportin 3 7q32.3 No
UBQLN4 1q21 No
UBR1 15q13 No
Table 6.1 Putative candidate retinal disease genes
Genomic positions and disease intervals in which some of the proposed putative 
ocular candidate disease genes lie (see Figure 6.1).
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Therefore it may be interesting to investigate any association Centrin 3 may have 
with other retinal disease proteins in the connecting cilium such as RPGR.
Figure 6.1 shows the putative links between RP2 and other retinal degeneration 
proteins, it also provides a means to highlight possible candidate disease genes. 
Table 6.1 shows the genomic position of several putative candidate retinal disease 
genes and whether there are any ocular or cilia-related disease loci mapping to their 
genomic regions (Table 6.1). Several proteins shown in Figure 6.1 are located within 
the mapped critical regions for ocular diseases, for example members of the Prefoldin 
complex (Table 6.1).
The ubiquitous expression profile of RP2 and its known and putative interacting 
partners means that the pathogenesis of RP2 mutations in RP remains unclear. 
However, there are several emerging pathways which when further investigated, will 
assist in not only the understanding of RP2’s retinal function, but that of many other 
retinal disease proteins.
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APPENDIX 1
REAGENTS, SOLUTIONS AND MEDIA 
General Reagents
6x loading dye:
0.4% Orange G, 0.03% Bromophenol Blue, 0.03% Xylene cyanol, 15% Ficoll 400, 10 
mM 1 M Tris-HCI (pH 7.5), 50mM EDTA (pH 8.0)
TAE buffer:
40 mM Tris-HCI, 40 mM Acetic Acid, 1 mM EDTA 
SOC media.
2% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.2% (v/v) 5 M NaCI, 0.25% (v/v) 1 M 
KCI, 1% (v/v) 1 M MgCI2, 1% (v/v) 1 M MgS04, 2% (v/v) 1 M glucose
Phosphate buffered saline (PBS):
145 mM NaCI, 3.6 mM NaH2P04, 10.5 mM Na2HP04
L-agar antibiotic plates:
1% (w/v) Bacto®-tryptone, 0.5% (w/v) Bacto®-yeast extract, 1% (w/v) NaCI, 1.5%
(w/v) Bacto®-agar
L-broth (LB):
1% (w/v) Bacto®-tryptone, 0.5% (w/v) Bacto®-yeast extract, 1% (w/v) NaCI
Tris-EDTA (TE) buffer:
10 mM Tris-HCI (pH 7.5), 1 mM EDTA
SDS-PAGE resolving gel:
375 mM Tris-HCI pH 8.8, 8-15% (v/v) acrylamide, 0.2-0.4% (v/v) bisacrylamide, 0.15% 
(w/v) ammonium persulphate (APS), 0.1% (w/v) SDS, 0.05% (v/v) TEMED
SDS-PAGE stacking gel:
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125 mM Tris-HCI pH6.8, 3% (v/v) acrylamide, 0.1% (v/v) bisacrylamide, 0.05% (w/v) 
ammonium persulphate (APS), 0.1% (w/v) SDS, 0.08% (v/v) TEMED
SDS-PAGE running buffer:
25 mM Tris-HCI, 190 mM Glycine, 3.5 mM SDS
2 x SDS-PAGE sample buffer:
125 mM Tris-HCI (pH6.8), 20% (v/v) Glycerol, 4% (v/v) SDS, 10% (v/v) 2-0 
Mercaptoethanol, 0.2% (w/v) Bromophenol Blue
Coomassie stain:
25% (v/v) Methanol, 25% (v/v) Acetic acid, 0.25% (w/v) Coomassie brilliant blue (R- 
250)
Coomassie de-stain solution:
25% (v/v) Methanol, 25% (v/v) Acetic acid
PBS-Tween20:
0.05% (v/v) Tween-20® in PBS
1 x Western blotting transfer buffer:
25 mM Tris-HCI, 190 mM Glycine, 20% (v/v) Methanol
Western blotting blocking buffer:
5% (w/v) “Marvel®” milk powder, 0.05% (v/v) Tween-20® in PBS
Southern blotting denaturation buffer:
1.5M NaCI, 0.5M NaOH
Southern blotting hybridisation solution:
0.05M P04 (pH 6.8), 2 x SSC, 5 ml 100x Denhardts solution (2% Ficoll, 2% BSA, 2% 
PVP), 10 pg/ml salmon sperm DNA, 10% dextran sulphate, 0.3% SDS, 0.15% NaPPi 
(Na4P4O7.10H2O)
Yeast-specific Reagents 
YPAD media:
1 % (w/v) Yeast extract, 2% (w/v) Bacto®-peptone, 2% (w/v) Dextrose, 0.004% (w/v) 
Adenine Sulfate
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YPAD agar plates:
1% (w/v) Yeast extract, 2% (w/v) Bacto®-peptone, 2% (w/v) Dextrose, 0.004% (w/v) 
Adenine Sulfate, 15% (w/v) Agar
LiOAc/TE:
10 mM LiOAC in TE
SD/glucose plates:
0.17% (w/v) Yeast nitrogen base without amino acids, 0.5% (w/v) Ammonium 
sulphate, 2% (w/v) Dextrose, 15% (w/v) Agar, 10% (v/v) appropriate x10 dropout 
solution
SD/galactose plates:
0.17% (w/v) Yeast nitrogen base without amino acids, 0.5% (w/v) Ammonium 
sulphate, 2% (w/v) Galactose, 1% (w/v) Raffinose, 15% (w/v) Agar, 10% (v/v) 
appropriate x10 dropout solution
NaOH/p-ME buffer:
1.85 M NaOH, 7.5% (3-Mercaptoethanol 
SU buffer:
5% (w/v) SDS, 125 mM Tris-HCI (pH 6.8), 0.1 mM EDTA, 0.005% (w/v) Bromophenol 
blue, 8 M Urea, 15 mg DTT/ml
10x Dropout Solution:
Amino Acid 
L-lsoleucine 
L-Valine
L-Adenine hemisulphate salt 
L-Arginine HCI 
L-Histidine HCI monohydrate 
L-Leucine 
L-Lysine HCI 
L-Methionine 
L-Phenylalanine
Weight (mg/litre) 
300 
1500 
200 
500 
200 
1000 
500 
200 
500
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L-Threonine* 2000
L-Tryptophan 500
L-Tyrosine 500
L-Uracil 200
L-Glutamic Acid 1000
L-Aspartic Acid* 1000
L-Serine 400
All amino acids can be autocalved with the exception of those marked *. These 
should be filter sterilised and added after the auoclaved solution has cooled to 55°C.
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PRIMER SEQUENCES
Oligo Name Sequence 5’-3’ Cloning
Restriction
Site
Purpose 
And Host 
Vector
RP2 Start (F) CGCCATGGGCT GCTT CTT CT CCAAGAG A/col PCR
pSos
RP2 41
(F)
CGCCATGGGAAT GTT C AGT GGACT GAAGGAT G A/col PCR
pSos
RP2 190(F ) CGCCAT GGGACCAGAAGAT GCT GT GGTT C AG A/col PCR
pSos
RP2 238 (F) CGCCAT GGGAGT GGT ATT ATTT GCT GGT GATT AC A/col PCR
pSos
RP2 200 (R) CGGT CGACTT AAGGAACAT AGT CCT GAACCACAGC Sa/I PCR
pSos
RP2 End (R) CGGTCGACTCATATTCCCATCTGTATATCAGC Sail PCR
pSos
pMyr Forward ACT ACT AGC AGCT GT AAT AC Sequencing
pMyr
pMyr Reverse CGTGAATGTAAGCGTGACAT Sequencing
pMyr
pSos Forward CCAAGACCAGGTACCATG Sequencing
pSos
pSos Reverse GCCAGGGTTTT CCCAGT Sequencing
pSos
Arl3 Forward CGGAATT CAT GGGCTT GCT CT CAATTTT G EcoRI PCR
pMyr
Arl3 Reverse CGGT CGACT CCCGCAGCT CCT GCAT C Sa/I PCR
pMyr
Arl6 Forward CGCT CGAGT AT GGG ATT GCT AG AC AG ACTTT C Xho\ PCR
pMyr
Arl6 Reverse CGGT CGACGCT GAGGTTTT CCAACT ATT AT C Sa/I PCR
pMyr
M13 Forward GTAAAACGACGGCCAGT Sequencing
pGem
TEasy
M13 Reverse GGAAACAGCTAT GACCATG Sequencing
pGem
TEasy
Arl3 C-term F CGGAATT CAT GGGCTT GCT CT CAATTTT G EcoRI PCR
pcDNA4/TO/
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vsv
A rl3 C-term R CCGCGGT AT AATTT CTT CTTT GCATT GAC Sacll PCR
pcDNA4/TO/
VSV
R P 2  pMyr F CGGAATT CAT GGGCT GCTT CTT CTCCAAGAG £coRI PCR
pMyr
R P 2  pMyr R CGCTCGAGTCATATTCCCATCTGTATATCAG Xho\ PCR
pMyr
A rl3  pSos F CGCCAT GGT CAT GGGCTT GCT CT CAATTTT G A/col PCR
pSos
A rl3  pSos R CGGCGGCCGCT CCCGCAGCT CCT GCAT C Not\ PCR
pSos
A rl6  pSos F CGCCATGGTTATGGGATTGCTAGACAGACTTTC A/col PCR
pSos
A rl6 pSos R CGGCGGCCGCGCTGAGGTTTTCCAACTATTATC Not\ PCR
pSos
Arl6 pCMV3 F GCGG AT CCC AT GGG ATT GCT AG AC AG AC Bamh I PCR
pCMVTag3b
Arl6 pCMV3 R GCCT CGAGT CAT GT CTT CACAGT CT GG Xho\ PCR
pCMVTag3b
SPAG 7  
pCM V3b F
GCGAATT CAT GGCGGACCT ACT GGGCT CC EcoR\ PCR
pCMVTag3b
SPA G 7  
pCM V3b R
GCCT CGAGCGCCT AGGAGGTT GGCGGCAAC Xho\ PCR
pCMVTag3b
540-562
F
GT ACGGT GGG AGGT CT AT AT AAG Sequencing
pEGFP-N1
745-724
R
GT CGCCGT CCAGCT CGACCAGG Sequencing
pEGFP-N1
Bovine Arl2 F CCAT CCT CAAGAAGTT CAACGG - PCR
Bovine Arl2 R GAT GAGGAGGGT CGCT CCG - PCR
Bovine Arl3 F GAAGACAT CAGCCACAT CACAC - PCR
Bovine Arl3 R GTT CCT GACCT GT CT CTT CAAAT C - PCR
Table 7.1 Oligonucleotide primers used for PCR and sequencing
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Appendix 1 -  Reagents, solutions and media
Oligo Name Sequence 5’-3’ Resultant
Change
RP2 Cys67Tyr F CT C ATT C AAG ACT AT G AG AACT GTAAC AT C TGT to TAT
RP2 Cys67Tyr R GAT GTTAC AGTT CT CAT AGT CTT G AAT GAG TGT to TAT
RP2 Cys86Tyr F GTTACC ATT GAT G ACT AT ACTAACT G C TGT to TAT
RP2 Cys86Tyr R GC AGTTAGT AT AGT CAT C AAT GGTAAC TGT to TAT
RP2 Arg118His F CCTGCC AAC AATTT CAT GTGCG AG ATT G CGT to CAT
RP2 Arg118His R CAATCTCGCACATGAAATTGTTGGCAGG CGT to CAT
RP2 Leu253Arg F GCCAGAAAACG AATT GAT GAG AT GGTT G CTA to CGA
RP2 Leu253Arg R C AACC AT CT CAT C AATTCGTTTT CT GGC CTA to CGA
Arl3 T31N F GCTGGCAAGAACACT CTT CT GAAGCAG ACC to AAC
Arl3 T31N R CT GCTT C AG AAG AGT GTTCTT GCC AGC ACC to AAC
Arl3 Q71LF GACATTGGTGGACTGAGGAAAATCAG CAG to CTG
Arl3 Q71LR CT G ATTTT CCT G AGT CC ACC AAT GT C CAG to CTG
Arl2 T30N F GCT GGA AAG AAC ACC ATC CTG ACA to AAC
Arl2 T30N R CAG GAT GGT GTT CTT TCC AGC ACA to AAC
Arl2 Q70L F GTG GGT GGC CTG AAG TCC CTG CAG to CTG
Arl2 Q70L R CAG GGA CTT CAG GCC ACC CAC CAG to CTG
RAN T24N F CT GGA AAA AAT ACA TTC GTT AAG ACT to AAT
RAN T24N R CTT AAC GAA TGT ATT TTT TCC AG ACT to AAT
RAN 43E F GTA GCT ACC GAG GGT GAG TTG to GAG
RAN 43E R CTC AAC ACC CTC GGT AGC TAC TTG to GAG
RAN Q69L F CA GCT GGT CTG GAG AAA TTT G CAG to CTG
RAN Q69L R C AAA TTT CTC CAG ACC AGC TG CAG to CTG
Table 7.2 Mutant oligonucleotide primers used for SDM
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